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ABSTRACT 
Nasopharyngeal carcinoma (NPC) is a highly malignant tumour arising from the epithelial 
lining of the nasopharynx and has geographical, genetic, environmental and viral cofactors. 
During the development and progression of NPC, a number of genetic abnormalities and 
expression changes in a wide variety of cellular genes are accumulated. Therefore, 
identification of these aberrations is critical for understanding the molecular basis of this 
disease. Here we examined both the chromosomal copy number changes and differential 
RNA expression profiles in NPC. Gene expression profiles identified a large number of 
differentially regulated genes involved in diverse functional processes (e.g. tumour promoting, 
tumour suppressing, apoptosis/anoikis- suppressing, and metastatic promotion), while genetic 
analysis detected extensive genomic abnormalities including large and small, discrete regions 
of copy number change and loci that exhibit uniparental disomy (UPD). The relationship 
between chromosomal copy number and level of gene expression were analysed in the list of 
tumour associated genes. This revealed that the direct copy number/expression link applies in 
about 60% of the instances of copy number loss/down-expression and less than 35% of 
instances of copy number gain/up-expression that were examined. When the gene expression 
data were analysed in the context of signalling pathways, it revealed that numerous 
components involved in the TGF-β, Wnt/β-catenin and Hedgehog pathways were universally 
upregulated in NPC tumours. The C666-1 cell line is the only line used in this study, and 
sample correlation and signalling pathway analysis demonstrated that the gene expression 
pattern of this line approximated to other NPC tumours, indicating that it could be a good 
tumour model for analysis of NPC. A preliminary in vitro investigation of signalling 
pathways revealed that the C666-1 cell line is intact in the activin and Hh signalling pathways 
but not in the TGF-β pathway. However, the C666-1 cells appear to resist activin-mediated 
cell growth inhibition.     
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CHAPTER 1 
Introduction 
1.1 Nasopharyngeal carcinoma (NPC) 
 
Nasopharyngeal carcinoma is a highly malignant tumour arising from the epithelial 
lining of the nasopharynx and is distinguished from other cancers of the head and 
neck by its distinct histopathology, racial and geographical distribution, clinical 
characteristics and treatment.  
 
1.1.1 Histopathology 
NPC is a squamous cell carcinoma with a worldwide distribution. Therefore, it is 
important to have a universal histopathological classification for standardised and 
comparable diagnosis and therapy around the world. However, since the beginning of 
the 20th century, several classification schemes for NPC have been proposed and this 
has led to considerable confusion. In 1978 the first international classification was 
proposed by the World Health Organisation (WHO) which classified NPC into 3 
subtypes based on the differentiation status of the tumour cells (Shanmugaratnam & 
Sobin, 1993). WHO type І is characterised by keratinising squamous-cell carcinomas 
(SCC). This type of NPC tumour presents as squamous differentiation with the 
presence of intracellular bridges and/or keratinisation, and the absence of cellular 
infiltrate. Type II is non-keratinising squamous carcinoma, which is neither anaplastic 
nor keratinising. It is a differentiated tumour with a stratified appearance and well-
defined cell borders. Cytologically, the tumour cells are of moderate size, variable in 
cell morphology (polygonal and/or spindled) and differentiation. Type III represents 
undifferentiated carcinomas that have distinct cytological characteristics. Typically, 
the cells appear to have prominent nucleoli, indistinct cytoplasm and poorly 
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delineated cell boundaries. The tumour cell morphology of this type is highly variable 
as it can feature clear cells, spindle cells or anaplastic cells. In areas with low 
incidence of NPC such as North America, around 25% of NPC patients are WHO 
type І, 12% are type П, and 63% are type Ш whereas in endemic areas such as South 
China, the histological distribution is approximately 2%, 3% and 95%, respectively 
(Wei & Sham, 2005).  
 
A modified WHO classification was proposed in 1991, which divided NPC tumours 
into two groups: keratinising squamous-cell carcinomas and non-keratinising 
carcinomas. The latter was then subdivided into differentiated and undifferentiated 
carcinomas. A criterion used in this classification is significantly correlated with EBV 
since non-keratinising carcinoma has a stronger association with EBV infection. In 
addition, in this classification therapeutic and prognostic significance has also been 
taken into account. It has been shown that non-keratinising carcinomas are more 
sensitive to radiotherapy and have better patient survival than keratinising squamous-
cell carcinoma (Marks et al., 1998). 
 
There is an even newer, 2005, WHO classification for NPC, which maintains the 
separation between keratinising squamous-cell carcinomas and non-keratinising 
carcinomas but they are more flexible in their subclassification. The main 
consideration for this classification is for determining treatment options and prognosis 
regardless of EBV infection, differentiation status or other factors. The 
histopathological classification of NPC has been reviewed in detail (Nicholls & 
Niedobitek, 2008).    
  
Chapter 1                                                                                                      Introduction 
 
3 
 
NPC is heterogeneous, often containing substantial numbers of tumour-infiltrating 
leucocytes, the majority of which are reactive T-lymphocytes (Nicholls et al., 1997; 
Gourzones et al., 2009). A large proportion of NPC cases show an extensive 
lymphocytic infiltrate. Although keratinising squamous cell carcinomas do not 
typically display lymphoid stroma, non-keratinising carcinomas have a predominant 
lymphoid infiltrate in up to 80% of this type of cases. Infiltrating leucocytes are often 
located around malignant tumour cell clusters but sometimes disseminated within 
epithelial cell nests. Depending on the pattern of tumour infiltrate, non-keratinising 
NPC can be further classified as either Regaud type if the tumour presents as a well-
defined collection of epithelial cells surrounded by infiltrate (solid cell type) or 
Schmincke type if the tumour cells are scattered and intermingle with the infiltrating 
cells (isolated cell type). Increasing lines of evidence suggest that the presence of 
infiltrating leucocytes plays an essential role in NPC progression by communicating 
with tumour cells in the microenvironment of NPC and secreting various cytokines 
and exosomes that suppress the immune system and facilitate NPC tumour growth 
(Tang et al., 1999; Gourzones et al., 2009; Yip et al., 2009). Nonetheless, on the other 
hand, it seems that it may also have adverse effects on tumour growth since earlier 
studies suggested that patients whose tumour cells are surrounded by an abundant 
leucocyte infiltrate have better prognosis (Zong et al., 1993).     
        
1.1.2 Epidemiology  
1.1.2.1 Racial and geographical distribution  
In most regions of the world, NPC is a rare malignancy with an incidence of less than 
1 per 100,000 population per year. For example, in the United States, incidence rates 
in white males and females are only 0.5 and 0.2 per 100,000 person-years, 
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respectively. In its endemic areas including Southern China, NPC reaches a frequency 
of up to 20 – 30 per 100,000 per year. Highest rates are reported among Cantonese in 
Southern China who inhabit the central region of Guangdong province as well as 
Hong Kong. Other provinces in mainland China next to Guangdong (Hunan, Fujian, 
Guangxi and Hainan) also have a relatively high incidence of NPC, whereas the 
incidence in Northern China is significantly lower than that in the South. An 
intermediate incidence (approximately 8 per 100,000 per year) has been observed in 
other areas of Southeast Asia (e.g. Thailand, Philippines, Malaysia and Singapore), 
Greece, Turkey and the Maghreb region of North Africa (Yu & Yuan, 2002; Chang & 
Adami, 2006; Tao & Chan, 2007).  
 
1.1.2.2 Aetiology of NPC  
The observation that Chinese emigrants from endemic areas, irrespective of their 
country of immigration, continue to have a high incidence of NPC, whereas the rate of 
this disease among ethnic Chinese born in North America is considerably lower than 
those born in China (Buell, 1974) suggests that both environmental and inherited 
factors play crucial roles in the development of NPC. 
 
1.1.2.2.1 Environmental factors 
There are some common features across the populations demonstrating an elevated 
risk of NPC. One of the strongest cultural habits correlated with carcinogenesis is the 
digestion of Cantonese-style salted fish. A large case-control study suggests that 
consumption of Cantonese-style salted fish during all time periods, especially in 
childhood, has a strong correlation with NPC (Yu et al., 1986). Intake of other 
preserved food and usage of Chinese herbs have been frequently observed in high-risk 
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populations of NPC, suggesting a link with NPC pathogenesis (Gallicchio et al., 
2006). Actually, extracts from preserved food including salted fish demonstrate the 
presence of carcinogenic nitrosamines/precursors, and genotoxic and EBV-activating 
substances (Shao et al., 1988; Poirier et al., 1989). EBV has been closely associated 
with NPC and will be introduced in the following sections. In addition, insufficient 
intake of fresh fruit and vegetables has been suggested to be another risk factor for 
NPC in endemic areas. Epidemiological studies indicate that occupational exposure to 
toxic pollutants in the air, wood dust, and textiles is linked to increased incidence of 
NPC (Armstrong et al., 2000; Li et al., 2006b). Long-term cigarette smoking and/or 
alcohol consumption have also been considered to be important contributions to NPC 
(Nam et al., 1992; Cheng et al., 1999).   
 
1.1.2.2.2 Genetic susceptibility 
Several lines of evidence suggest that genetic predispositions contribute to the high 
prevalence of NPC in southern Chinese populations. An earlier linkage study on 
Chinese sib pairs with NPC identified an NPC susceptibility locus at the HLA (human 
leucocyte antigen) region (Lu et al., 1990). Further studies in Taiwanese suggest that 
genes associated with susceptibility to NPC in the HLA region are within the HLA-A 
locus (Lu et al., 2003a; Lu et al., 2005). In recent years, family-based association 
studies identified several putative genetic susceptibility loci in NPC including 
chromosomes 3p21, 4 and 5p13 (Zeng et al., 2006; Hu et al., 2008a). However, since 
the chromosomal regions identified are quite large, the candidate NPC-related genes 
have not been determined. A number of case-control studies reveal that genetic 
polymorphisms for several genes including CYP2E1, GSTM1, XRCC1 and hOGG1 
are associated with susceptibility of NPC. CYP2E1 is responsible for metabolic 
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activation of nitrosamines (an EBV activating agent) and other related carcinogens. 
Several variant forms of this gene are strongly associated with NPC development in 
Chinese populations (Hildesheim et al., 1997; Jia et al., 2009). GSTM1 is mainly 
involved in the detoxification of carcinogens and the absence of GSTM1 (GSTM1 
null genotype) moderately increases risk of NPC (Nazar-Stewart et al., 1999). 
XRCC1 and hOGG1 are two enzymes that participate in the DNA repair system, 
genetic polymorphisms of which are correlated with an elevated risk of NPC (Cho et 
al., 2003). The development and progression of NPC have also included a number of 
acquired genetic changes (e.g. gene amplification, deletion and mutation) and 
epigenetic changes (methylation) that contribute to carcinogenesis by altering the 
expression of genes essential for a wide range of functions, such as proliferation, 
apoptosis, differentiation, invasiveness and metastasis. This will be discussed in 
Section 1.4. 
 
1.1.2.2.3 EBV infection 
In addition to the environmental and genetic factors, NPC is consistently associated 
with EBV infection (Raab-Traub, 2002). This association was initially suggested on 
the basis of serological studies and has been subsequently supported by the detection 
of viral genomes and gene products in NPC tumour cells. At least 95% of NPC 
tumours are associated with EBV. The WHO type II and III NPCs are consistently 
associated with EBV regardless of geographical distribution and ethnic origin 
(Andersson-Anvret et al., 1979), whereas WHO type І is less frequently EBV-
associated, especially for the cases in nonendemic areas. In NPC tumour cells EBV 
exists in a state of type II latency (see Section 1.2.5) (Brooks et al., 1992; Busson et 
al., 1992). Since there are variable morphological characteristics of NPC-affected 
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tissues, the pathological diagnosis of NPC is usually based on the location of the 
tumour in the nasopharynx and the presence of EBV in the tumour cells. The presence 
of clonal EBV genomes in the early preinvasive dysplastic lesion or carcinoma in situ 
of the nasopharynx contrasts with its absence either in normal nasopharynx or in low-
grade dysplasia, suggesting that EBV infection is an early, possibly initiating event in 
the progression of NPC (Pathmanathan et al., 1995). EBV infection and viral gene 
function in NPC development will be further discussed in Section 1.2. 
 
1.1.3 Clinical presentation and treatment 
In Southeast Asia NPC develops in all age groups of the population with a peak 
incidence in the range of 40-60 years, whereas in North Africa the distribution of 
NPC according to age is bi-modal, with the first peak between 10 and 20 years of age 
accounting for up to 20% of NPC patients and the second between 40 and 60 years of 
age accounting for nearly 60% of patients (Ellouz et al., 1978; Daoud et al., 2003). 
Anatomically, NPC usually arises in the ostium of the Eustachian tube in the lateral 
wall of the nasopharynx also called “pharyngeal recesses”. The nasopharynx has a 
rich vascular supply and lymphatic drainage system. These characteristics of anatomy 
define the symptomatology, the route of tumour spread and treatment of NPC. 
Headache, a nose bleed, a stuffed nose with bloody drainage, and serious otitis media 
are usually the earliest clinical symptoms of this disease. The clinical diagnosis of 
NPC mainly depends on clinical presentation, nasopharyngoscopy and biopsy. 
However, the majority of NPC is diagnosed at an advanced stage because initial 
symptoms of the disease may appear relatively innocuous. NPC can easily spread 
regionally resulting in early lymph-node involvement in the neck, which could 
actually be the first clinical presentation. NPC is also highly metastatic, with most 
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distant metastases appearing within 18 months of the first symptoms (Cvitkovic et al., 
1993; Tao et al., 2008). Bone is the most frequent metastatic site, followed by lung 
and liver (Micheau et al., 1987; Hui et al., 2004). Juvenile forms of NPC have an 
even higher frequency of lymph node and distant metastases
 
 than those of adult forms 
(Daoud et al., 2003).  
Following the development of various detection systems that take advantage of the 
presence of EBV in NPC, increasing numbers of patients can be diagnosed at an early 
stage of the disease, which is of great help to the therapy and prognosis of patients. In 
endemic areas such as Southern China, EBV serology has been generally used for 
screening of NPC. EBV antibody titres (IgA) are usually elevated in sera of NPC 
patients compared to healthy controls, in addition, the levels increase from early stage 
(stages I or II) to advanced stage (stages III or IV) (Henle & Henle, 1976). 
Furthermore, quantitative detection of circulating EBV DNA has been demonstrated 
to be a powerful method for NPC patients in early diagnosis, and prediction of 
progression and prognosis (Lo et al., 2000b; Stevens et al., 2006). 
 
In contrast to other types of head and neck cancers, NPC is sensitive to radiation. 
Thus, the standard treatment for NPC is radiotherapy, whereas local relapses and 
distant metastases still frequently occur after radiotherapy alone, especially for 
locoregionally advanced patients. Concurrent chemoradiotherapy with or without 
adjuvant chemotherapy significantly improves patient survival rates (Al-Sarraf et al., 
1998). Despite the improvement in treatment, distant metastasis remains a major 
cause for failure of treatment. The median survival rate after distant metastasis is only 
around 9-12 months (Ma & Chan, 2006). The prognosis of NPC patients mainly 
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depends on disease stage (tumour size, lymph node involvement and distant 
metastasis), although it is also influenced by patients’ characteristics (gender and age), 
and treatment. Patients that are diagnosed at an early stage (stage І and П) have better 
prognosis, whereas those with lymph-node and distant metastasis have a much poorer 
prognosis. Women appear to have better survival than men (Sham & Choy, 1990). 
Taking advantage of the close association between EBV and NPC, some novel 
treatment approaches such as immunotherapy and gene therapy targeting EBV genes 
have been recently investigated (Busson et al., 2004). These may provide new 
avenues for the treatment of NPC patients.    
 
1.2 Epstein-Barr virus 
 
1.2.1 The natural history of EBV  
EBV (Epstein-Barr virus) is a ubiquitous human gammaherpesvirus that was 
recognised and designated in 1964 (Epstein et al., 1964). EBV infects more than 
90% of the adult population of the world. Following primary infection, the 
individual remains a lifelong carrier. In developing countries, EBV infection 
typically occurs during early childhood and is often asymptomatic, whereas in 
developed countries, infection often occurs during adolescence or adulthood and 
may cause symptomatic disease presenting as the characteristic clinical features of 
infectious mononucleosis (IM), including fever, sore throat, malaise and 
lymphoadenopathy (Slots et al., 2006). Saliva is the main vehicle for EBV 
transmission from individual to individual, whereas organ and bone marrow 
transplantation is another risk for EBV infection.  
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1.2.2 EBV and human disease 
EBV is associated with a number of human diseases. In early serological studies, 
high antibody titres to EBV were observed in patients with Burkitt’s lymphoma 
(BL) (Henle & Henle, 1966), IM, and undifferentiated NPC (Henle et al., 1968). 
EBV is also associated with Hodgkin’s lymphoma (HL), T-cell lymphoma and 
gastric carcinoma (Baumforth et al., 1999). In individuals with primary 
immunodeficiencies e.g. X-linked lymphoproliferative  syndrome, EBV infection 
frequently leads to fatal IM and B-cell lymphomas (Tatsumi & Purtilo, 1986), 
whereas patients with acquired immunosuppression will have increased risk of 
developing lymphoproliferative disorders (e.g. post-transplant lymphoproliferative 
disease (PTLD)) (Cohen, 2003). Experimental evidence in support of EBV having 
oncogenic potential is derived from its ability to infect and transform normal 
human B-cells in vitro resulting in indefinitely proliferating lymphoblastoid cell 
lines (LCLs) (Henle et al., 1967).   
 
1.2.3 EBV in vitro and in vivo infection 
EBV preferentially infects B lymphocytes, inducing growth transformation. EBV 
infection of B-cells in vivo has been well characterised. It uses the normal biology 
of B-cells to gain access to and persist within memory B-cells for the lifetime of 
the host (Thorley-Lawson, 2005). Complement receptor type 2 (CR2/CD21) is 
essential for the attachment of EBV to the surface of B-cells in an interaction 
mediated by the viral envelope glycoprotein gp350 (Nemerow et al., 1987; Young 
et al., 2007). 
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Although EBV infection of B-cells is well documented, infection of epithelial cells 
remains poorly understood in vitro. The epithelial cell environment appears to be 
unfavourable to the establishment of EBV stable infection. The resistance of  
epithelial cells to EBV infection in vitro has been associated with the absence of EBV 
receptors, CD21 (Shapiro & Volsky, 1983; Fingeroth et al., 1999), since epithelial 
cells overexpressing introduced CD21 can be efficiently infected by EBV (Li et al., 
1992; Knox et al., 1996). In addition, the observation that only epithelial cells 
impaired in their ability to differentiate appear to be capable of sustaining a stable 
EBV infection suggests that EBV infection is related to the differentiation status of 
the epithelial cells (Knox et al., 1996), an association that has also been observed in 
vivo (Young et al., 1991).  
 
In spite of the inefficiency of EBV infection of epithelial cells in vitro, early studies 
have observed EBV replication in epithelial cells in vivo. However, later work with 
more sensitive EBV detection techniques frequently failed to detect EBV in a variety 
of normal epithelial tissues (Niedobitek et al., 1989; Karajannis et al., 1997; 
Niedobitek et al., 2000), including nasopharyngeal epithelial cells (Sam et al., 1993), 
suggesting that EBV infection of normal epithelial cells is not a common event.  
 
Successful infection of human epithelial cells by EBV in vitro was achieved by cell-
to-cell contact between epithelial cells and EBV-producing B-cells (e.g. from the BL 
cell line, Akata) without any additional manipulations such as introduction of the 
known EBV receptor (CD21) gene or addition of polymeric immunoglobulin A 
against viral gp350 in culture (Imai et al., 1998; Shannon-Lowe et al., 2006). This 
raises the possibility that EBV’s ability to infect epithelial tissues such as 
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nasopharyngeal epithelium in vivo might be due to the close proximity of lytically 
infected B-cells that have the ability to produce virus and release it into saliva. 
 
1.2.4 The structure and variation of the EBV genome 
The EBV genome is composed of linear double stranded DNA, approximately 172 
kilobase (kb) pairs in length with a coding potential for more than 85 genes. The 
genome contains a series of 500bp terminal direct repeats (TRs) and internal repeat 
sequences (IRs), which divide the EBV genome into short and long, largely unique 
sequence domains. The B95.8 strain of EBV was the first human herpesvirus to have 
its genome completely cloned and sequenced (Baer et al., 1984). The structure of the 
EBV genome and its latent genes are represented in Figure 1.1.  
 
EBV is divided into two subtypes, EBV type 1 (EBV1) and EBV type 2 (EBV2), 
based on sequence variation in a subset of the EBNA genes including EBNA2, 
EBNA3A, EBNA3B, and EBNA3C (Dambaugh et al., 1984; Sample et al., 1990). 
EBV1 and EBV2 are also dramatically different in their geographical distribution. 
Although both types are widespread in equatorial Africa and Papua New Guinea 
(Young et al., 1987), EBV1 is the predominant subtype in Caucasian and Asian 
populations including those showing a high frequency of NPC (Chang et al., 2009).  
 
Increasing development in molecular technology allows the identification of EBV 
strain variation in a wider range of loci. In particular, polymorphisms within LMP1 
have been investigated extensively and the variations have been described in 
numerous EBV-associated tumours. There are six major variants of LMP1: Alaska, 
China 1, China 2, China 3, North Carolina, and Mediterranean, classified according to  
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Figure 1.1: The Epstein–Barr virus genome. 
(a) Electron micrograph of the EBV virion.  
(b) Diagram showing the location and transcription of the EBV latent genes on the 
double-stranded viral DNA episome.  
(c) Location of open reading frames for the EBV latent proteins on the BamHI 
restriction-endonuclease map of the prototype B95.8 genome.  
 
Figure reproduced from: Lawrence S. Young & Alan B. Rickinson 
Epstein–Barr virus: 40 years on 
Nature Reviews Cancer 4: 757-768 (2004) 
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the geographical region from which the initial isolate was derived. A combined data 
analysis of 187 Asian LMP1 variants suggests that the China 1 LMP1 variant is the 
prevalent strain and is present in approximately 85% of the population in this area. In 
China 1 LMP1, two common polymorphisms have been reported containing a specific 
30bp deletion in the C-terminus domain and loss of an XhoI restriction site in the N-
terminus (Sung et al., 1998; Saechan et al., 2006; Nagamine et al., 2007). The 30bp 
deletion of LMP1 was found in a higher frequency of Asian NPC patients compared 
to healthy controls (Miller et al., 1994; Edwards et al., 1999). In addition, this 
variation had a significantly higher frequency in advanced NPC patients (stage III and 
IV), suggesting a link with development and progression of this malignancy 
(Tiwawech et al., 2008).  
 
1.2.5 EBV lytic replication and latency states 
Following EBV infection, cells display either a productive lytic infection or a latent 
infection. Lytic replication results in production of EBV virions by performing 
multiple rounds of replication. Whereas in latent infection, the virus does not replicate 
and produce virions but replicates along with the host DNA as an extrachromosomal 
episome. The host cells carrying the viral genome constitutively express a limited set 
of viral gene products called latent genes (see Figure 1.1). Three major patterns of 
EBV latent gene expression have been classified so far, and they are associated with 
particular human diseases (Young & Rickinson, 2004).  
  
Latency III infection is found in LCLs and PTLD. All the viral latent genes are 
expressed in latency III: six nuclear antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, 
EBNA3C and EBNA-LP), three latent membrane proteins (LMP1, LMP2A and 
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LMP2B), two non-polyadenylated RNAs (EBER1 and EBER2), the BamHI-A 
rightward transcripts (BARTs) and viral miRNAs (Young & Rickinson, 2004). 
 
Latency II is found in NPC, Hodgkin’s and T- and NK- lymphomas and is  
characterised by a more restricted pattern with the expression of only one of the 
nuclear antigens (EBNA1), all three latent membrane proteins, the EBERs and the 
BARTs (Brooks et al., 1992).  
 
Type I latency is associated with BL and is characterised by the expression of only 
EBNA1, the EBERs and BARTs (Rowe et al., 1987). Some reports have documented 
expression of LMP1 and EBNA2 in a small proportion of cells in a few cases of 
endemic BL (Niedobitek et al., 1995).   
 
1.2.6 The functions of EBV genes in NPC tumourigenesis  
As mentioned in the previous section, EBV is consistently detected in NPC as a 
latency II infection. Functional studies have shown that viral latent genes have 
substantial functions in the regulation of cellular gene expression, alteration of cell 
phenotype, cell growth and differentiation, thereby leading to a highly invasive and 
malignant tumour. The potential contributions of the individual viral genes to the 
development of NPC are summarised in the following.     
 
1.2.6.1 LMP1 
LMP1 is the first EBV latent gene found to have oncogenic potential to transform 
established rodent cell lines and alter phenotypes of both lymphoid and epithelial cells 
(Wang et al., 1985; Martin et al., 1993). It is variably present in NPC and has also 
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been detected in preinvasive lesions of the nasopharynx (Pathmanathan et al., 1995). 
Early studies in NPC biopsies using RT-PCR revealed that LMP1 transcripts are 
expressed in greater than 80% of NPC samples (Brooks et al., 1992) whilst 
immunohistochemical staining data from different studies have shown LMP1 protein 
to be variably expressed in the range of 20% – 70% of NPC biopsies (Horikawa et al., 
2001; Sarac et al., 2001; Shao et al., 2004; Burgos, 2005; Li et al., 2007; Chen et al., 
2010). However, when a more sensitive antibody was used, all NPC biopsies 
displayed positive LMP1 staining despite a variable proportion of positive tumour 
cells. In addition, a high frequency of LMP1 expression is closely associated with the 
juvenile form of NPC (Khabir et al., 2005). Although the significance of 
heterogeneous expression of LMP1 protein in NPC has not been addressed, along 
with patient age it might be partly due to the sensitivity of the method used for 
detection. 
 
LMP1 is involved in the regulation of several signalling pathways in NPC including 
the NF-κB, PI3K/Akt, MAPK, and JAK/STAT pathways (Tsao et al., 2002; Zheng et 
al., 2007), thereby modulating a number of target genes involved in a wide range of 
cellular functions including apoptosis, proliferation, differentiation, invasiveness and 
metastasis, all of which are important for the development and progression of NPC. 
 
LMP1 may exert its function in apoptosis by upregulating anti-apoptotic genes e.g. 
Survivin, TNFAIP3 and BCL-2 (Laherty et al., 1992; Deng et al., 2003; Faqing et al., 
2005). However, a correlation between TNFAIP3, BCL-2 upregulation and LMP 
expression has not been demonstrated (Codd et al., 1999; Murono et al., 1999).  
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LMP1 regulates the cell cycle progression of NPC tumour cells either by increasing 
the kinase activity of the CDK4/Cyclin D1 complex or decreasing the activity of 
p16/p21 (Deng et al., 2003; Ai et al., 2005). LMP1 is also a key modulator in the 
differentiation process. Although the mechanisms by which LMP1 prevents epithelial 
cell terminal differentiation have not been fully addressed, it appears to be due, at 
least in part, to changes in the surface phenotype and differentiation responsiveness 
(Dawson et al., 1990; Zheng et al., 1994). 
 
Transformation by LMP1 results in alterations in cell phenotypes. One of the 
alterations is reduction of cell-to-cell interactions, which facilitates invasiveness and 
metastasis of tumour cells. Loss of E-cadherin expression has been frequently 
observed in NPC and is closely associated with metastasis and poor prognosis (Zheng 
et al., 1999). LMP1 is considered to be responsible for the reduction and switch of E-
cadherin expression in NPC (Tsai et al., 2002; Shair et al., 2009). LMP1 upregulates 
the expression of the matrix metalloproteinases (MMPs) MMP1, MMP3 and MMP9 
in NPC, and their upregulations are correlated with invasiveness and metastasis 
(Horikawa et al., 2000; Lu et al., 2003b; Lee et al., 2007). Extensive growth of 
tumour cells also requires angiogenesis for nutrient supplement and metabolic waste 
trafficking. LMP1 induces expression of potent angiogenesis regulators, COX-2, 
VEGF, and receptor for advanced glycation end products (RAGE), contributing to 
tumour cell metastasis (Murono et al., 2001; Fendri et al., 2008; Tsuji et al., 2008). 
However, in contrast with these observations, a study in North African NPCs shows 
that there is no relationship between LMP1 expression and metastatic behaviour 
(Khabir et al., 2005), whilst in addition, an earlier study reported that LMP1-negative 
NPC tumours appear to have an increased tendency to recur and metastasise (Hu et al., 
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1995). The molecular basis for these discrepancies is poorly understood and more 
studies are required to uncover the complexity of LMP1 functions in NPC.         
 
1.2.6.2 LMP2A and LMP2B 
Although the roles of LMP2A and LMP2B have been investigated mainly in B-cells 
(Longnecker, 2000), they have both been shown to alter epithelial cell behaviour such 
as adhesion and motility (Allen et al., 2005). In agreement with this study, LMP2A-
expressing epithelial cells have been observed to become more migratory and 
invasive (Pegtel et al., 2005). LMP2A also has transforming properties in epithelial 
cells, and this is possibly mediated by activation of the PI3K/Akt pathway. LMP2A-
expressing cells are more tumourigenic and the tumours show poorer differentiation 
and higher proliferation than LMP2A-negative controls (Scholle et al., 2000).  
 
In vivo studies indicate that LMP2A and LMP2B are consistently associated with 
NPC and might contribute to its pathogenesis. A serological study demonstrated that 
antibody responses to LMP2A and LMP2B were present in sera of more than 95% 
NPC patients (Lennette et al., 1995). This finding supports earlier observations that 
LMP2A and -2B transcripts were consistently expressed in NPC (Brooks et al., 1992; 
Busson et al., 1992). More recent work reveals that LMP2A protein is expressed in 
approximately 50% of NPC tumours (Heussinger et al., 2004) and that a high level of 
LMP2A expression correlates with poor prognosis (Pegtel et al., 2005).  
 
1.2.6.3 EBNA1 and EBERs   
EBNA1 is consistently expressed in all EBV-associated malignancies including NPC.  
It has been suggested to have oncogenic potential in NPC in an early study (Brooks et 
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al., 1992). Further in vitro studies reveal that EBNA1-expressing NPC cells are able 
to form more metastatic, less differentiated tumours when inoculated into mice 
compared to their negative counterparts (Sheu et al., 1996). Recent studies 
demonstrate that EBNA1 is a potent cellular transcriptional regulator in NPC cancer 
cells as it modulates TGF-β, NF-κB and AP-1 signalling pathways (Wood et al., 2007; 
O'Neil et al., 2008; Valentine et al., 2010).  
 
In addition to EBNA1, two small non-coding RNAs, EBERs 1 and 2 are ubiquitously 
expressed in all EBV-associated tumours including NPC. EBERs are the most 
abundant viral transcripts in NPC tumour cells, and a recent study reveals that the 
expression of EBERs can be regulated by EBNA1 (Owen et al., 2010). The EBERs 
have been shown, by in situ hybridisation to be present in nearly all NPC tumour cells, 
but generally absent in the adjacent normal tissue or in only a few scattered lymphoid 
cells. Thus, they have been frequently used as target molecules for detection of EBV 
infection and for diagnosis of NPC (Wu et al., 1991; Murono et al., 1997). In addition, 
it has been shown that abundant expression of EBERs is essential to induce the initial 
transformation of epithelial cells. Thus they might make an important contribution to 
the oncogenesis of NPC (Yoshizaki et al., 2007). 
 
1.2.7 In vitro and in vivo model systems of NPC  
To investigate NPC tumourigenesis and its metastatic potential, it is important to use 
EBV-positive NPC cell models since NPC is consistently associated with EBV 
infection. However, the establishment of NPC cell lines is difficult due to limited 
tissue quantity and contamination by other cell types. Moreover, as was mentioned in 
previous sections, EBV infection of epithelial cells is much less efficient than that of 
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B-cells because epithelial cells, including NPC cells, express no or only low levels of 
the CR2 receptor. Therefore, although there are several NPC cell lines that have been 
established, most of them either do not harbour EBV or have lost it during long-term 
culture (Gullo et al., 2008). The single exception is the C666-1 cell line, which is a 
subclone of its parental cell line, C666, established from an NPC xenograft of a 
southern Chinese patient with undifferentiated NPC. This cell line consistently 
maintains EBV in long term culture. The expression pattern of EBV genes in C666-1 
is latency type П, as in authentic NPC tumours (Cheung et al., 1999). In addition to 
the C666-1 cell line, the successful establishment and characterisation of EBV-
positive NPC xenografts (e.g. C15, C17, xeno-666, xeno-2117 and xeno-1915) also 
provide good vehicles for investigation of NPC. They have been extensively used for 
identifying the genetic alterations and delineating aberrant signal transduction 
pathways in NPC (Busson et al., 1988; Huang et al., 1989; Wong et al., 2003a; 
Friboulet et al., 2008). 
 
1.3 Cancer genetics 
 
Cancer, which develops from single somatic cells and their progeny, is essentially a 
somatic genetic disease arising from the accumulation of a series of genetic changes 
at different chromosomal loci that lead to changes in gene activity, and so to altered 
cell phenotypes. Eventually, a cell population that evolves to be capable of escaping 
the normal controls in proliferation and territory can become a cancer (Ponder, 2001).  
 
1.3.1 Somatic genetic changes in cancer 
Genetic changes can be caused by genomic instability, which is a cardinal feature of 
almost all cancer cells and are usually a result of defects of the DNA repair system 
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that are either inherited from germinal cells and/or acquired in somatic cells during 
tumour development. The types of genetic aberrations in somatic cells underlying 
cancer include point mutations in coding or regulatory sequences, changes in whole 
chromosomes, high level chromosomal amplification, smaller regions of 
chromosomal loss/gain, loss of heterozygosity (LOH) and uniparental disomy (UPD) 
(Balmain et al., 2003).  
 
Of these genetic alterations, LOH is defined as when both alleles of a chromosomal 
pair are heterozygous originally and they have become homozygous or hemizygous. 
This usually represents the loss of normal function of one allele of a gene by mutation 
in which the other allele was already inactivated (Presneau et al., 2003). LOH 
represents a key step in the inactivation of multiple tumour suppressor genes. UPD 
arises when an individual inherits both copies of a chromosome pair from one parent 
(either maternal or paternal), whereas no copy of this  chromosome comes from the 
other parent (Engel, 1980). Acquired UPD can be considered to be one form of LOH 
or called copy neutral LOH. A UPD region is typically larger than 2Mb and includes 
only copy-number-neutral changes. UPD, especially acquired whole chromosomal 
UPD, can occur in somatic cells and is usually associated with cancer (Tuna et al., 
2009).  
 
1.3.2 Hallmarks of cancer 
Genetic abnormalities will increase and involve more and more chromosomal regions 
following the progression of cancer and lead to further alterations in cell physiology. 
Six essential alterations to cell physiology that succeed genetic changes and 
collectively dictate malignant growth were summarised by Hanahan and Weinberg 
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and termed ‘Hallmarks of Cancer’ (Hanahan & Weinberg, 2000). They are self-
sufficiency in growth signals, insensitivity to anti-growth signals, evasion of apoptosis, 
limitless replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis. These altered cells are subjected to selection, and eventually only a cell 
population that manifests all the six characteristics can develop into cancer.        
 
1.3.3 Tumour suppressor genes (TSGs) and oncogenes 
To achieve and sustain these hallmarks, a number of genes that affect tumour cell 
behaviour are involved in this process. According to whether they activate or inhibit 
cellular proliferation, these cancer genes can be divided into two main groups, 
oncogenes or TSGs, respectively. 
 
An oncogene is defined as a gene that contributes to the production of cancer by 
activating cellular proliferation, leading to unregulated cell growth and differentiation 
(Ponder, 2001). Oncogenes are generally mutated forms of proto-oncogenes that are 
functionally involved in the control of normal cellular growth and differentiation. 
Oncogenes are usually inappropriately activated by “gain-of-function mutations”. The 
mechanism of oncogene activation has been associated with chromosomal 
amplification which could result in increased expression or activity of related genes 
(Mitelman et al., 1997).    
 
Tumour suppressor genes are also normal cellular genes with the function of 
inhibiting cellular proliferation, and they are usually inactivated by ‘loss of function’ 
mutations in cancer development (Weinberg, 1991). In 1971, Knudson proposed a 
“two hit” hypothesis of carcinogenesis based on an epidemiological investigation of 
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retinoblastoma (Knudson, 1971). The hypothesis suggests that cancer is caused by 
two mutational events. In the dominantly hereditary cancer, mutation in one of the 
two copies of a TSG is inherited from the germinal cells and mutation of the second 
copy of the gene occurs in somatic cells; whereas in the non-hereditary cases, both 
events occurring in a somatic cell are needed for it to develop into a tumour clone. 
This indicates that tumour-suppressor genes are inactivated either when a germline 
mutation occurs in one allele or somatic inactivation at a later stage occurs in the 
other allele or when sequential somatic inactivation of both alleles occurs. TSGs have 
been frequently detected at the DNA level in regions of chromosomal loss, especially 
regions with LOH (Solomon et al., 1991). 
 
1.3.4 Identifying chromosomal abnormalities and cancer-related genes in 
tumours 
The ability to examine genetic aberrations that develop during the progression of 
cancer is increasing rapidly, owing to advanced molecular techniques, powerful 
analytical tools and the almost-complete genome sequence information. The regions 
of chromosomal loss, gain, and LOH give clues to the locations of abnormal genes 
involved in carcinogenesis.   
 
In earlier genetic studies, karyotyping was used to calculate chromosome numbers, 
and to detect large chromosomal alterations such as rearrangements and deletions. In 
karyotyping chromosomes of cancer, tumour cells are grown in tissue culture, spread 
on glass slides and stained after cells have been arrested in metaphase by adding the 
drug colchicine. The chromosomes of these cells then can be photographed and 
analysed. To detect much smaller chromosomal abnormalities, other more sensitive 
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techniques have been used, such as fluorescence in situ hybridisation (FISH) and 
comparative genomic hybridisation (CGH). FISH uses a labelled specific segment of 
chromosome to hybridise with the chromosomal DNA of a tumour cell and is 
visualised under a fluorescence microscope. This technique allows a rapid detection 
of one gene or one specific region of chromosomal abnormality (deletion or gain) 
(Trask, 1991).  
 
CGH is capable of detecting and mapping DNA copy-number variation across a 
whole genome. With CGH, tumour DNA and normal reference DNA are labelled with 
two different fluorescent markers and then hybridised simultaneously to normal 
chromosome spreads. Copy number changes in a tumour are determined by the 
comparison of the fluorescence ratios along the length of chromosomes. Multiple 
regions of chromosomal abnormalities can be detected by this technique (Kallioniemi 
et al., 1992). More recently, the advanced CGH technique, array-based CGH (aCGH) 
that has high resolution and allows more accurate localisation of specific genetic 
alterations by hybridising with arrayed genomic DNA or cDNA clones on a genome-
wide level, has been widely used to survey copy number aberrations in cancer 
(Kallioniemi, 2008).  
 
Another method of screening for small areas of chromosomal imbalance is to use 
microsatellites (short tandem repeat sequences) as markers to do allelic imbalance 
analysis (Naidoo & Chetty, 1998). In this technique if one of the heterozygous 
markers (multiple repeats) becomes homozygous (a single repeat) in the tumour, this 
suggests that an allele has been lost, and this type of chromosomal abnormality is 
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determined as LOH. The alleles can also be gained in the case of chromosomal 
duplications. 
 
1.3.5 Single nucleotide polymorphism microarrays (SNP arrays) 
The techniques mentioned above have several limitations in detecting genetic 
abnormalities. Firstly, the resolution is limited. Although array-based CGH has highly 
increased resolution compared to the others, it is still limited by the number of clones 
that can be deposited on the arrays. Secondly, these techniques require large amounts 
of starting material. In addition, they cannot simultaneously detect copy number 
aberrations and LOH status. Recently developed SNP arrays provide a high-resolution 
platform for simultaneously detecting several types of genetic changes in cancer at the 
level of the individual allele, which allows more insight into the mechanism of 
tumourigenesis and is a more successful strategy for mapping TSGs and oncogenes 
(Dutt & Beroukhim, 2007; Kloth et al., 2007; Lin et al., 2008).  
 
A SNP is defined as a single base polymorphism when the frequency of the minor 
allele exceeds 1% in at least one population; otherwise it is considered a variant or 
mutation (Botstein & Risch, 2003). The principle of detecting genetic changes by 
SNP array analysis is based on the correlation between alleles at nearby sites, 
predicting chromosome abnormalities on a genome-wide scale by using a smaller 
number of representative SNPs as markers (Gabriel et al., 2002). 
 
The two major technologies of SNP arrays involve oligonucleotide probes either 
spotted on gene chips (Affymetrix) or adsorbed on beads (Illumina). Advances in 
Affymetrix SNP arrays in recent years have enabled rapid increases in the number of 
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SNPs (from 10K, 50K, 100K, 500K to commercially available 900K SNPs across the 
genome) that can be genotyped in parallel in a single experiment (Dutt & Beroukhim, 
2007; McCarroll et al., 2008). Taking advantage of the high resolution, SNP arrays 
have been widely used for combination analyses of genetic copy number changes and 
genetyping in a number of cancers and made great progress in exploring the 
mechanisms of cancer development and progression (Kloth et al., 2007; Purdie et al., 
2007; Chen & Chen, 2008; Gardina et al., 2008; Gunnarsson et al., 2008). 
 
1.4 NPC genetics  
 
Like all other cancers, NPC is a genetic disease. During the development and 
progression of NPC, multiple acquired genetic aberrations (e.g. chromosomal loss, 
gain or LOH) are accumulated along with the effects of environmental factors, EBV 
infection as well as some inherited genetic susceptibilities, all acting together. These 
genetic abnormalities are often considered to be related to altered gene function, for 
example, activation of oncogenes is associated with amplification and inactivation of 
TSGs is correlated with homozygous deletion or LOH. The altered gene function is 
essential for NPC carcinogenesis by driving the progressive transformation of normal 
nasopharyngeal cells into highly malignant directions. Determining the genetic 
changes in NPC, therefore, can identify a number of TGSs and oncogenes that are 
involved in disruption of normal cellular mechanisms and multiple cellular signalling 
pathways. In addition, this could reveal the molecular basis of NPC pathogenesis and 
find biomarkers for early diagnosis and prediction of prognosis. Such findings could 
also provide insights for better planning of strategies of prevention and treatment for 
this disease.  
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1.4.1 Somatic genetic aberration in NPC 
Since the late 1980s, cytogenetic studies such as karyotyping were firstly explored to 
detect genetic alterations in NPC. By karyotype analyses of EBV-positive NPC 
xenografts and cell lines, recurrent structural abnormalities on chromosomes 1, 3p, 
11q, 12 and 17 were identified. Especially, deletions of 3p were consistently observed 
(Huang et al., 1989; Bernheim et al., 1993; Wong et al., 2003a). However, the studies 
using karyotyping are limited due to the difficulty of culturing primary NPC tumour 
cells in vitro. Subsequently, CGH has been widely used for examination of 
chromosome losses or gains in a large number of primary NPC biopsies and has 
provided invaluable information. These studies have demonstrated a high incidence of 
multiple chromosome changes in NPC. Consistent findings include frequent deletions 
on chromosomes 1p, 3p, 9p, 9q, 11q, 13q, 14q and 16q and frequent gains on 
chromosomes 1q, 3q, 8q and 12. The most frequent chromosomal regions of loss or 
gain observed are 3p and 12 (Chen et al., 1999; Hui et al., 1999; Fang et al., 2001). 
The delineation of the minimal overlapping regions of genetic changes provides 
important hints for the identification of potential oncogenes and/or TSGs in NPC. In 
recent years, the higher resolution of array-based CGH has been used to detect genetic 
abnormalities on a genome-wide level in NPC. In addition to previously characterised 
regions, several novel minimal regions of chromosomal gains (3q27.3-28, 8q21-24, 
11q13.1-13.3, and 12q13) have been identified in 26 NPC biopsies with array-based 
CGH analysis, with oncogene cyclin D1 (CCND1) at 11q13.3 verified to be amplified 
and overexpressed in NPC (Hui et al., 2005). Furthermore, several consistent small 
regions of amplification as well as novel potential oncogenes in NPC have been 
identified in other aCGH studies, for example, amplifications of MYCL1 in 1p34.3, 
TERC and PIK3CA at 3q26.3, and LTβR at 12p13.3 (Hui et al., 2002b; Or et al., 
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2010). In a comparison with findings from Asian NPC patients, one study using 
conventional CGH and aCGH demonstrates that Mediterranean NPCs have higher 
frequencies of gains at 1q and losses at 13q (Rodriguez et al., 2005).   
 
A meta analysis of a combination of 12 CGH studies in a total of 188 NPC cases from 
southern Asia also reveals hot spots for chromosomal gains in more than 20% of cases 
at 1q, 3q, 8q and 12, and chromosome losses on 3p, 11q, 14q and 16q (Li et al., 
2006c). A tree model analysis from 4 studies suggests that the loss of 3p and gain of 
12q might be important early events (Shih-Hsin Wu, 2006). A recent study in 
Taiwanese NPC patients using aCGH demonstrates that amplification of GPR160 and 
SKIL at 3q26.2-q26.32, and deletion of TSGs ADAMTS9 and LRIG1 at 3p12.3-p14.2 
have significance in predicting prognosis of NPC (Sheu et al., 2009).  
 
LOH, the somatic conversion of heterozygous germline alleles to homozygosity, is a 
critical event in the inactivation of multiple TSGs. Traditional study of LOH with 
highly informative polymorphic markers is the most common approach for the 
analysis of allelic imbalance in NPC. This technique can detect small regions of 
chromosomal changes that are usually overlooked by CGH analyses. Using 
microsatellite polymorphic markers, the most frequent allelic losses were found on 
chromosomes 3p, 9p, 11q and 14q (Huang et al., 1991; Hu et al., 1996; Hui et al., 
1996; Deng et al., 1998; Mutirangura et al., 1998; Shao et al., 2001). Additional 
studies of normal nasopharyngeal epithelia, dysplastic lesions and NPC cases from a 
high-risk population (Southern Chinese) and a low-risk population (central/northern 
Chinese and/or Caucasians from Toronto) reveal precancerous lesions and NPC cases 
from both populations have a high incidence of LOH on chromosome 3p and 9p, 
whereas normal nasopharyngeal epithelia from the high-risk region show a 
Chapter 1                                                                                                      Introduction 
 
29 
 
significantly higher incidence of  3p and 9p LOH than do those from the low-risk 
region (Chan et al., 2000; Chan et al., 2002). This indicates that LOH of 3p and 9p are 
early events in NPC development. In addition, the increased risk of NPC in Southern 
Chinese may be related to the high incidence of these early events occurring in the 
normal nasopharyngeal epithelium. 
 
1.4.2 NPC-related genes 
Recurrent chromosomal regions of loss or gain are generally considered to be 
associated with inactivation of TSGs or activation of oncogenes. To identify these 
NPC-related genes and elucidate the mechanisms of NPC tumourigenesis, particular 
interest has been put on the genes located within the critical and commonly involved 
regions of loss or gain.  
 
1.4.2.1 Chromosome loss and TSGs 
Chromosome 3p 
Allelic loss of chromosome 3p is the most frequent genetic change in NPC, with an 
incidence of greater than 90% in all primary NPC patients from Southern China 
(Chan et al., 2000; Lo et al., 2000a). In particular, LOH studies have identified 
multiple tumour suppressor loci including 3p13-14.3, 3p21 and 3p21-25 (Huang et al., 
1991; Hu et al., 1996; Deng et al., 1998; Chan et al., 2000).  
 
3p21.3 is believed to be the region harbouring the most potential TSGs since a high 
incidence of deletion at 3p21.3 has been consistently observed (Huang et al., 1991; 
Hu et al., 1996; Cheng et al., 1998; Chan et al., 2000). Several well-established TSGs 
have been identified in this region, including RASSF1 and ZMYND10. RASSF1 has 
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been shown to function as an effector to mediate apoptosis and inhibit cell cycle 
progression (Vos et al., 2000; Shivakumar et al., 2002). Downregulation of RASSF1 
has been associated with both the development and progression of NPC (Peng et al., 
2003). A more recent study reveals a possible role for EBV in this process, since 
LMP1 suppresses RASSF1 expression (Man et al., 2007). Restoration of RASSF1 
expression in a RASSF1 deficient NPC cell line, C666-1, inhibited cell growth in 
vitro and reduced tumourigenesis in vivo. This provides functional evidence for 
RASSF1 as a target tumour suppressor gene (Chow et al., 2004). ZMYND10, also 
known as BLU, is a candidate 3p21.3 TSG located upstream of RASSF1. It is an E2F-
regulated, stress-responsive gene whose transcripts are ubiquitously expressed in 
normal nasopharyngeal epithelia but frequently absent or reduced in NPC cell lines 
and biopsies (Liu et al., 2003; Qiu et al., 2004; Ayadi et al., 2008). Functional studies 
demonstrate that stable expression of ZMYND10 suppresses tumour formation in vivo 
(Yau et al., 2006).  
 
There are several other potential TSGs identified at 3p21.3 such as LTF 
(lactotransferrin) and LFLARS2 (leucyl-tRNA synthetase 2, mitochondrial) or close 
to 3p21.3 such as DLEC1 (deleted in lung or esophageal cancer 1) and MLH1 (MutL 
homologue 1, colon cancer, nonpolyposis type 2) at 3p22.3, RARB (Retinoic acid 
receptor, beta) at 3p24, which have been shown to be inactivated in NPC and might 
contribute to carcinogenesis (Wong et al., 2003b; Yi et al., 2006; Kwong et al., 2007; 
Zhou et al., 2009). In addition to the above loci, 3p14.2 is another potential TSG locus 
on 3p with candidate TSG FHIT (fragile histidine triad protein) involvement (Sung et 
al., 2000). Mutation, LOH and abnormal expression of FHIT have been observed in 
NPC tumours (Deng et al., 2001; Ko et al., 2002). A recent publication reveals that 
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LOH and abnormal expression of FHIT in NPC are correlated with advanced clinical 
stage and higher titres of EBV capsid antigen (EBVCA-IgA) (Deng et al., 2010).  
Although these observations suggest that FHIT might play an important role in NPC 
tumourigenesis, functional evidence for its tumour suppressor effect is still lacking. 
 
Chromosome 9p   
In addition to 3p, 9p is another region showing high frequency of loss in NPC (Huang 
et al., 1994; Mutirangura et al., 1998; Lo et al., 2000a). LOH analyses have 
delineated an overlapping tumour suppressor locus at 9p21-22 in which two CDK 
inhibitors, p16 (CDKN2A) and p15 (CDKN2B) are involved and considered to be 
candidate TSGs in NPC (Huang et al., 1994; Lo et al., 1995). P16 and p15 inhibit cell 
cycle progression from G1 to S phase, and inactivation of these two genes will result 
in uncontrolled cell proliferation. Loss of expression of p16 protein has been 
frequently detected in NPC tumours and is associated with NPC development, local 
recurrence and prognosis (Baba et al., 2001; Hwang et al., 2002; Makitie et al., 2003; 
Lin et al., 2006a). The observation that deletion of p16 during the establishment of 
immortalisation of nasopharyngeal epithelial cells suggests that it might have a 
critical function in the malignant transformation of nasopharyngeal epithelial cells (Li 
et al., 2006a). Restoration of p16 expression in NPC cells significantly inhibited cell 
growth and tumourigenicity (Wang et al., 1999).  
 
Chromosome 11q 
Loss of 11q is also a frequent event in NPC, and LOH studies delineated two distinct 
regions of deletion, 11q13.3-22 and 11q22-24 (Hui et al., 1996; Lo et al., 2000a; Fang 
et al., 2001). Several potential TSGs have been identified in these two regions 
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including GSTP1 (11q13), TSLC1 (11q23.2), THY1 (11q23.3) and ATM (11q22-23) 
(Cheng et al., 2002; Hui et al., 2002a; Lo & Huang, 2002; Tao & Chan, 2007). 
TSLC1 (also called CADM1) that was firstly reported to be a TSG in human non-
small cell lung cancer plays a role as a cell adhesion molecule and exerts its TSG 
function by altering cell-cell interactions and controlling growth. Loss of TSLC1 
expression has been observed in NPC and this is associated with lymph node 
metastasis (Hui et al., 2003; Lung et al., 2004). Restoration of TSLC1 expression 
inhibits cell growth and suppresses tumour formation in NPC cell lines by arresting 
cells in G1 phase (Lung et al., 2006). A more recently identified TSG, THY1, has 
been found to have a very similar tumour suppressor function to TSLC1 in NPC 
tumour cells (Lung et al., 2005; Lung et al., 2008; Lung et al., 2009). 
 
Although ATM has long been postulated to be a TSG in NPC, a recent investigation 
provides new evidence supporting its tumour suppressor function. In this study, 
downregulation of ATM expression has been observed at the both mRNA and protein 
levels in NPC tumour biopsies. In addition, in NPC cell lines, ATM expression was 
reduced only in the EBV-positive NPC cell line, C666-1, but not in five EBV-
negative cell lines, indicating its association with EBV-infection (Bose et al., 2009).          
   
Chromosomes 13q, 14q and 16q 
Two distinct, smaller regions of deletion at 13q14.3-22 and 13q31-34 were delineated 
by LOH studies. Mapping of the critical regions of these loci suggests that some 
candidate TSGs might be involved (Tsang et al., 1999; Lo et al., 2000a; Shao et al., 
2002). Of the genes encoded in these regions, EDNRB located at 13q22 has been 
shown to be downregulated in NPC tumour cells, an effect that has been speculated to 
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be associated with the high frequency of promoter hypermethylation in NPC (Lo et al., 
2002; Zhou et al., 2007).  
 
Allelic loss at 14q is a very common event in NPC, and it has been observed in more 
than 80% of NPC tumours (Mutirangura et al., 1998; Shao et al., 2002). Although the 
monochromosome transfer technique supports the growth suppressive activity of 14q, 
especially two critical regions, 14q11.2-13.1 and 14q32.1, the TSGs involved in this 
region have been poorly understood so far (Cheng et al., 2003). 
 
LOH of 16q has been detected in greater than half of NPC cases, and high resolution 
allelotyping of microdissected primary NPC samples has mapped the deletion to a 
minimal region of 16q22-23 (Lo et al., 2000a; Fang et al., 2001). CDH1 (also called 
E-cadherin) is the only known candidate TSG involved in this minimal region. This 
gene encodes a cell adhesion molecule whose loss of function is thought to contribute 
to cancer progression by increasing proliferation, invasion, and/or metastasis. 
Downregulation of CDH1 expression has been consistently observed in NPC tumours 
and that is associated with NPC progression and prognosis (Zheng et al., 1999; Huang 
et al., 2001; Li et al., 2004; Xie et al., 2010). Potential TSGs involved in other regions 
of 16q have also been identified including BRD7 (16q12) and RBL2 (16q12.2). The 
observation that BRD7 expression was reduced in NPC biopsies and cell lines 
suggests its tumour suppressor potential, while the finding that BRD7 can inhibit NPC 
cell growth through negatively regulating β-catenin and ERK1/2 pathways provides 
further functional evidence (Peng et al., 2007).  
 
 
Chapter 1                                                                                                      Introduction 
 
34 
 
1.4.2.2 Chromosomal gain and oncogenes 
In previous CGH studies, recurrent gains in NPC tumours have been frequently 
detected on chromosomes 1q, 3q, 8q 12p and 12q (Hui et al., 1999), whereas the 
putative oncogenes involved are still poorly understood. Later high-resolution array-
based CGH studies and FISH analysis delineated the minimal regions of gain (e.g. 
3q27.3-28, 8q21-24, 11q13.1-13.3, and 12q13) and recognised several NPC-related 
oncogenes (e.g. CCND1, PIK3CA and LTβR) (Hui et al., 2002b; Hui et al., 2005; Or 
et al., 2005; Or et al., 2010). 
 
Chromosome 3q 
Gain of 3q is one of the most frequent genetic events occurring in NPC. The candidate 
oncogenes identified so far are found at 3q26-28, including PIK3CA (3q26.3), TERC 
(3q26), EVI1 (3q26.2) and TP73L (3q28) (Hui et al., 2002b; Or et al., 2005; Tao & 
Chan, 2007). PIK3CA encodes the catalytic subunit of PI3Ks that regulate signalling 
pathways involved in cell proliferation, motility, and adhesion. A high frequency of 
amplification and overexpression of PIK3CA in NPC tumours has been observed. 
PIK3CA amplification has been associated with aggressive progression and poor 
prognosis of Tunisian NPC patients (Fendri et al., 2009). TP73L (also called p63) 
includes wild-type p63 and mutated p63 (DeltaN-p63), and the latter is the oncogenic 
form. DeltaN-p63 is invariably expressed in NPC tumours, and its expression is 
associated with the differentiation status of NPC (Guo et al., 2006). The oncogenic 
function of DeltaN-p63 in NPC can be accomplished by blocking p53-mediated 
transactivation and apoptosis (Crook et al., 2000).  
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Chromosomes 8q and 11q13 
Frequent gains have also been found at 8q. However, the potential oncogenes 
involved in this region are not fully understood. Only the well-known oncogene, c-
myc (8q24.2), was found to have high copy number gains and be overexpressed in 
NPC (Fan et al., 2000). Although chromosome 11q is frequently deleted in NPC,  
gain of a small portion of 11q (11q13.1-13.3) was observed in more than 60% of NPC 
tumours (Hui et al., 2005). Of the genes encoded in this region, CCND1 and FGF3 
are considered to be candidate oncogenes (Fan et al., 2000; Hui et al., 2005). CCND1 
(cyclin D1) interacts with cyclin dependent kinases CDK4 and CDK6 whose activity 
is required for cell cycle G1/S transition resulting in DNA synthesis. Amplification 
and overexpression of this gene have been frequently observed in NPC tumours. 
Silencing of CCND1 expression in NPC cell lines by using interfering RNA 
significantly decreased cell proliferation, suggesting an oncogenic function of this 
gene in NPC cells (Hui et al., 2005). 
 
Chromosome 12q13 
12q has been considered to be another most frequent chromosomal gain in NPC. (Or 
et al., 2005; Or et al., 2010). FISH mapping delineated the amplicon to a 1.24 Mb 
region at 12q13.3 in which 13 genes were involved. Among these genes, LTβR 
(lymphotoxin beta receptor) is the only one consistently overexpressed in both NPC 
xenografts and primary tumours (Or et al., 2010). This gene is a member of the 
tumour necrosis factor (TNF) family of receptors, modulating activation of the NF-κB 
signalling pathway. Overexpression of LTβR results in increased NF-κB activity and 
cell proliferation in nasopharyngeal epithelial cells, whereas knockdown of LTβR 
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inhibits tumour growth. This suggests LTβR might be a potential oncogene 
facilitating NPC tumour growth (Or et al., 2010).  
 
In addition to the potential oncogenes introduced above, several other genes such as 
BCL2 at 18q21.3 (Chen et al., 2008; Fendri et al., 2010), EGFR at 7p12.1 (Hui et al., 
2002b), TNFAIP3 (A20) at 6q23 (Codd et al., 1999), BIRC3 at 11q22 (Friboulet et al., 
2008), MET at 7q31 (Horikawa et al., 2001; Qian et al., 2002), BMI1 at 10p11(Song 
et al., 2006; Qin et al., 2008), that are either involved in other regions of gain or have 
been shown to have oncogenic potential in carcinogenesis, have also been considered 
to be candidate NPC-associated oncogenes.  
Genetic changes and TSGs/oncogenes in NPC have been reviewed (Lo & Huang, 
2002; Tao & Chan, 2007; Lo, 2008). 
 
1.4.3 Abnormal cellular signals in proliferation and apoptosis 
Genetic analyses in NPC have identified a number of chromosomal abnormalities as 
well as TSGs/oncogenes that contribute to carcinogenesis. It is inevitable that for the 
NPC-associated genes already mapped, the emphasis will shift from genetics to 
functional analysis. In common with other cancers, the development of NPC can be 
considered as a disruption in normal cellular proliferation and apoptosis. The critical 
signals resulting in uncontrolled proliferation or abnormal apoptosis contribute to 
NPC tumourigenesis. 
 
A number of cellular signals can affect cell proliferation including those genes 
involved in cell cycle progression such as CDKN2A (p16) and cyclin D1. The cell 
cycle progression is regulated by cyclin-CDK complexes, and their activity is 
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regulated by binding with CDK inhibitors. Cyclin D1 is one of the most important 
cyclins and is required for cell cycle progression from G1 to S phase. Normal cyclin 
D1 activity can be regulated by p16 (CDK4 inhibitor). Therefore, a balance between 
p16 and cyclin D1 expression is important for maintaining a normal cell cycle 
progression. However, frequent loss of p16 expression and overexpression of cyclin 
D1 in NPC tumours disrupt the balance of p16/cyclin D1 and lead to uncontrolled 
DNA synthesis (Zhang et al., 2009). C-myc is another cell cycle-related gene that 
interferes with regulators of G1/S transition (de Nigris et al., 2003). Downregulation 
of c-myc expression can cause a significant arrest of NPC cells in S phase and disturb 
cell proliferation (Liu et al., 2009). In addition, a recent publication suggests that 
DeltaNp63 is also involved in the regulation of cell cycle progression in NPC. 
Silencing DeltaNp63 expression results in cell cycle arrest in G1 phase, which is 
probably achieved by upregulation of p27 and p57 (Chiang et al., 2009). Loss of 
function of TSLC1 and THY1 in NPC are critical proliferative signals since 
overexpression of these two genes in NPC cell lines can result in G1 arrest and inhibit 
proliferation (Lung et al., 2006; Lung et al., 2009). 
  
Critical signals for inhibition of apoptosis are also involved in NPC development. 
BCL-2 is believed to play an essential role in regulation of apoptosis. Overexpression 
of BCL-2 has been consistently detected in NPC tumours (Sheu et al., 1997) and is 
associated with poor prognosis of patients (Chen et al., 2009). An induction of cell 
apoptosis or a regression of tumour growth can be achieved in NPC tumours by 
blocking the antiapoptotic function of BCL-2 by a BCL-2 family inhibitor or 
antisense oligonucleotides. Especially, a significant effect has been observed in those 
NPC cells with high expression of BCL-2 (Yip et al., 2005; Hu et al., 2008b). 
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TNFAIP3 is also a protein that protects cancer cells from apoptosis. TNFAIP3 
expression can be induced by LMP1, and stable expression of TNFAIP3 in epithelial 
cells blocks p53-mediated apoptosis (Fries et al., 1996). TNFAIP3 expression has 
been shown to be upregulated in NPC. Another antiapoptotic protein, BIRC3, that has 
been shown to be amplified and overexpressed in several cancers, was recently found 
also to be overexpressed in NPC biopsies and xenografts. In addition, using an 
inhibitor of BIRC3 results in degradation of this gene product, induces apoptosis and 
blocks clonal cell growth in NPC cells (Lu et al., 1993; Codd et al., 1999; Friboulet et 
al., 2008).  
 
1.4.4 Dysregulation of signalling pathways 
In addition to the dysfunction of TSGs and oncogenes, multiple, aberrant signalling 
pathways can also play essential roles in carcinogenesis. These include the NF-кB, 
Wnt/β-catenin, and TGF-β signalling pathways. 
 
1.4.4.1 The NF-кB signalling pathway 
Dysregulation of NF-кB signalling is one of the most important components for NPC 
tumourigenesis as almost all NPC tumours show overexpression of NF-кB signalling 
cascades (Lo et al., 2006). The NF-кB signalling is activated by LMP1, and then 
results in activation of a number of antiapoptotic and proliferative signals, including 
BCL-2, COX-2, and VEGF (Murono et al., 2001). It also induces the accumulation of 
p53 protein and upregulates its transactivity, disturbing cell cycle progression (Deng 
et al., 2003). Furthermore, NF-кB modulates the activity of telomerase and results in 
cell immortalisation by binding with human telomerase reverse transcriptase (hTERT) 
(Ding et al., 2005).  
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1.4.4.2 The TGF-β signalling pathway 
The TGF-β superfamily constitutes a large number of growth and differentiation 
factors which include TGF-β, activin/inhibins, nodal and bone morphogenic proteins 
(BMPs). These proteins mobilise complex signalling networks to regulate cellular 
differentiation, proliferation, motility, adhesion and apoptosis. The deregulation of 
various components of this pathway plays a critical role in the progression of several 
types of cancer (Moses & Serra, 1996; Massague, 1998).  
 
The process of intracellular signal transduction from membrane-bound receptors into 
the nucleus is straightforward and quite similar between TGF-β superfamily members. 
The TGF-β ligands bind to transmembrane kinase type ІІ receptor and phosphorylat e 
type І receptors. The activated type І receptors then phosphorylate and activate 
specific intracellular mediators, SMAD proteins, which are direct substrates with the 
demonstrated ability to mediate gene responses to TGF-β signalling. The activated 
SMAD signalling results in nuclear translocation and activation of substrate genes 
(Massague & Chen, 2000) (Figure 1.2). In vertebrates, the SMAD proteins are 
classified into three functional groups: 1) receptor activated SMADs, which include 
SMAD1, 2, 3, 5 and 8; 2) the co-mediator SMAD, SMAD4; and 3) inhibitory SMADs, 
SMAD6 and 7 (Heldin et al., 1997). The type І receptors for TGF-β, activin and 
Nodal, utilise receptor SMADs 2 and 3, whereas BMP receptors utilise SMAD1, 5 
and 8. Once phosphorylated, receptor SMADs associate with the co-activator SMAD4 
to form active SMAD complexes, which in turn translocate into the nucleus and 
activate transcriptional responses (Abdollah et al., 1997; Heldin et al., 1997). TGF-β, 
activins and BMPs can induce the expression of inhibitors SMAD6 and SMAD7 
which act as a negative-feedback loop to dampen TGFβ-mediated SMAD  
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Figure 1.2: The transforming growth factor beta (TGF-β) signalling pathway. 
 
TGF-β binds to the type П receptor (TGFBR2) and phosphorylates the type І receptor 
(TGFBR1), which then phosphorylates SMAD2 or SMAD3. Activated SMAD2 or 
SMAD3 associates with SMAD4 and they translocate into the nucleus where they 
modulate transcription of a number of target genes. SMAD7 inhibits TGF-β signalling 
by preventing the activation of SMAD2 or SMAD3 by TGFBR1. 
 
Figure reproduced from: Rebecca L. Elliott and Gerard C. Blobe 
Role of Transforming Growth Factor Beta in Human Cancer.  
J Cli Oncol 23: 2078-2093 (2005) 
. 
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transcription. The inhibitor SMADs bind to TGF-β family member receptors and 
inhibit the activation of receptor SMADs by these receptors (Nakao et al., 1997). 
Normally, SMAD6 selectively inhibits BMP signalling, whereas SMAD7 mainly 
suppresses TGF-β and activin signalling (Nakao et al., 1997; Hata et al., 1998). 
Besides SMAD-mediated transcription, TGF-β also activates SMAD-independent 
signalling cascades, including MAPK, Rho-like GTPases, PI3K and PP2A signalling 
pathways, and induces various cellular functions (Derynck et al., 2001). 
   
TGF-β can function as a tumour suppressor during the early stages of cancer and a 
tumour promoter during the more advanced stages of tumour progression. Thus, TGF-
β can either stimulate or inhibit cell proliferation depending on the cell type or the 
underlying genetic or epigenetic changes present within the cell (Hartsough & Mulder, 
1997). TGF-β acts as a potent growth inhibitor for many tumour types of epithelial 
origin, a property that underscores its tumour suppressor function (Yue & Mulder, 
2001; Marinari et al., 2008). Although the precise mechanism for this growth 
inhibitory effect remains elusive, the ability of TGF-β to inhibit growth through cell 
cycle G1/S arrest by inducing the expression of cyclin kinase inhibitors p15(Ink4b), 
p21(Cip1) and p27(Kip1) has been well-established (Hannon & Beach, 1994; Zhang 
et al., 2002; Nakamura et al., 2009). The increased expression of cyclin kinase 
inhibitors block phosphorylation of the retinoblastoma protein by cyclin and cyclin-
dependent kinases, allowing hypophosphorylated Rb protein binding to transcription 
factor E2F or directly suppressing c-myc (Laiho et al., 1990; Li et al., 1997). The 
growth inhibitory effects of TGF-β are mediated primarily through TGF-β -mediated 
SMADs activation. Mutations in either TGF-β receptors or downstream components 
such as SMADs can result in loss of responsiveness to TGF-β signalling, thereby 
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blocking the growth inhibitory effect of TGF-β on cancer cell growth (Markowitz & 
Roberts, 1996; Forrester et al., 2005; Biswas et al., 2008). For example, in one study, 
restoration of TGFBR2 expression in an RІІ-deficient cancer cell line reduced its 
tumourigenic potential (Wang et al., 1995). Another convincing line of evidence 
supporting the tumour suppressor function of TGF-β signalling is that overexpression 
of TGF-β1 can suppress mammary tumour formation (Pierce et al., 1995). 
 
The loss of TGF-β receptor or SMAD function accounts for only a relatively small 
proportion of cases in which tumour cells become resistant to TGF-β mediated growth 
inhibition. More often, loss of TGF-β growth-inhibitory responsiveness in cancer cells 
occurs following changes in cellular phenotype and the surrounding 
microenvironment. At some point during the development and progression of 
malignancies, TGF-β switches to stimulate the proliferation of a number of epithelial-
derived cancer cells acting as a tumour promoting factor by building a positive 
environment for tumour cell growth and survival. For example, TGF-β can enhance 
tumourigenesis by stimulating the proliferation of mesenchymal cells, increasing 
ECM (extracellular matrix ) production and accelerating migration (Ellenrieder et al., 
2001; Zavadil & Bottinger, 2005). Advanced human tumours often become resistant 
to TGF-β induced growth inhibition and even secrete elevated levels of TGF-β 
(Derynck et al., 2001). A study in a model of breast cancer cell lines further 
demonstrated that TGF-β switch ed  from tu mou r su p p ressor in the early stag e to  a 
tumour promoter in the late stage of cancer (Tang et al., 2003).  
 
Aberrant expression of TGF-β signalling has been observed by microarray analysis of 
NPC (Sriuranpong et al., 2004; Zeng et al., 2007).  Earlier studies revealed that NPC 
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patients had significantly higher TGF-β1 levels in serum than did controls. Moreover, 
the elevated TGF-β1 was closely associated with advanced stage, recurrence and 
survival of NPC patients (Xu et al., 1999). Although the function of TGF-β signalling 
in NPC carcinogenesis still remains to be elucidated, this finding suggests it might act 
as a tumour promoter contributing to development and progression of NPC. Further 
studies are required to understand better its role in NPC. 
 
1.4.4.3 The Wnt signalling pathway 
The Wnt signalling pathway has a central role in embryogenesis and in adult tissue 
homeostasis (Logan & Nusse, 2004; Clevers, 2006). Wnt signalling can be subdivided 
into the canonical Wnt/β-catenin and the non-canonical Wnt signalling pathway. Non-
canonical Wnt pathways transduce Wnt signalling either to the RhoA and JNK 
pathway or to the Ca2+
 
-releasing pathway involving diverse functions such as 
cochlear hair cell morphology, heart induction, tissue separation, as well as 
independent roles in both development and tumourigenesis in vertebrates by binding 
to Frizzled (FZD) receptors (Veeman et al., 2003). The canonical Wnt pathway is the 
best understood Wnt pathway, given its frequent deregulation in epithelial cancers. 
The canonical Wnt ligands, such as WNT3A, regulate the stability of the transcription 
cofactor β-catenin which co-operates with Tcf/Lef transcription factors to regulate 
expression of a wide range of target genes such as CCND2 and MYC. Abnormal 
activation of the Wnt/β-catenin signalling pathway is associated with a number of 
human diseases including various types of human cancer (Giles et al., 2003). As the 
general outline of the Wnt/β-catenin signalling pathway has been established, we will 
focus on this pathway in the following.   
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Wnt signalling is initiated by binding with two distinct cell surface receptors and 
inducing a ligand-receptor complex formation. The first receptor is a member of the 
FZD group of proteins, which are seven-span transmembrane receptors, and the 
second is the low-density-lipoprotein receptor-related proteins (LRP)-5 and -6. The 
interaction of WNTs with FZD receptors can be modulated by a number of secreted 
factors, which act as antagonists by binding either to Wnts or LRP receptors. 
Dickkopf (DKK) is one of the secreted proteins structurally distinct from WNTs, 
which can block Wnt signalling by binding with LRP6 receptor (Mao et al., 2001). In 
the absence of antagonists, WNT ligand binding to receptors results in 
hyperphosphorylation of Dishevilled (DVL), which inhibits the activity of GSK3β 
and recruits AXIN to the plasma membrane. GSK3β substrates are generally 
functionally inhibited by the activation of GSK3β, as is the case for one of its 
substrates, β-catenin (CTNNB1). β-catenin undergoes ubiquitination and degradation 
after phosphorylation by GSK3β (Clevers, 2006). The β-catenin degradation complex 
consists of GSK3β, AXIN and Adenomatous polyposis coli (APC). AXIN and APC 
form a structural scaffold that allows GSK3β to phosphorylate β-catenin in the 
absence of Wnt signalling. When Wnt signalling is present, GSK3β is phosphorylated, 
inhibiting β-catenin phosphorylation and its subsequent degradation. Thus, the 
stabilised β-catenin accumulates in the nucleus and complexes with the DNA binding 
transcription factors (TCF/LEF) to enhance the expression of a specific subset of 
genes in determining cell fate and proliferation (Giles et al., 2003; Huang & He, 
2008).  
 
More recent gene expression profiling demonstrates that expression of several central 
components engaged in the Wnt pathway are abnormally regulated, such as 
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upregulation of WNT5A, FZD7 and downregulation of AXIN2, indicating that 
dysregulation of the Wnt signalling pathway might be a key event in NPC 
tumourigenesis (Sriuranpong et al., 2004; Zeng et al., 2007). This has also been 
supported by the observation of constitutive activation of Wnt signalling and silencing 
of WIF-1 (Wnt inhibitory factor-1) in NPC cell lines (Lin et al., 2006b). Although the 
Wnt pathway is involved in a wide range of biological functions including directing 
cell proliferation, the function of its constitutive activation in NPC tumourigenesis is 
still poorly understood. Therefore, a greater understanding of this pathway in NPC is 
likely to contribute to NPC diagnosis, treatment and prognosis.  
 
1.5 A possible model for NPC pathogenesis 
 
The development and progression of NPC is a multi-step process and may take a long 
time. Although the molecular basis is still unclear, environmental factors (e.g. intake 
of preserved food, exposure to various carcinogens), EBV infection and genetic 
susceptibility are believed to be three major contributors. To understand the process 
of NPC tumourigenesis, particular focus has been put on early lesions of the 
nasopharynx. As inflammation and infection are very common in the upper 
respiratory tract, mild dysplasia can usually be detected in normal nasopharyngeal 
tissue. This is a reversible lesion whereas precancerous lesions such as severe 
dysplasia and carcinoma in situ are irreversible changes. The precancerous lesions are 
rarely detected in routine examination of nasopharyngeal biopsies. This may be due to 
the fact that the process of transition from precancerous lesions to an NPC appears to 
be quick, probably as a result of the contributions of various tumour-promoting 
factors (e.g. some genetic changes, EBV infection as well as continuous 
environmental carcinogens).  
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Despite limited investigations from early events of NPC, genetic changes and EBV 
infection in precancerous lesions have been documented in several studies (e.g. 
deletions of 3p and 9p, overexpression of BCL-2, and activation of telomerase). LOH 
analyses in normal nasopharyngeal epithelia, dysplastic lesions and NPC cases from 
endemic and non-endemic areas reveal that a high frequency of LOH of 3p and 9p 
occurs not only in precancerous lesions and NPC cases but also in normal 
nasopharyngeal epithelia, suggesting that LOH of 3p and 9p are early events in NPC 
development. The observation that normal epithelial cells from high-risk regions 
show significantly higher incidence of 3p and 9p LOH than those from low-risk 
regions indicates that exposure to specific environmental factors in endemic areas 
may contribute to these genetic changes (Chan et al., 2000; Chan et al., 2002). The 
loss of 3p and 9p is closely associated with loss of function of RASSF1 and CDKN2A 
which will disturb cell cycle progression and result in unlimited cell proliferation. The 
findings that EBV infection is present in early high-grade dysplastic lesions or 
carcinoma in situ of the nasopharynx but absent either in normal nasopharynx or in 
low-grade dysplasia, suggest that EBV infection may be important for driving the 
malignant transformation of nasopharyngeal epithelial cells (Pathmanathan et al., 
1995). Expression of latent EBV genes such as LMP1, LMP2A and EBNA1 will lead 
to  abnormal regulation of a number of signalling pathways, for example, the NFκB, 
and the TGFβ p athways that are in volved  in  reg u lation of cell ap op tosis and 
proliferation. Oncogene activation including BCL-2 overexpression and telomerase 
activation has also been observed in a high proportion of dysplastic lesions, 
suggesting that their functions in antiapoptosis and cell immortalisation occur from 
the early stages and contribute to NPC development (Sheu et al., 1997).  
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Following these genetic alterations and EBV infection in precancerous lesions of the 
nasopharynx, multiple genetic changes are accumulated in the later stage of NPC 
development, such as deletions of 11q, 13q, 14q and 16q, and gains of 3q, 8q and 12q. 
These genetic aberrations are correlated with more TSG inactivation and oncogene 
activation (e.g. inactivation of THY1, ATM, TSLC1 and E-cadherin, and activation of 
Cyclin D1 , PIK3 CA and  LTβR) that will eith er sp eed u p NPC d evelopment o r 
contribute to NPC invasiveness and metastasis. A possible model for NPC 
pathogenesis has been proposed and is represented in Figure 1.3. 
 
1.6 Aims and objectives 
NPC tumour cells carry a number of genetic abnormalities and exhibit expression 
changes in a wide variety of cellular genes as well as components of signalling 
pathways. Therefore, identification of these aberrations is critical for understanding 
the molecular basis of this disease. The aim of this study was to examine 
chromosomal aberrations using SNP array analysis, and to characterise cellular gene 
expression patterns using expression microarray analysis in NPC tumours. For doing 
this, frozen samples from 21 NPC biopsies and 4 normal epithelia, alongside the NPC 
cell line C666-1 were used. The DNA copy number and expression analyses were 
carried out in the same 13 NPC samples, thus, it is possible to assess the relationship 
between gene expression level and DNA copy number in the same sample set. The 
validation of array data was undertaken by using standard techniques such as q-PCR, 
RT-PCR and immunohistochemistry staining analysis.       
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Figure 1.3: A possible model for NPC pathogenesis.  
A possible model of NPC pathogenesis is proposed in the above scheme. Loss of 
heterozygosity (LOH) of 3p and 9p occurs early in the pathogenesis of NPC, possibly as a 
result of exposure to environmental cofactors. This leads to low-grade preinvasive lesions 
that, after additional genetic and epigenetic events become susceptible to EBV infection. 
Many more genetic changes are then accumulated, which act together with environmental 
and EBV cofactors, resulting in development and progression of NPC.    
Figure reproduced from: Lawrence S. Young & Alan B. Rickinson 
Epstein–Barr virus: 40 years on 
Nature Reviews Cancer 4: 757-768 (2004) 
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The C666-1 cell line is the only line used in the array analysis. The gene expression 
pattern in C666-1 cells and in authentic NPC tumour samples can be analysed and 
compared. This would allow us to assess whether the C666-1 cell line is a good model 
to represent authentic NPC. It was hoped that the information obtained from array 
analysis would allow us to develop in vitro model systems for more detailed 
functional investigations of NPC pathogenesis.  
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CHAPTER 2 
Materials and Methods 
2.1 Microarray analysis 
2.1.1 Sample preparation 
2.1.1.1 Frozen tissue collection and selection 
In all instances, local ethical rules applicable at the site and date of collection were 
followed. The work was approved by South Birmingham Research Ethics Committee, 
reference numbers H1207/95 and 06/Q2702/50. 
The snap frozen biopsies diagnosed as NPC (undifferentiated, non-keratinising 
carcinoma) were obtained from the Associated Hospitals of Guangdong Medical 
College, Zhanjiang, China; Queen Mary Hospital, Hong Kong; Institut Gustave 
Roussy, Villejuif, France and Oran Hospital, Algeria. The biopsies were frozen 
immediately in liquid nitrogen with or without optimal cutting temperature compound 
(OCT) after isolation from patients. All the samples had concurrent formalin fixed 
material which was used and retained by local pathologists for diagnosis. Samples 
were transported on dry ice and stored in liquid nitrogen until used. A total of 21 
frozen samples were used for array analysis. 17 samples that showed good quality of 
morphology and well-defined islands of tumour cells with minimal numbers of 
infiltrating lymphocytes were selected as tumour samples for array analysis. 4 
biopsies were used as normal controls for expression array analysis, among them, 3 
were chosen from the transported frozen samples that had sufficient areas of normal 
epithelium but without showing any tumour tissues. Another normal control was 
derived from tonsil tissue that contained an extensive region of stratified squamous 
epithelium. Except for gender and ethnic origin, no further patient or case information 
was available. One NPC cell line, C666-1, and 12 tumour biopsies were used for both 
Chapter 2                                                                                     Materials and Methods 
51 
 
SNP array and expression array analysis, 2 tumour samples were used only for SNP 
array analysis, and 7 biopsies (3 tumours and 4 normals) were used only for 
expression array analysis. The EBV status of tumour biopsies was determined by PCR 
using BamHI-specific primers (Section 2.2.4). The biopsies and their information are 
listed in Table 2.1. 
 
Table 2.1: Frozen biopsies used for array analysis 
 
Designation Definition Origin Patient Ethnicity Gender EBV Status 
XY5 T Guangdong  Cantonese M + 
XY6 T Guangdong  Cantonese F + 
XY8 T Guangdong  Cantonese M + 
XY23 T Guangdong Cantonese M + 
125855 T Hong Kong  Cantonese F + 
173570 T Hong Kong Cantonese M + 
68(8) T Hong Kong Cantonese M + 
MDIG T France Italian M + 
MKAV T France Italian M + 
MKEC T France Maghreb M + 
MMAH T France Maghreb F - 
MOUZ T Algeria Algerian F + 
      
DNA only      
XY16 T Guangdong Cantonese M + 
235326 T Hong Kong Cantonese F + 
      
RNA only      
400(3) T Hong Kong Cantonese M ND 
YH7  T Guangdong Cantonese F ND 
YH8  T Guangdong Cantonese M ND 
MSTA  N Algeria Algerian U ND 
MBEZ  N Algeria Algerian U ND 
MHAU N France Italian M ND 
T3 N UK UK U ND 
 
“DNA only” indicates that only SNP array data were obtained from these biopsies 
whilst “RNA only” signifies that only expression array data were obtained. T = 
tumour; N = normal; U = unknown; ND = not determined. 
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2.1.1.2 Cutting and staining for cryosections 
Before being cut, the frozen biopsies transported from liquid nitrogen were kept 
within the cryotome at -20ºC for approximately 5 minutes, and then fixed in OCT 
(Tissue-Tek). 8 micron cryosections were cut using a cryotome (CM1900, Leica) and 
placed onto PALM membrane slides (P.A.L.M. Microlaser Technologies). The 
sections were then air dried on ice for about 1 minute followed by H&E 
(haematoxylin and eosin) staining. Briefly, the slides were immersed in ice-cold 75% 
ethanol for 2 minutes, tapped dry and stained with ice-cold haematoxylin and eosin 
(9:1) containing 1% NucleoGuard (AmpTec, Hamburg) for 30 seconds. Excess stain 
was tapped off and the slides were washed in ice-cold nuclease-free water for about 
30 seconds, 75% ice-cold ethanol for 1 minute and then 100% ice-cold ethanol for 1 
minute. The slides were air dried and kept on ice for microdissection immediately. 
 
2.1.1.3  Laser microdissection and pressure catapulting (LMPC) 
LMPC was performed using a PALM Microlaser system (PALM, Microlaser 
Technology, Bernried, Germany) containing a PALM MicroBeam instrument. 
Different areas of cells of interest were selected and caught on PALM Adhesive Caps. 
A minimum of 200,000 µm2 (mostly between 300,000 to 500,000 µm2
 
) of cells was 
obtained for each RNA and DNA extraction, and the purity of target tumour or 
normal cells collected by PALM was more than 90% in all cases. Immediately, after 
LMPC, the collected cells in the PALM tubes were processed for RNA extraction and 
the cells for DNA extraction were kept at -20 ºC until required.  
 
 
Chapter 2                                                                                     Materials and Methods 
53 
 
2.1.1.4 Total RNA preparation for expression array 
RNA extraction and purification  
The RNA from LMPC samples was extracted by using the RNeasy Mini kit (Qiagen) 
supplemented with N-carrier and NucleoGuard (AmpTec). 100µl of RLT buffer 
(Qiagen) supplemented with 1µl of N-carrier and 1 µl of NucleoGuard (AmpTec) 
were placed into each LMPC tube. The tubes were closed with adhesive caps 
containing LMPC samples, then inverted and incubated at room temperature for 15 
minutes. Subsequently, the extracted RNA was cleaned up using a Qiagen RNeasy 
mini kit with on-column DNase treatment according to the manufacturer’s 
instructions. 100 µl of column-eluted RNA were then collected by ethanol 
precipitation. 2 µl P-carrier (AmpTec), 10 µl of 3M sodium acetate and 220 µl of 
ethanol were added and mixed well. The RNA suspension was stored at - 20ºC until 
used. When required for the next experiment, the RNA suspension was spun in a 
microcentrifuge for 15 minutes at 13,000 rpm, and the pellet was washed twice with 
80% ethanol, then air dried and dissolved in 12 µl of RNase-free water. The purified 
RNA was used immediately in the next process.  
Total RNA extraction from C666-1 cells was as described in Section 2.2.1 and 
cleaned up as above.  
 
RNA amplification and labelling 
The purified RNA was then subjected to three rounds of mRNA amplification, 
followed by biotin labelling using an ExpressArt TR mRNA amplification Nano kit 
(AmpTec) and an Affymetrix IVT labelling kit. This experiment was performed by Dr. 
John Arrand and the detailed process was as described in the manufacturer’s manuals.  
2.1.1.5 Genomic DNA preparation for SNP array 
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DNA extraction from LMPC samples 
The LMPC cells on PALM adhesive caps were suspended in 100 µl of lysis buffer (10 
µl proteinase K (>600 mAU/ml), 50 µl 10% Tween 20, 440 µl TE buffer (10 mM 
Tris-HCl, 1 mM EDTA, pH 8). The tubes were inverted, sealed with Parafilm and 
incubated at 55 ºC for 3 hours, followed by shaking vigorously to resuspend any 
material still sticking to the caps. The samples were briefly spun and incubated at 
95ºC for 5 minutes. After adding 4 µl of glycogen (20mg/ml) and 10 µl 3M sodium 
acetate (pH 5.5), the solution was transferred into a new 1.5 ml eppendorf tube, and 
then 250 µl of ethanol were added to precipitate the DNA. Subsequently, the samples 
were mixed well and incubated at room temperature for 2 minutes then centrifuged at 
room temperature for 15 minutes at 13,000rpm. The sample was washed with 200 µl 
of 70% ethanol and spun at 13,000rpm for 5 minutes at room temperature, then air 
dried.  
DNA extraction from C666-1 cells was performed by Dr. John Arrand as described 
previously (Arrand et al., 1983).           
 
DNA amplification 
The air dried DNA was subjected to DNA amplification using a Genomiphi V2 DNA 
amplification kit (GE Healthcare). Following the manufacturer’s protocol, for 
multiple samples a master mix for each of the following steps was prepared. For each 
reaction, the air dried DNA was resuspended in the mixture of 1 µl of DEPC water 
and 9 µl sample buffer and incubated at 95 ºC for 3 minutes then cooled down to 4 ºC 
quickly. In the meantime, a 10 µl amplification reaction was prepared on ice with 9 µl 
of reaction buffer and 1 µl of enzyme mix. The cooled sample was added to 10 µl of 
the above reaction mix and incubated at 30ºC for 1.5 hours for amplification. This 
Chapter 2                                                                                     Materials and Methods 
55 
 
was followed by enzyme inactivation by heating to 65 ºC for 10 minutes then cooling 
to 4ºC. The amplified DNA was precipitated by adding 20 µl water, 4 µl of a solution 
containing 1.5 M sodium acetate and 250mM EDTA, and 100 µl ethanol. DNA was 
recovered by centrifugation for 15 minutes at full speed using a microcentrifuge. The 
pellet was washed with 500 µl ethanol, centrifuged for 5 minutes at full speed, air 
dried and dissolved in 20 µl reduced TE buffer (10mM Tris, 0.1mM EDTA, pH 8.0). 
The final solution was stored at 4 ºC until used. 
 
DNA quantity and quality control             
The quantity of amplified DNA was measured using a Nanodrop 1000 
spectrophotometer (Thermo Scientific). A minimum of 3 µg of DNA was obtained 
after amplification. Ratios (OD260/OD280
 
) for all the amplified samples were between 
1.8 – 1.9. The size of amplified DNA was checked by electrophoresis on a 0.8 % 
agarose gel. All cases showed a large proportion of DNA larger than the resolving 
capability of the gel, indicating that this material was greater than 2 kb in length.  
2.1.2 500K SNP array protocol 
 
2 x 250 ng of amplified DNA was used for the Mapping 500K SNP array experiment. 
The mapping 500K system consists of two 250K arrays (Nsp and Sty) that was 
provided by Affymetrix. All the reagents and protocols used in the 500K SNP array 
experiment were recommended by the manufacturer. A brief description is given in 
the following. 
 
For each reaction, 5 µl of diluted DNA (50ng/µl) was added into a master mix 
containing either NspІ or StyІ enzyme and incubated at 37 ºC for 2 hours then 65 ºC 
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for 20 minutes. The adaptor-primer NspІ / StyІ was then ligated to the digested DNA 
samples at 16 ºC for 3 hours, 70 ºC for 20 minutes. The ligated DNA was diluted and 
subjected to PCR amplification. The PCR conditions were optimised preferentially to 
amplify fragments in the range of 200 bp to 1,100 bp.  For quality control, the PCR 
products were run on a 2% agarose gel. The product was purified and concentrated 
using a vacuum cleanup plate then quantified on a Nanodrop spectrophotometer. 90µg 
of each product was then fragmented by adding fragmentation reagent, incubated at 
37 ºC for 35 minutes and 95 ºC for 15 minutes. The fragmented products were 
checked on a 4 % agarose gel to ensure that the size was less than 200 base pairs. The 
fragmented samples were then labelled using DNA labelling reagent. The labelled 
samples were stored at – 20 ºC until used.                  
 
2.1.3 Hybridisation to Affymetrix Arrays 
 
The biotinylated RNA was fragmented and hybridised to Affymetrix Human Genome 
U133Plus2 Arrays containing nearly 33,000 substantiated human genes according to 
the Affymetrix protocol (Affymetrix, 2004, GeneChip Expression Analysis Technical 
Manual). The labelled DNA from C666-1 and LMPC samples was hybridised onto 
the Mapping 500K Arrays according to the Affymetrix protocol (Affymetrix, 2006, 
GeneChip Mapping 500K Assay Manual). 
 
All arrays were washed and stained on an Affymetrix FS450 fluidics station then 
scanned using an Affymetrix GeneChip 3000 7G scanner as described in Affymetrix 
procedures. GCOS software (Affymetrix) was used for instrument control and data 
acquisition. All the steps described above can be found on the Affymetrix web 
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site http://www.affymetrix.com. The procedure of hybridisation to Affymetrix Arrays 
was performed by Ms Sim Sihota. 
 
2.1.4 Microarray data analysis 
 
SNP array data were processed by using GTYPE 4.1 (Affymetrix), analysed by both 
copy number analysis tool v4 (CNAT v4) and genotyping console v2.1 with default 
settings. An unpaired analysis was used for calculation of copy number. The reference 
samples used in the analysis were data from 40 healthy female controls with mixed 
origins (23 Chinese, 10 Japanese and 7 Utah residents of Central European descent) 
that were downloaded from the HapMap project (http:// 
www.hapmap.org/downloads/index.html.en). The physical position of all SNPs on the 
arrays was mapped according to the Human Genome (Build 35, hg17). 
 
Expression array data were normalised and processed to give expression values using 
the “log scale robust multi-array analysis” (RMA) protocol (Irizarry et al., 2003) 
within the “Affy” package of Bioconductor (http://www.bioconductor.org).  
Statistical analysis for significance and fold-change was performed using Rank 
Products (RP) analyses  with percentage of false positives set to less than 10% 
(Breitling et al., 2004). Data were also analysed using GCOS (Affymetrix) at the 
default settings except that the target signal was set to 100. Gene expression heatmaps 
were generated from the data obtained from the RP analysis using dChip software (Li 
& Wong, 2001). A sample correlation heatmap was generated with the “heatmap” 
function of R (http://www.r-project.org) using complete linkage clustering and 1-r 
(Pearson correlation) as the measure of dissimilarities. The expression array analyses 
were performed by Dr. Wenbin Wei. 
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2.2 Molecular biology techniques 
 
2.2.1 RNA extraction 
Cells were grown in 75cm2 tissue culture flasks to approximately 80-90% confluence. 
Total RNA was extracted using Trizol Reagent (Invitrogen, UK), and the 
manufacturer’s instructions were slightly modified. Briefly, monolayers of cells were 
lysed by the addition of 7.5ml Trizol reagent and the lysates were scraped and 
transferred to a 15ml polypropylene screw cap tube (Sarstedt, Germany). Samples 
were fully homogenised by shaking vigorously for 2 minutes. 1.5ml of chloroform 
were added, shaken for 2 minutes, and then centrifuged for 30 minutes, 4 oC at 3,000 
rpm. The aqueous phase was transferred to a fresh 15ml polypropylene screw cap tube, 
and an equal volume of isopropanol was subsequently added, mixed by inversion and 
incubated at room temperature for 10 minutes to precipitate RNA. The pellet was 
obtained by centrifugation for 30 minutes, 4oC at 3,000 rpm. The supernatant was 
carefully removed and the pellet was washed in 75% ethanol overnight at -20oC.  The 
following day, the sample was centrifuged for 10 minutes, 4o
RNA concentration was determined using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific) and samples diluted to 1µg/µl using DEPC treated water. RNA 
was stored at -80°C ready for use. 
C at 3,000 rpm, the 
ethanol was removed and the pellet was air dried for 5-10 minutes then resuspended 
in 200µl DEPC treated water.  
 
 
2.2.2 cDNA synthesis 
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cDNA was synthesised using Superscript II reverse transcriptase (Invitrogen, UK). 
For each reverse transcription reaction, 1µg of RNA, 0.5µl of 3µg/µl random primers 
and DEPC treated water to a final volume of 11µl were added to a PCR tube and 
incubated at 70°C for 5 minutes to denature any dsRNA, and then cooled to 25°C. 
Meanwhile, master mixes were prepared by adding (per reaction) 4µl of 5x first 
strand buffer, 2 µl of 0.1M DTT, 1µl of RNase inhibitor, 1µl of dNTP mix and 1 µl of 
Superscript II. 9 µl of the above mix were added to each preheated tube and mixed 
well. The cDNA synthesis was then carried out in a thermal cycler using the 
programme: 25°C for 10 minutes, 42°C for 1 hour, 90°C for 5 minutes and then hold 
at 4°C. 
 
2.2.3 Reverse Transcriptase-polymerase chain reaction (RT-PCR) 
RT-PCR was performed in a 50 µl reaction mix consisting of 1µl cDNA, 1µl 100pM 
forward primer, 1µl 100pM reverse primer, 25µl 2x GoTaq Green Master Mix 
(Promega) and 22µl DEPC treated water. The GoTaq master mix contains Taq 
polymerase, PCR buffer, 400µM dNTP mix, 3mM MgCl2
 
 and DNA loading dye. 
PCR conditions were: an initial denaturation at 94 °C for 5 minutes, 35 cycles of 
amplification at 94 °C for 1 minute, annealing for 40 seconds (variable temperature 
for different primer sets) and 72 °C for 1 minute, a final extension at 72°C for 10 
minutes. The products of RT-PCR were then kept at 4 °C prior to agarose gel 
electrophoresis.  
 
 
2.2.4 Polymerase chain reaction (PCR) 
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PCR reactions and conditions were as described above except for using 200ng of 
genomic DNA as template rather then cDNA. 
 
The primers used for RT-PCR and PCR were obtained from Alta Bioscience or 
Sigma-Aldrich. The sequences of primers and their annealing temperatures are 
presented in Table 2.2.  
Table 2.2: Primer list for PCR 
  
Primer Name Primer Sequence 5’-3’ 
Annealing 
Temperature 
ºc 
Product Size 
(bp) 
GAPDH Fwd 
GAPDH Rev 
GCCTCCTGCACCACCAACTG 
GGACGCCTGCTTCACCACCTTCT 
60 300 
TGFβ1 Fwd 
TGFβ1 Rev 
GTTGAGCCGTGGAGGGGAAA 
CTGCGTGTCCAGGCTCCAAAT 
58 386 
TGFβ2 Fwd 
TGFβ2 Rev 
AAATGGATACACGAACCCAA 
GCTGCATTTGCAAGACTTTAC 
55 250 
TGFβ3 Fwd 
TGFβ3 Rev 
AAGTGGGTCCATGAACCTAA 
GCTACATTTACAAGACTTCAC 
55 250 
TGFβRІІ Fwd 
TGFβRІІ Rev 
GCAGTGGGAGAAGTAAAAGAT 
GGGAGCCGTCTTCAGGAAT 
56 301 
SMAD2 Fwd 
SMAD2 Rev 
CGAAATGCCACGGTAGAAAT 
CGGCTTCAAAACCCTGATTA 
57 259 
SMAD3 Fwd 
SMAD3 Rev 
CCAGCCATGTCGTCCATCC 
TTTTCCCCAAGCCTGCCCTC 
57 388 
SERPINE1Fwd 
SERPINE1Rev 
GTGGTCTGTGTCACCGTATC 
GTAGTTGAATCCGAGCTGCC 
55 440 
TGFBI Fwd 
TGFBI Rev 
GGAAGGAGTCTACACAGTCTTT 
CCTCTGGGAAGCCCTGGAAAA 
51 399 
INHBB Fwd 
INHBB Rev 
GCCAGGAGCGCGCGTTTCCGAAATC 
CCGCTCGCCCCGCTCAAACAAG 
55 280 
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ACVR2B Fwd 
ACVR2B Rev 
TCCCTCACGGATTACCTCA 
CCTCCTCAAAAGGCAGCA 
56 440 
BAM HI-W Fwd 
BAM HI-W Rev 
ACGTAAGCCAGACAGCAGCC 
 
TTTGTGTGGACTCCTGGCG 
56 114 
 
 
2.2.5 Agarose gel electrophoresis  
PCR products were fractionated and analysed by electrophoresis on 0.8 – 2% w/v 
agarose gels depending on the size of PCR products. Agarose powder was dissolved 
in a suitable volume of 1x TBE buffer (Tris-borate-EDTA, 10.8g Tris, 4.5g Boric acid 
and 0.74g EDTA make up to 1 litre with SDW, pH 8.0) by boiling in a glass conical 
flask. The boiled solution was cooled by rinsing in tap water. Ethidium bromide was 
added into the cooled solution to a final concentration of 0.5µg/ µl and mixed gently. 
The solution was then poured into a sealed casting tray inserted with a gel comb. The 
gel was left to set for about 1 hour and the tray was placed into a horizontal 
electrophoresis tank filled with sufficient 1x TBE buffer. After removing the gel 
comb, a DNA ladder (100bp or 1kb plus, Invitrogen) and the PCR products were 
loaded into the wells. The samples were allowed to run for about 1 hour at a suitable 
voltage prior to visualisation of ethidium bromide stained bands using a UV 
transilluminator. 
 
2.2.6 Quantitative PCR (q-PCR) for determination of gene copy number  
DNA copy number predicted by SNP array analysis was verified by q-PCR using an 
ABI 7500 sequence Detection System (Applied Biosystems, ABI). All the probes and 
primers were designed by using Primer Express 3.0 software (ABI). The sequences 
are listed in Table 2.3. Taqman probes were synthesised containing a 5’ FAM reporter 
dye and 3’ TAMRA quencher (Eurogentec).  25µl PCR reactions were prepared by 
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the ad dition of 1 2 .5  μl of 2 x Taqman Universal PCR Mastermix (Applied 
Biosystems), 5 μl of a combination of forward and reverse primers, 1 μl of probe (a 
final concentration of 300nM primers and 200 nM probe in each reaction), 1.5 μl 
DEPC treated water and 5 μl of genomic DNA containing either 1.32ng or 13.2ng 
input DNA. A calibrator DNA derived from the X50-7 cell line was serially diluted 
into 100,000, 20,000, 5,000, 1,000, 200, 50, and 10 copies on the basis of 3.3pg per 
haploid genome. Each sample was assayed at 2 concentrations in duplicate and 
calibration was also prepared at the same time in each assay. The PCR conditions 
consisted of an initial incubation (2 min, 50°C), an activation step (10 min, 95°C) and 
40 rounds of amplification (denaturation for 15 s at 95°C, annealing and extension for 
1 min at 60°C).  
 
The data were analysed by using 7500 fast system SDS software v1.3.1 (ABI). The Ct 
value was determined according to the real time changes in fluorescence and a 
standard curve was then generated from the Ct value of the calibrator DNA. For each 
target gene, the copy number of the unknown DNA sample was quantified by 
comparing with the reference gene CYP7A1 for which a DNA copy number of 2 was 
confirmed by SNP array prediction and previous q-PCR analysis.  
 
Table 2.3: Primer and probe list for q-PCR 
Gene                         Primer and Probe Sequences 5’-3’ 
 
FHIT 
 
Primer Forward: TGGGAGGGAGATGGATTCTTTA 
Reverse: CTTCTGAGCCTAACCAGCCAAA 
Probe: TGGACAGACTGGAGGCCAATCTTGTATTTATATTC 
IL20RA 
 
Primer Forward: AAGTGTTGGCATCAGTTTTCCA 
Reverse: GAGAAAATGAAACCTATCTCATGCAA 
Probe:  CTGCACATATAACCCCCATTCCTCCATG 
MAP3K5 
 
Primer Forward: GTCAATGATAGCCTTCCACAGTGT 
Reverse: GAAATGTTCGTTTCACCATGTTCT 
Probe: CACAGCATCCCTCCCCTGTTTAAAGACA 
Chapter 2                                                                                     Materials and Methods 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.7 q-PCR for determination of gene expression changes  
Cellular gene expression changes in C666-1 cells relative to controls cells were 
determined by q-PCR analysis using commercial Taqman Gene Expression Assay 
primer and probe mixes purchased from ABI (See Table 2.4). Each 25µl q-PCR 
reaction was prepared by adding 1µl (50ng) of cDNA, 1.25µl of primers and probe 
mix for both the target gene and the reference gene (GAPDH), 12.5µl of 2x Taqman 
Universal PCR Mastermix and 9µl of PCR H2O. Each reaction was assayed in 
triplicate and analysed using 7500 fast system SDS software v1.3.1. The Ct value was 
generated according to the real time changes in fluorescence. The average Ct was 
calculated for both target and reference gene and the dCt (Cttarget – CtGAPDH
CDKN2A 
) was 
Primer Forward: GCGTGAGCTGAGGCAAGAC 
Reverse: TCCAAAGCTCAGAGCATTCATTT 
Probe:  CTGGTCTCCCGGGCTGAACTTTCTG 
FGF20 
Primer Forward: CCACTGGTCTAGGTAAGAAATGTGTAAA 
Reverse: CAAAGACGGAACTCCAAGAGATG 
Probe: TCTGATGCCTCTTGGACCTGGCG 
KIAA1967 
Primer Forward: GGGCGGTTCCTGGAGATT 
Reverse: GAGGAGGGCCCAGAAGAGAT 
Probe: TTCTCTTTCCCCATAGGCACAGCTTCAA 
CLU 
Primer Forward: TGGGAGGCGCCGTATTTATA 
Reverse: TTGGGCGTGAGTCATGCA 
Probe: CTCGCGCACACACCCCCTTTG 
NRG1 
Primer Forward: TCTACATCCACCACTGGGACAA 
Reverse: CCCCTCCATTCACACAGAAAG 
Probe: TTCTCCTTCTCCGCACATTTTACAAGATGG 
 
IKBKB 
 
Primer Forward: TTGCTTATAGAGTTAGCACGACATCA 
Reverse: TCCCAGGCCCCACATG 
Probe: ATGAGCTGGTCACCTTCCCTGACAACG 
CYP7A1 
Primer Forward: TGATATGTTGGTGGAAAGGATTACTAA 
Reverse:  TAGACGGGTGCTTGTTGAATGT 
Probe:  TCCATCCATTCATGCATCCGTCCATA 
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obtained. The ddCt (dCtC666-1 – dCtcontrol
Table 2.4: Taqman primer and probe mixes 
) was then determined and fold change of 
gene expression in C666-1 cells was calculated by using the formula 2^-ddCt.  
 
Gene ABI QPCR Primer/Probe 
Reference Number 
GAPDH 
 
4310884E 
E2F5 
 
Hs00231092_ml 
BMP2 
 
Hs00154192_ml 
MAPK1 
 
Hs01046830_ml 
NEDD9 
 
Hs00610590_ml 
HES1 
 
Hs00172878_ml 
ID1 
 
Hs00357821_ml 
CLDN1 
 
Hs01076359_ml 
 
 
2.3 Immunohistochemistry staining (IHC) 
2.3.1 Tissue array construction 
The formalin-fixed, paraffin-embedded blocks were obtained from the archives of the 
Pathology Department, Cancer Center, Sun Yat-Sen University (Guangzhou, 
Guangdong, China) during 2007. The matching H&E-stained slides were reviewed 
and screened, and samples containing both NPC tumour and adjacent nasopharyngeal 
mucosae were chosen for tissue microarray construction. Each patient case was 
represented by a mean of 4 cores with 2 tumours and 2 normal nasopharyngeal 
mucosae taken using a 0.6-mm punch. In total, 40 cases were used to construct two 
TMAs with 176 cores. The final numbers assessed were slightly variable for different 
markers due to failure of taking target tissues and additional losses during block 
trimming and staining procedures. 
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2.3.2 IHC staining in formalin fixed paraffin embedded (FFPE) sections 
FFPE sections were deparaffinised in xylene and rehydrated through ethanol to 
distilled water, then incubated with 3% hydrogen peroxide for 15 minutes to quench 
endogenous peroxidase. Antigen retrieval was performed using the agitated low 
temperature epitope retrieval (ALTER) method (Reynolds et al., 2002), or by heating 
in low pH retrieval buffer (Vector Laboratories) for 20 minutes at 880W in a 
microwave oven. Sections were then rinsed with PBS (see Section 2.5.2), primary 
antibody was added and incubated for 60 minutes at room temperature. After three 
brief washes with PBS containing 0.05% Tween 20 a peroxidase-based secondary 
antibody (Dako EnVision™ Detection System, Denmark; or Anti-goat Ig, Immpress) 
was added and incubated for 30 minutes at room temperature. The final peroxidase-
labelled complex was visualised using diaminobenzidine (DAB). The tissue sections 
were counterstained with hematoxylin, dehydrated, and mounted with coverslips. 
When staining for individual genes, negative control included omission of primary 
antibody whilst positive controls included tissues of previously documented positive 
immunoreactivity. 
The antibodies used in IHC are listed in Table 2.5. 
Table 2.5: Primary antibody list for IHC staining 
 
Primary antibody Species Dilution Supplier 
MSH3(S-16) Goat 1:50 Santa Cruz  
TGFBI(HPA008612) Rabbit 1:150 Sigma 
ITGA2(CD49b,611016)) Mouse 1:100 Becton Dickinson 
CLU Mouse 1:6000 Santa Cruz 
EZH2 Mouse 1:200 Cell Signalling 
JAK1(sc-1677) Mouse 1:100 Santa Cruz 
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SKIL(HPA013920) Rabbit 1:800 Sigma 
WNT5A Rabbit 1:50 Santa Cruz 
KLF4(AF3640) Goat 1:100 R&D 
LCN2(HPA002695) Rabbit 1:100 Sigma 
ANXA1(HPA011271) Rabbit 1:800 Sigma 
TNFAIP3(HPA002116) Rabbit 1:20 Sigma 
CD44 (v6) Mouse 1:200 R&D Systems 
CTNNB1(610153) Rabbit 1:400 Becton Dickinson 
TGFBR1 (sc-398) Rabbit 1:200 Santa Cruz 
TGFBR2 (sc-220) Rabbit 1:150 Santa Cruz 
SMAD2(51-1300) Rabbit 1:300 Zymed 
SMAD4 (OP111) Mouse 1:50 Cell Signalling 
SP1 (sc-59) Rabbit 1:400 Santa Cruz 
SERPINE1 (sc-8979) Rabbit 1:300 Santa Cruz 
ID1 (sc-448) Rabbit 1:300 Santa Cruz 
BTG1(HPA005972) Rabbit 1:50 Sigma 
APC(SC-895) Rabbit 1:25 Santa Cruz 
PTCH1 (ab53715) Rabbit 1:200 Abcam 
SHH (ab73958) Rabbit 1:20 Abcam 
 
 
 
2.3.3 IHC staining for frozen sections 
8 micron cryosections were cut, air dried and fixed in 10% formalin for about 20 
minutes. The sections were then incubated in 3% hydrogen peroxide for 15 minutes, 
followed by antigen retrieval in low pH buffer for 20 minutes (High power, 
microwave). The remaining procedures were the same as for FFPE samples.      
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2.3.4 IHC scoring 
For each tissue core on the tissue array, a semiquantitative scoring system was used 
for evaluation of IHC staining, in which both intensity of staining and percentage of 
positive cells of interest were represented. A staining index (values 0-9) was obtained 
by multiplying the intensity of staining (negative = 0, weak = 1, moderate =2, or 
strong = 3) by the proportion of positive cells of interest (≤30% = 1, 30% -70% = 
2, >70% = 3). The expression values for tumour and normal controls of each 
individual case were obtained from the mean values of two representative cores.  
 
2.4 In situ hydridisation (ISH) 
EBERs staining was performed in the tissue arrays using digoxigenin-labelled probes. 
All the solutions and containers used in the experiment were sterile. Briefly, the 
sections were deparaffinised in xylene and dehydrated in absolute ethanol twice for 5 
minutes then washed in PBS buffer for 5 minutes.  The slides were then treated with 
100 μl of pronase E (10mg/ml stock pronase E diluted at 1:160 in DEPC water) per 
slide for exactly 5 minutes at room temperature. After washing with PBS and 
dehydration in ethanol, a gene frame (AB gene house) was placed around the tissue 
section. Meanwhile, the digoxigenin-labelled sense and antisense probes to EBERs 
(Barletta et al., 1993) were heated at 80ºC for 30 seconds and diluted with 
hybridisation solution at 1:100. A suitable amount of the above probe was applied to 
the slides (sense probe to EBERs used as a negative control), sealed with a siliconised 
cover slip and incubated at 50º C overnight. The following day, the cover slips and 
gene frames were removed and the sections were washed once with 2 x SSC for 5 min, 
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twice with 0.1 x SSC for 5 min and once with PBS. This was followed by incubation 
in diluted blocking serum according to the manufacturer’s protocol (Vectastain 
universal quick kit) for 10 minutes and mouse anti-digoxigenin antibody (diluted at 
1:1000 with PBS) for 1 hour. After washing with PBS, the diluted secondary antibody 
(Vectastain universal quick kit) was added to the slides and incubated for 10 minutes, 
washing with PBS again. The diluted tertiary complex was then added, incubated for 
5 minutes then washed with PBS. Finally, the slides were visualised using 
diaminobenzidine (DAB), counterstained with hematoxylin, immersed in ethanol, and 
mounted with coverslips. 
 
2.5 Tissue culture 
2.5.1 Basic media  
RPMI 1640 (1Χ) liquid supplemented with L-glutamine (2mM) and adjusted to pH 
7.0, was purchased from GIBCO Ltd and supplied in 500ml sterile bottles. Medium 
was stored at 4ºC. 
 
Keratinocyte serum-free (1X) liquid supplemented with 25mg of Bovine pituitary 
extract (BPE) and adjusted to pH 7.0, was purchased from GIBCO Ltd and supplied 
in 500ml sterile bottles.  Medium was stored at 4o
 
C.  
2.5.2 Other sterile solutions and supplements 
Foetal bovine serum (FBS) pre-screened for virus/mycoplasma contamination was 
purchased in sterile 500ml bottles from GIBCO Ltd. FBS was aliquoted into 50ml 
sterile bottles and stored at -20ºC. 
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Penicillin/streptomycin antibiotic solution (5,000 units/ml penicillin-G and 5mg/ml 
streptomycin) was purchased from Gibco Ltd, filter sterilised and used at 5ml/500ml 
medium. 
 
Trypsin (1x) supplied in 100ml sterile bottles containing 2.5g/L trypsin (0.25%) and 
0.38g/L EDTA was purchased from GIBCO Ltd. Trypsin was aliquoted and stored at 
-20ºC. 
 
Phosphate buffered saline (PBS) (8g/L NaCl, 0.2g/L KCl, 1.15g/L Na2HPO4, 0.2g/L 
KH2PO4
 
) was purchased in tablet form Oxoid Ltd. 10 tablets were dissolved in 1L of 
distilled water, and 500ml aliquots were sterilised by autoclaving at 115ºC for 10min.  
Fibronectin derived from human plasma was purchased at a concentration of 1mg/ml 
from Sigma-Aldrich and stored at 4o
 
C. To coat tissue culture vessels, the stock 
solutions were diluted into 10ng/ml in sterile PBS.  
Opti-MEM reduced-serum medium (1X) liquid was purchased from Invitrogen and 
supplied in 500ml sterile bottles.  Medium was stored at 4o
 
C.  
2.5.3 Cell lines and their media 
C666-1 is an EBV-positive NPC cell line (Cheung et al., 1999).  
Medium: 10% FBS, 2mM glutamine and antibiotics in RPMI 1640. Cells should be 
plated into vessels previously coated with 10ng/ml fibronectin by incubating at 37oC 
for at least 1 hour or 4o
 
C overnight. 
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OKF6 tert-1 is a human immortalised normal oral epithelial line (Peng et al., 2006). 
Medium:  2mM glutamine and antibiotics in Keratinocyte serum-free medium. 
 
2.5.4 Maintenance of cell lines 
The cell lines were maintained in incubators at 37oC supplied with 5% CO2.
Adhesive cells grown in 75 cm
  
2
 
 flasks were fed twice a week and split when they 
reached 90-95% confluence. The cells were washed in PBS and trypsinised with 5ml 
of 1x trypsin. The cells were returned to the incubator until they dislodged from 
vessels, usually spending 5-10 minutes depending on cell types. Cells were recovered 
in 10ml of complete growth medium containing serum to inactivate the trypsin and 
pelleted by centrifuge at 1500rpm for 5 minutes. The supernatants were removed. 
Cells were resuspended in fresh medium, counted using a haemocytometer, and plated 
out at a density required by the experimental design.  
2.5.5 Cryopreservation of cell lines 
Adhesive cells were trypsinised and pelleted as described as above. Pellets were 
resuspended in freezing medium containing 50% complete medium, 40% FCS and 
10% DMSO (Dimethyl sulphoxide, Fisher Scientific) pre-chilled at -20oC for 10 
minutes. Typically, 1x106 cells were resuspended in 1ml freezing medium and 
transferred to cryotubes (Nunc). The cryotubes were placed into a Mr Frosty (Nalgene) 
and stored at -80oC overnight allowing cells to freeze gradually. The following day, 
the cryotubes were transferred to a liquid nitrogen freezer (-140o
 
C) for long-term 
storage.  
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Cells from frozen ampoules were recovered by thawing rapidly in a 37ºC water bath. 
Cell suspensions were gently transferred into a sterile universal tube (Sterlin) 
containing warm normal growth medium. The suspensions were spun at 1500rpm for 
5 minutes. The cell pellets were resuspended in normal growth medium and seeded 
into a tissue culture flask.  
 
2.6 Immunoblotting   
2.6.1 Solutions 
Resolving Gel Buffer 
500ml solution of 1.5M Tris requires 90.86g Tris dissolved in SDW, pH 8.8 with 
concentrated HCl. 
Stacking Gel Buffer 
500ml solution of 0.25M Tris requires 15.14g Tris dissolved in SDW, pH 6.8 with 
concentrated HCl. 
1x Running Buffer 
 A 10 x solution requires 30g Tris, 144g glycine, and 10g SDS. Make up to 1 litre 
with SDW, pH 8.3-8.8. Dilute 1/10 with SDW prior to use. 
1x Transfer Buffer 
10 litres requires 30g Tris and 144g glycine dissolved in 8 litres of SDW and 2 litres 
of methanol. 
10x Tris Buffered Saline-Tween (TBS-T) 
10 litres requires 60.5g Tris, 200g NaCl, 25ml Tween-20, pH 7.6 with concentrated 
HCl and made up to 2.5 litres with SDW. 
5% Milk blocking buffer 
5% (w/v) powdered non-fat milk dissolved in TBS-T. 
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5% bovine serum albumim (BSA) blocking buffer 
5% (w/v) powdered BSA dissolved in TBS-T and filtered. 
Stripping Buffer 
100mM Tris-HCl pH 6.8, 2% (w/v) SDS, 50mM 2-mercaptoethanol 
 
2.6.2 Preparation of protein extracts and determination of protein 
concentration 
Cells were washed once in PBS and lysed in 100μl protein lysis buffer containing 
protease inhibitors (Novagen). The cell lysates were collected using a cell scraper 
(Sarstedt, Germany) and transferred into pre-chilled eppendorf tubes. The samples 
were mixed well and kept on ice for a minimum of 30 minutes. Following sonication 
for 15 seconds, the samples were centrifuged at 13,000rpm for 5 minutes at 4ºC to 
pellet cell debris. The supernatants were transferred to new eppendorf tubes and 
protein concentrations were determined using a Bradford Protein Assay kit. Briefly, 
10μl BSA standards were prepared in distilled water at concentrations of 100, 200, 
300, 400 and 500μg/ml, and 10μl of protein samples at a dilution of 1:10 in distilled 
water were added into a 96-well plate in duplicate. 200μl of Bradford reagent at a 
dilution of 1:5 in distilled water were then added to each well and incubated at room 
temperature for 5 minutes. The absorbance at 595nm of the samples was read on a 
BioTek automated microtitre plate reader. A standard curve was generated and the 
sample protein concentrations were determined. A minimum of 30μg protein samples 
used for immunoblotting were diluted at 1:2 in Laemmli sample buffer (Bio-Rad) 
containing 10% β-mercaptoethanol, boiled at 95ºC for 5 minutes and stored at -20ºC 
until required.      
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2.6.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
BioRad apparatus (165-3322) was used for SDS-PAGE. An appropriate percentage 
resolving gel (5-15%) depending on the size of protein of interest was prepared and 
poured into the gel cassettes. Once the resolving gel had set, a 4% stacking gel was 
prepared and gel combs were inserted. Gel combs were removed after the gel had set 
and the gels were placed into an electrophoresis tank and submerged in running buffer. 
Equal amounts of protein samples were loaded onto the gel alongside a rainbow 
protein ladder (Fermentas). Electrophoresis was then carried out at 135V for about 90 
minutes.  
 
2.6.4 Western blotting 
Following electrophoresis the resolved proteins were transferred to a nitrocellulose 
membrane (Pall-Life Sciences, 66-485). The gel and membrane were tightly 
sandwiched between two layers of 3MM filter paper (Whatman, UK) pre-soaked in 
transfer buffer. The sandwich was placed into a transfer tank filled with transfer 
buffer and run at 90v for 90 minutes on ice. The membrane was blocked in 5% milk 
at room temperature for one hour and then incubated at 4ºC overnight in primary 
antibodies at appropriate dilutions (Table 2.6). The following day, after 3 x 5 minute 
washes in 1x TBS-T buffer, the membrane was incubated in corresponding HRP-
conjugated secondary antibody at room temperature for one hour (Table 2.7). 
Following a further 3 x 5 minute washes in 1x TBS-T buffer, the antigen-antibody 
complexes were detected by Enhanced Chemiluminescence (ECL, GE healthcare) 
according to the manufacturer’s instructions, wrapped in Saran Wrap and exposed to 
Hyperfilm (GE healthcare) for an appropriate period of time. The film was developed 
on a Kodak X-OMAT-1000 Processor. 
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Table 2.6: Primary antibody list for immunoblotting 
Antibody  Species Dilution Product 
Size (kDa) 
Supplier 
β-actin Mouse 
monoclonal 
1:5000 42 Sigma 
SERPINE1-1 Mouse 
monoclonal 
1:500 47 BD Biosciences 
(612024) 
p21(c-19) Rabbit polyclonal 1:500 21 Santa Cruz  
(sc-397) 
pSMAD2 
(Ser465/467) 
Rabbit polyclonal 1:1000 58 Cell Signalling 
Technology (3101) 
 
Table 2.7 Secondary antibody list for immunoblotting 
Antibody Dilution Supplier 
Anti-Mouse peroxidase 1: 1000 DAKO 
Anti-Rabbit peroxidase 1: 1000 DAKO 
 
2.7 Immunofluorescence (IF) staining 
 
Cells were tryspinised and resuspended in normal growth medium at a concentration 
of 6 x 105/ml.  1.5 - 3 x 104 cells were seeded onto each dot of sterile teflon coated 
slides (Henley) in a sterile petri dish with 1ml of PBS, and then left to adhere for 24 
hours at 37oC. Cells were then washed in PBS and fixed in 4% PFA pH 7.4 (20g PFA 
in 500ml PBS) for 10min. Subsequently, the fixed cells were permeabilised in 0.5% 
Triton X-100 (in PBS) for 5min and blocked in 50μl of 20% HINGS (heat inactivated 
normal goat serum diluted in PBS) for at least 1hr. 25µl Primary antibody (diluted at 
the appropriate concentration in 20% HINGS) was added to each microdot and 
incubated at 37oC for 1hr or at 4oC overnight (Table 2.8). Following 3x 5min washes 
in PBS, the cells were incubated in 25 µl AlexaFluor488 or AlexaFluor594-
conjugated goat anti-rabbit immunoglobulin (Molecular Probes, diluted in 20% 
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HINGS at 1:1000) for 1hr at room temperature in the dark. After 3x 5min washes in 
PBS, the slides were then mounted with DABCO (1,4-diazabicyclo[2.2.2]octane) 
anti-fading agent for visualisation by fluorescence microscopy. 
Table 2.8: Primary antibody list for IF staining 
Primary antibody Species Dilution Supplier 
PTCH1 (ab53715) Rabbit 1:50 Abcam 
SMO (ab38686) Rabbit 1:100 Abcam 
GLI1 (ab92611) Rabbit 1:50 Abcam 
 
 
2.8 Transfection of plasmid DNA into Mammalian cells 
Liposome transfection of cultured eukaryotic cells was carried out using 
lipofectamine LTX and plus reagent (Invitrogen, UK). Briefly, 24-well plates were 
seeded at a density of 0.5-2x105cells/well and allowed to adhere overnight. The 
following day, the cells that reached 50-80% confluence were washed once with Opti-
MEM and replaced with 500μl of fresh growth medium. For each transfection, a 
suitable amout of plasmid DNA was diluted in 100μl Opti-MEM. 1μl of plus reagent 
was then added and DNA complex was formed by incubating at room temperature for 
5 minutes. 2 μl of lipofectamine LTX were added directly to the diluted DNA 
complex and incubated at room temperature for 30 minutes. The lipid–DNA 
transfection mix was added into each well and mixed by gentle swirling of each plate 
before being returned to the incubator. After 4-6 hours, the transfection mix was 
removed and replaced with normal growth medium. The cells were incubated at 37ºC 
with 5% CO2
 
 for 24 hours or 48 hours until further treatment.        
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2.9 Stimulation of cells with human recombinant cytokines 
Cells were seeded at a suitable density in appropriate vessels depending on the nature 
of the experiments. 16 hours (for western blotting) or 5 hours (for luciferase reporter 
assays) prior to stimulation, the medium was replaced with serum free medium to 
reduce the background level of cytokines that are naturally present in serum. The cells 
were then stimulated in the serum free medium with the appropriate concentration of 
recombinant cytokine for varying lengths of time depending on the individual 
experiment, or left unstimulated as a control.     
Table 2.9: Human recombinant cytokines 
Cytokine Supplier 
Recombinant Human Transforming Growth Factor Beta 1 (TGFβ1) Peprotech (100-21) 
Recombinant Human activin A Peprotech (120-14) 
Recombinant Human Sonic Hedgehog (SHH) Peprotech (100-45) 
 
 
2.10 Luciferase reporter assays 
Reporter assays were carried out using the Dual-Luciferase Reporter Assay System 
(Promega, UK) whereby the activities of both firefly (Photinus pyralis) and Renilla 
(Renilla reniformis) luciferase can be measured from the same sample sequentially. 
Firefly luciferase was used to measure the activity of the reporter of interest, whilst 
Renilla activity provided an internal control for transfection efficiency and cell 
viability. In triplicate, cells were plated in 24-well plates and grown in normal growth 
medium until 70% confluence was achieved. Cells were co-transfected with 50ng of a 
luciferase reporter construct and a plasmid expressing Renilla luciferase (See Table 
2.10) for 24 hours using lipofectamine LTX and plus reagent as described in section 
2.8. All wells were then serum starved for 5 hours, and incubated in the presence or 
absence of a serial dilution of either TGF-β1 or activin A cytokine, or SHH (2µg/ml) 
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for 16 hours. Cells were washed with PBS and wells drained completely prior to the 
addition of 120µl of 1x passive lysis buffer (PLB; Promega, UK). Complete lysis and 
homogenisation of samples was achieved by using a cell scraper. 20µl of sample from 
each well were added into a 96 well plate. Using the luminescence setting on a Victor 
plate reader firefly activity was determined immediately after the addition of 25µl of 
LARII. 25µl of Stop & Glo was then added to each well to quench the firefly 
luciferase activity and initiate measurement of the Renilla luciferase. Relative 
luciferase activity was determined by normalising the firefly luciferase value to that of 
the Renilla. 
 
Table 2.10: Luciferase reporter constructs used in transfection of Mammalian 
cells. 
 
 
  
 
 
2.11 Flow cytometry analysis (FACS analysis) 
Cells were seeded at a density of 1-4x105 into 6cm dishes and grown in normal 
growth medium for 1 day before treatment. The following day, the cells were washed 
gently with PBS then serum free medium with or without TGF-β1 (10ng/ml) or 
activin A (100ng/ml) cytokines was added and the cells were incubated for 5 days. 
Following treatment, the cells were trypsinised, washed, and resuspended in 500µl 
PBS. These cells were fixed by adding 500µl of 70% ethanol and stored at -20 o
Plasmid vector 
C 
Abbreviation 
PAI-1 reporter p3TP-lux 
Smad3 reporter (CAGA)12 
GLI1 reporter p8xGLI1 
Renilla luciferase p-RL-TK 
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overnight. The fixed cells were washed, resuspened in 500µl PBS containing 10µg PI 
(propidium iodide) and 5mg RNase A, and then incubated at 37 oC for 30 minutes. 
The cell cycle program was run on a FACS machine (XL-MCL, Beckman Coulter) 
for at least 20,000 individual events per reaction. Data were extracted and cell cycle 
analysis was done using Multicycle AV software (Phoenix). 
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CHAPTER 3 
 
Expression changes in cellular tumour-associated genes  
 
3.1 Introduction 
 
NPC exhibits expression changes in a number of cellular genes. The expression 
microarray technique allows simultaneous monitoring of the expression of thousands 
of genes (Russo et al., 2003). Thus, identification of differences in the gene 
expression profile between NPC tumour and normal nasopharyngeal epithelial cells 
could reveal a variety of functional groups of genes and signalling pathways whose 
dysregulation may play critical roles in NPC development and progression.      
 
Cellular gene expression profiles in NPC have been investigated in a number of 
previous studies. Earlier studies used low-density cDNA arrays on NPC biopsies or 
NPC-derived cells (Fung et al., 2000; Xie et al., 2000). More recently, advanced 
technologies such as the development of microdissection and increasingly higher-
density microarrays have been widely used in expression profiling of NPC , which 
revealed aberrant expression of a number of genes involved in a variety of functions 
such as control of cell growth, survival, and invasion, and signalling pathways 
including Wnt/β-catenin, TGFβ, and MAPK pathways (Sriuranpong et al., 2004; Lee 
et al., 2007; Zeng et al., 2007; Liu et al., 2009; Zhang et al., 2009). PTPRG was 
identified as a candidate NPC TSG by comparing gene expression in tumourigenic 
and nontumorigenic NPC chromosome 3 microcell hybrids (Cheung et al., 2008). The 
potential TSG ATM was found to be associated only with EBV-positive cell lines 
(Bose et al., 2009), and downregulation of MHC class І antigen presentation genes is 
highly correlated with increased EBNA1 expression (Sengupta et al., 2006). A 
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comparison of gene expression profiles in NPC cell lines with or without metastasis 
revealed that the expression of several transcription factors was associated with NPC 
progression (Su et al., 2010) 
  
In the present study, we compared global gene expression in microdissected cells 
from 4 normal epithelial samples, and 15 NPC tumour samples that were obtained 
from high- and intermediate- incidence areas, as well as C666-1 cells. The expression 
array data identified a large number of differentially-expressed oncogenes, tumour 
suppressor genes and genes involved in various functional processes and signalling 
pathways. The differential expression of several genes identified by expression array 
was verified at the protein level by IHC staining in NPC tumour and normal 
nasopharyngeal epithelial (NP) cells.  
 
3.2 Sample correlation analysis   
 
16 NPC samples (15 NPC biopsies and 1 NPC cell line, C666-1) together with 4 
reference samples from normal epithelial cells were used for global gene expression 
profiling. The sample information is listed in Table 2.1. The quality of the data from 
expression arrays is highly dependent on RNA quality and tumour purity. A mixture 
of stromal cells, extensive lymphoid infiltrate and other non-neoplastic cells within 
the NPC tumour makes it difficult to obtain pure tumour cells. To overcome the noise 
of the admixed non-neoplastic cells, LMPC was carried out to collect purified 
populations of tumour or normal epithelial cells from frozen biopsies. Representative 
images of LMPC performed in NPC tumour and normal epithelia are shown in Figure 
3.1. RNA was extracted from microdissected cells, amplified, labelled and hybridised 
to Affymetrix Human Genome U133Plus 2.0 microarrays. 
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Figure 3.1: Microdissection of NPC tumour and normal epithelial cells. The 
selected frozen biopsies of NPC tumour and normal epithelia were cut into 8μm 
sections, stained with H&E then subjected to microdissection. Panel A displays 
normal epithelium and the cells within the circled area were microdissected. Panel B 
shows a well-defined island of NPC tumour cells. 
 
A  Normal B Tumour 
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As described in Table 2.1, the tumour and normal samples used for expression array 
analyses are from different geographical origins and contain both genders. To 
estimate the degree of relatedness between the samples a correlation heatmap was 
generated by analysing the normalised expression array intensity values of global 
gene probesets in individual samples (Figure 3.2). The figure indicates that 4 normal 
samples (MSTA, MBEZ, MHAU and T3) are closely correlated with each other, 13 
tumours (12 biopsies and the C666-1 cell line) are tightly clustered with each other 
but not correlated with the normal controls. 3 tumour biopsies (YH8, 68(8) and XY8) 
do not correlate with the other 13 tumour samples, with the 4 normal controls or with 
each other. Taking the above results together: (i) no substantial geographical or 
gender differences are found between tumour samples; (ii) the C666-1 cell line 
appears to be a good tumour model to mimic real NPC tumours since it is closely 
correlated with the other 12 NPC biopsies; (iii) tonsillar epithelium appears to mimic 
nasopharyngeal epithelium. However, it is unclear why 3 of the NPC tumours do not 
cluster with the other 13.  
 
3.3 Global gene expression array data analysis  
 
Initially the gene expression array data generated from the 16 NPC samples and 4 
normal samples were normalised and processed using RMA and RP to identify 
differentially expressed genes. The data were then subjected to further hierarchical 
clustering analysis using dChip software. The heatmap generated from dChip showed 
a distinct clustering of expression between tumour and normal. The results displayed 
that a large number of genes were differentially regulated, of which the majority were 
upregulated (Figure 3.3).  
 
83 
 
MKAV 
MDIG 
XY6 
400(3) 
MKEC 
MMAH 
125855 
MOUZ 
173570 
C666-1 
XY23 
 XY5 
YH7 
T3 
MHAU 
MBEZ 
MSTA 
XY8 
 68(8) 
YH8 M
K
A
V 
M
D
IG
 
XY6 
400(3) 
M
K
EC
 
M
M
A
H
 
125855 
M
O
U
Z 
173570 
C
666-1 
XY23 
XY5 
YH
7 
T3 
M
H
A
U
 
M
B
EZ 
M
STA
 
XY8 
68(8) 
YH
8 
   
Tumours 
Normals 
Tumours 
Tumours 
Tumours 
Normals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Sample correlation analysis. RNA from 15 NPC biopsies, 1 NPC cell 
line C666-1, and 4 reference samples from normal epithelial cells were used for gene 
expression profiling. A correlation heatmap was generated from the normalised 
expression array intensity values of global gene probesets in individual samples. 4 
normal samples (MSTA, MBEZ, MHAU and T3) are closely correlated with each 
other. 13 tumours including 12 biopsies and the C666-1 cell line are tightly clustered 
with each other but not correlated with the normal controls. 3 tumour biopsies (YH8, 
68(8) and XY8) do not correlate with the other 13 tumour samples, the 4 normal 
controls or each other. 
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Figure 3.3: Global gene expression profiling. 
 
 
The expression array data generated from16 tumours and 4 normal controls were 
normalised and processed using RMA and RP. This identified a number of 
significantly differentially regulated genes, which were visualised using dChip 
software for hierarchical clustering analysis. The heatmap shows a distinct clustering 
of expression patterns between tumours and normal samples. The expression level of 
each gene in individual sample is colour coded: blue for down-regulation, red for up-
regulation, and white for unchanged.  
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When the data were processed using RP analysis, the differentially regulated genes 
and the overall fold change in the expression between tumours and normals were 
determined. However, because this method compares mean expression values it could 
miss some potential tumour-related genes whose expression changes occurred in only 
a minority of cases. Thus, the data were also analysed with GCOS taking advantage of 
the “present/absent” calls that this method provides. If a gene is called as “present” by 
GCOS, it indicates that the level of gene expression is clearly detected by the 
expression array, whereas if it is called as “absent”, it indicates that the signal of gene 
expression is too low to be reliable. To define the up- and down- regulated genes the 
following criteria were used: within individual tumours, a gene was called 
upregulated if (1) it was called “present” in the sample of interest and (2) its GCOS 
normalised expression level was ≥1.5 times more than the mean of the normal 
samples. A downregulated gene was defined as one in which (1) the gene was called 
by GCOS as “present” in all of the 4 normal samples and (2) the gene expression 
level in the tumour sample was ≥1.5 times less than the mean of the normals. 
      
3.4 Validation of expression array data 
 
To validate the reliability of expression array data we constructed two tissue arrays 
containing NPC tumour and patient-matched normal epithelial cells. Figure 3.4 shows 
the two tissuearray blocks, corresponding slides with H&E staining, and 
representative images of NPC tumour tissue and its matched normal nasopharynx. 
There are 22 matched cases in each tissuearray block, and each case is represented by 
4 cores containing 2 cores of tumour and 2 of normal. To confirm the EBV status in 
the samples, in situ hybridisation for the EBERs was performed (Figure 3.5). The 
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Figure 3.4: NPC tumour and matched normal tissuearrays.  
 
To validate the expression array data, two tissuearrays containing NPC tumour and 
matched normal epithelial cells were constructed. There are 22 matched cases in each 
tissuearray, and each case is represented by 4 cores containing 2 cores of tumour and 
2 of normal. The figure shows two tissuearray blocks (A), corresponding slides with 
H&E staining (B) and representative images of NPC tumour tissue and its matched 
normal nasopharynx (C). T = tumour, N = normal. 
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Figure 3.5: EBERs staining in NPC tumour and normal epithelial cells. EBERs 
staining was performed in tissuearrays. The examples of EBERs staining in NPC 
tumour (T) and normal epithelial cells (N) are presented. NPC tumour cells show 
positive nuclear localisation, whereas no or rare nuclear accumulation of EBERs is 
observed in normal epithelial cells and lymphocytes.  
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positive nuclear localisation of EBERs in the NPC tumours but absence in the normal 
epithelial cells confirmed the presence of EBV in NPC tumours and absence in the 
normal controls.  
 
The differential expression of genes of interest identified by expression array analysis 
was validated at the protein level by IHC staining in tissuearrays. Because of the 
limited material in the tissuearrays, staining for most of the genes was performed in 
only one tissuearray. When evaluating the staining the following are excluded: (1) 
overlapped cores, (2) edge of the cores which can be overstained, (3) damaged cores 
(4) cores without target tissue. Additionally, due to losses in block trimming and 
staining procedures, the number of cases evaluated for individual genes was variable. 
The criteria used for scoring IHC staining are described in Section 2.3.4. In addition, 
IHC staining for some genes was also performed in frozen sections which were cut 
from the same biopsies used for array analysis.   
 
3.5 Tumour-related genes 
 
A large number of differentially expressed genes were identified, and we focused our 
attention on those genes with known function whose up- or down-regulation in NPC 
tumours may play critical roles in determining the malignant phenotypes of NPC. 
According to previous studies and the findings from our data, the differentially 
expressed genes were involved in diverse functions of biological processes including 
tumour promoting, tumour suppression, apoptosis/anoikis- suppressing or metastasis. 
For some of the genes of interest IHC staining data for validation of their array-
predicted expression are presented. Since a large number of differentially expressed 
genes were identified, IHC staining could include only a small proportion of them. 
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Therefore, some of them were compared with previous published studies of IHC 
staining. The agreement of the current and previous data further verified the reliability 
of our array data and supports the idea that these genes are important for NPC 
tumourigenesis.  
 
To find further information relating to the molecular basis of the pathogenesis of NPC, 
the expression array data of the individual tumour-related genes were also analysed in 
the context of their copy number changes determined by SNP array analysis. This is 
described in detail in Chapter 4. In some cases, the up-regulated genes were found to 
be amplified in several samples and down-regulated genes were frequently deleted, 
whereas for some of the genes of interest, the expression level did not correlate with 
DNA copy number.  
 
3.5.1 Oncogenes 
 
Activation of oncogenes and inactivation of tumour suppressor genes is a critical step 
in NPC tumourigenesis. In spite of the increased understanding of genetic changes 
and gene expression patterns in NPC in recent years, information of oncogene 
activation is still limited in this type of cancer. To identify putative oncogenes that 
may be important in NPC our expression array data were first analysed for 
differentially expressed genes that were up-regulated in 4 or more tumours. This gene 
list was then compared with a list of putative oncogenes derived from the literature. 
The common genes included in these two gene lists were defined as putative NPC 
oncogenes (Table 3.1). 159 putative oncogenes that showed upregulation in 4 or more 
NPC tumours are defined in this list. Examination of these oncogenes in individual 
tumours revealed that the mean number of oncogenes upregulated in each tumour was  
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Table 3.1: 159 Putative oncogenes upregulated in at least 25% of samples. 
Gene 
Symbol Gene Title location 
Number 
(%) with 
copy gain 
Number 
(%) up 
regulated 
Validated 
up 
regulated 
ETS1 
v-ets erythroblastosis virus E26 
oncogene homolog 1 (avian) 11q24.3 1*(7) 16 (100)  
TFRC transferrin receptor (p90, CD71) 3q29 0 (0) 16 (100)  
EIF4A2 
eukaryotic translation initiation 
factor 4A, isoform 2 3q27.3 0 (0) 15 (94)  
TPR 
translocated promoter region (to 
activated MET oncogene) 1q31.1 4*(27) 15 (94)  
NCOA3 nuclear receptor coactivator 3 20q13.12 1 (7) 15 (94) NPC OG 
RPL22 ribosomal protein L22 1p36.31 0*(0) 15 (94)  
RBM15 RNA binding motif protein 15 1p13.3 1*(7) 15 (94)  
RHEB Ras homolog enriched in brain 7q36.1 2 (13) 15 (94)  
EZH2 
enhancer of zeste homolog 2 
(Drosophila) 7q36.1 2 (13) 15 (94) 
10/14 
(71%) 
PSIP1 
PC4 and SFRS1 interacting protein 
1 9p22.3 0*(0) 14 (88)  
WHSC1 
Wolf-Hirschhorn syndrome 
candidate 1 4p16.3 0*(0) 14 (88) 
11/18 
(61%) 
LIFR 
leukemia inhibitory factor receptor 
alpha 5p13.1 6 (40) 14 (88)  
AKT3 
v-akt murine thymoma viral 
oncogene homolog 3 (protein kinase 
B, gamma) 1q44 3*(20) 14 (88)  
TOP1 topoisomerase (DNA) I 20q12 1 (7) 14 (88)  
ECT2 
epithelial cell transforming sequence 
2 oncogene 3q26.31 2 (13) 14 (88)  
FUS 
fusion (involved in t(12;16) in 
malignant liposarcoma) 16p11.2 1*(7) 14 (88)  
RAB12 
RAB12, member RAS oncogene 
family 18p11.22 2 (13) 14 (88)  
RAB18 
RAB18, member RAS oncogene 
family 10p12.1 0*(0) 14 (88)  
RAB28 
RAB28, member RAS oncogene 
family 4p15.33 6 (40) 14 (88)  
RAN 
RAN, member RAS oncogene 
family 12q24.33 2 (13) 14 (88)  
RAP1A 
RAP1A, member of RAS oncogene 
family 1p13.2 1*(7) 14 (88)  
DEK DEK oncogene (DNA binding) 6p22.3 1*(7) 14 (88)  
JAK2 
Janus kinase 2 (a protein tyrosine 
kinase) 9p24.1 0*(0) 14 (88)  
JUN jun oncogene 1p32.1 3 (20) 14 (88)  
RAP2B 
RAP2B, member of RAS oncogene 
family 3q25.2 0(0) 14 (88)  
RAP1B 
RAP1B, member of RAS oncogene 
family  12q15 4 (27) 13 (81)  
SKIL SKI-like oncogene 3q26.2 3 (20) 13 (81) 
25/34 
(73.5%) 
TRIM33 tripartite motif-containing 33 1p13.2 1*(7) 13 (81)  
LCP1 lymphocyte cytosolic protein 1  13q14.12 0*(0) 13 (81)  
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PICALM 
phosphatidylinositol binding clathrin 
assembly protein 11q14.2 1*(7) 13 (81)  
TPM3 tropomyosin 3 1q21.3 4 (27) 13 (81)  
CIITA 
class II, major histocompatibility 
complex, transactivator 16p13.13 1*(7) 13 (81)  
RAP2C 
RAP2C, member of RAS oncogene 
family Xq25 n/a 13 (81)  
CLTC clathrin, heavy chain (Hc) 17q23.1 1 (70) 13 (81)  
TCF3 
transcription factor 3 (E2A 
immunoglobulin enhancer binding 
factors E12/E47) 19p13.3 0*(0) 12 (75)  
CRKL 
v-crk sarcoma virus CT10 oncogene 
homolog (avian)-like 22q11.21 0 (0) 12 (75)  
FGFR1OP2 FGFR1 oncogene partner 2 12p11.23 7 (47) 12 (75)  
FYN 
FYN oncogene related to SRC, 
FGR, YES 6q21 3*(20) 12 (75)  
KRAS 
v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog 12p12.1 7 (47) 12 (75)  
MLLT6 
myeloid/lymphoid or mixed-lineage 
leukemia (trithorax homolog, 
Drosophila); translocated to, 6 17q12 0*(0) 12 (75)  
NOLC1 
nucleolar and coiled-body 
phosphoprotein 1 10q24.32 0*(0) 12 (75) NPC OG 
PAFAH1B
2 
platelet-activating factor 
acetylhydrolase, isoform Ib, beta 
subunit 30kDa 11q23.3 0*(0) 12 (75)  
TRIM24 tripartite motif-containing 24 7q34 3 (20) 12 (75)  
ZNF384 zinc finger protein 384 12p13.31 6 (40) 12 (75)  
SET 
SET translocation (myeloid 
leukemia-associated) 9q34.11 0*(0) 11 (69  
TPD52 tumor protein D52 8q21.13 5*(33) 11 (69  
WHSC1L1 
Wolf-Hirschhorn syndrome 
candidate 1-like 1 8p12 7 (47) 11 (69)  
JAK1 
Janus kinase 1 (a protein tyrosine 
kinase) 1p31.3 3 (20) 11 (69) 5/11 (45%) 
BCL6 
B-cell CLL/lymphoma 6 (zinc finger 
protein 51) 3q27.3 0 (0) 11 (69)  
SFRS3 
splicing factor, arginine/serine-rich 
3 6p21.31 0*(0) 11 (69)  
CCND2 cyclin D2 12p13.32 7 (47) 11 (69)  
LASP1 LIM and SH3 protein 1 17q12 0*(0) 11 (69)  
PATZ1 
POZ (BTB) and AT hook containing 
zinc finger 1 22q12.2 1*(7) 11 (69)  
PML promyelocytic leukemia 15q24.1 0*(0) 11 (69)  
GNA12 
guanine nucleotide binding protein 
(G protein) alpha 12 7p22.2 1 (7) 11 (69)  
COX6C cytochrome c oxidase subunit VIc 8q22.2 5*(33) 11 (69)  
DDX10 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 10 11q22.3 0*(0) 11 (69)  
GOLPH3 golgi phosphoprotein 3  5p13.3 6 (40) 11 (69)  
MAF 
v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog 
(avian) 16q23.1 2*(13) 11 (69)  
NRAS neuroblastoma RAS viral (v-ras)  1p13.2 1*(7) 11 (69) NPC OG 
YES1 v-yes-1 Yamaguchi sarcoma viral 18p11.32 2 (13) 11 (69)  
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oncogene homolog 1 
MERTK 
c-mer proto-oncogene tyrosine 
kinase 2q13 1 (7) 11 (69)  
RAB23 
RAB23, member RAS oncogene 
family 6p12.1 4*(27) 11 (69)  
RAB27A 
RAB27A, member RAS oncogene 
family 15q21.3 1*(7) 10 (63)  
RAB2A 
RAB2A, member RAS oncogene 
family 8q12.1 5*(33) 10 (63)  
SOX2 
SRY (sex determining region Y)-
box 2 3q26.33 5 (33) 10 (63)  
HOXA9 homeobox A9 7p15.2 3 (20) 10 (63)  
RAB14 
RAB14, member RAS oncogene 
family 9q33.2 0*(0) 10 (63)  
RAB21 
RAB21, member RAS oncogene 
family 12q21.1 5 (33) 10 (63)  
RAB24 
RAB24, member RAS oncogene 
family 5q35.3 0*(0) 10 (63)  
MYST3 
MYST histone acetyltransferase 
(monocytic leukemia) 3 8p11.21 7 (47) 10 (63)  
GNA13 
guanine nucleotide binding protein 
(G protein), alpha 13 17q24.1 2 (13) 10 (63)  
CRK 
v-crk sarcoma virus CT10 oncogene 
homolog (avian) 17p13.3 0*(0) 10 (63)  
ETV7 ets variant gene 7 (TEL2 oncogene) 6p21.31 1*(7) 10 (63)  
AKT2 
v-akt murine thymoma viral 
oncogene homolog 2 19q13.2 0 (0) 10 (63)  
CDK4 cyclin-dependent kinase 4 12q14.1 4 (27) 10 (63)  
COL1A1 collagen, type I, alpha 1 17q21.33 1 (7) 10 (63)  
BMI1 
BMI1 polycomb ring finger 
oncogene 10p12.31 0*(0) 10 (63) NPC OG 
RAB1A 
RAB1A, member RAS oncogene 
family 2p14 1 (7) 10 (63)  
GNAS GNAS complex locus 20q13.32 1 (7) 10 (63)  
CCNB1IP1 cyclin B1 interacting protein 1 14q11.2 2*(13) 9 (56)  
RAB22A 
RAB22A, member RAS oncogene 
family 20q13.32 1 (7) 9 (56)  
RAB7L1 
RAB7, member RAS oncogene 
family-like 1 1q32.1 5 (33) 9 (56)  
CEBPA 
CCAAT/enhancer binding protein 
(C/EBP), alpha 19q13.11 0*(0) 9 (56)  
HSP90AB1 
heat shock protein 90kDa alpha 
(cytosolic), class B member 1 6p21.1 1*(7) 9 (56)  
LPP 
LIM domain containing preferred 
translocation partner in lipoma 3q28 0 (0) 9 (56)  
RAB5A 
RAB5A, member RAS oncogene 
family 3p24.3 0*(0) 9 (56)  
RABL5 
RAB, member RAS oncogene 
family-like 5 7q22.1 2*(13) 9 (56)  
RRAS 
related RAS viral (r-ras) oncogene 
homolog 19q13.33 0*(0) 9 (56)  
MYB 
v-myb myeloblastosis viral 
oncogene homolog (avian) 6q23.3 3*(20) 9 (56)  
RAB40B 
RAB40B, member RAS oncogene 
family 17q25.3 0 (0) 9 (56)  
IKZF1 IKAROS family zinc finger 1 7p12.2 2 (13) 8 (50)  
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(Ikaros) 
FLI1 Friend leukemia virus integration 1 11q24.3 1*(7) 8 (50)  
CBL 
Cas-Br-M (murine) ecotropic 
retroviral transforming sequence 11q23.3 0*(0) 8 (50)  
TP63 tumor protein p63 3q28 0 (0) 8 (50) NPC OG 
MYBL1 
v-myb myeloblastosis viral 
oncogene homolog (avian)-like 1 8q13.1 5 (33) 8 (50)  
MYCN 
v-myc myelocytomatosis viral 
related oncogene, neuroblastoma 
derived (avian) 2p24.3 2 (13) 8 (50)  
RAB9A 
RAB9A, member RAS oncogene 
family Xp22.2 n/a 8 (50)  
RRAS2 
related RAS viral (r-ras) oncogene 
homolog 2 11p15.2 2*(13) 8 (50)  
WNT5A 
wingless-type MMTV integration 
site family, member 5A 3p14.3 0*(0) 8 (50) 
10/23 
(43.5%) 
RAB43 
RAB43, member RAS oncogene 
family 3q21.3 0 (0) 7 (44)  
RAF1 
V-raf-1 murine leukemia viral 
oncogene homolog 1 3p25.1 0*(0) 7 (44)  
REL 
v-rel reticuloendotheliosis viral 
oncogene homolog (avian) 2p16.1 1 (7) 7 (44)  
PIK3CA 
Phosphoinositide-3-kinase, catalytic, 
alpha polypeptide 3q26.32 4 (27) 7 (44) NPC OG 
RAP2A 
RAP2A, member of RAS oncogene 
family 13q32.1 0*(0) 7 (44)  
RAB27B 
RAB27B, member RAS oncogene 
family 18q21.2 2*(13) 7 (44)  
RAB34 
RAB34, member RAS oncogene 
family 17q11.2 2*(13) 7 (44)  
MSI2 musashi homolog 2 (Drosophila) 17q22 2 (13) 7 (44)  
RAB11A 
RAB11A, member RAS oncogene 
family 15q22.31 0*(0) 7 (44)  
MALT1 
mucosa associated lymphoid tissue 
lymphoma translocation gene 1 18q21.32 2*(13) 7 (44)  
PTTG1 pituitary tumor-transforming 1 5q33.3 0*(0) 7 (44)  
ELL 
elongation factor RNA polymerase 
II 18p13.11 0*(0) 7 (44)  
KTN1 kinectin 1 (kinesin receptor) 14q22.3 1*(7) 7 (44)  
GMPS guanine monphosphate synthetase 3q25.31 0 (0) 7 (44)  
ETV6 ets variant gene 6 (TEL oncogene) 12p13.2 7 (47) 7 (44)  
PDGFRA 
platelet-derived growth factor 
receptor, alpha polypeptide 4q12 1*(7) 7 (44)  
DDIT3 DNA-damage-inducible transcript 3 12q13.3 5 (33) 7 (44)  
RALA 
v-ral simian leukemia viral 
oncogene homolog A (ras related) 7p14.1 2 (13) 7 (44)  
RET ret proto-oncogene 10q11.21 0*(0) 7 (44)  
AKT1 
v-akt murine thymoma viral 
oncogene homolog 1 14q32.33 0 (0) 7 (44)  
IL21R interleukin 21 receptor 16p12.1 1*(7) 6 (38)  
RELB 
v-rel reticuloendotheliosis viral 
oncogene homolog B, nuclear factor 
of kappa light polypeptide gene 
enhancer in B-cells 3 (avian) 19q13.32 0 (0) 6 (38)  
SS18L1 
synovial sarcoma translocation gene 
on chromosome 18-like 1 20q13.3 0*(0) 6 (38)  
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THRB 
thyroid hormone receptor, beta 
(erythroblastic leukemia viral (v-
erb-a) oncogene homolog 2, avian) 3p24.2 0*(0) 6 (38)  
RAB6A 
RAB6A, member RAS oncogene 
family 11q13.4 1*(7) 6 (38)  
HRAS 
v-Ha-ras Harvey rat sarcoma viral 
oncogene homolog 11p15.5 0 (0) 6 (38) NPC OG 
MAFB 
v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog B 
(avian) 20q12 1 (7) 6 (38)  
MET 
met proto-oncogene (hepatocyte 
growth factor receptor) 7q31.2 2 (13) 6 (38) NPC OG 
BRAF 
v-raf murine sarcoma viral oncogene 
homolog B1 7q34 3 (20) 6 (38)  
MLLT3 
myeloid/lymphoid or mixed-lineage 
leukemia (trithorax homolog, 
Drosophila); translocated to, 3 9p21.3 0*(0) 6 (38)  
HMGA2 high mobility group AT-hook 2 12q14.3 5 (33) 6 (38)  
MLL 
myeloid/lymphoid or mixed-lineage 
leukemia (trithorax homolog, 
Drosophila) 11q23.3 0*(0) 6 (38)  
VAV1 vav 1 oncogene 19p13.3 0*(0) 5 (31)  
VAV2 vav 2 oncogene 9q34.2 0*(0) 5 (31)  
PBX1 Pre-B-cell leukemia homeobox 1 1q23.3 4 (27) 5 (31)  
SKI 
v-ski sarcoma viral oncogene 
homolog (avian) 1p36.33 0*(0) 5 (31)  
USP6 
ubiquitin specific peptidase 6 (Tre-2 
oncogene) 17p13.2 0*(0) 5 (31)  
MYCL1 
v-myc myelocytomatosis viral 
oncogene homolog 1, lung 
carcinoma derived (avian) 1p34.2 2 (13) 5 (31)  
ERBB4 
v-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (avian) 2q34 1 (7) 5 (31)  
FCRL4 Fc receptor-like 4 1q23.1 4 (27) 5 (31)  
HOXA13 homeobox A13 7p15.2 3 (20) 5 (31)  
MNX1 homeobox HB9 7q36.3 1 (7) 5 (31)  
NIN ninein (GSK3B interacting protein) 14q22.1 1*(7) 5 (31)  
EGFR 
epidermal growth factor receptor 
(erythroblastic leukemia viral (v-
erb-b) oncogene homolog, avian) 7p11.2 3 (20) 5 (31) NPC OG 
FGFR1 
fibroblast growth factor receptor 1 
(fms-related tyrosine kinase 2, 
Pfeiffer syndrome) 8p12 6 (40) 5 (31)  
CHIC2 cysteine-rich hydrophobic domain 2 4q12 1*(7) 5 (31)  
ETV1 ets variant gene 1 7p21.2 2 (13) 4 (25)  
NUMA1 nuclear mitotic apparatus protein 1 11q13.4 1*(7) 4 (25)  
PDE4DIP 
phosphodiesterase 4D interacting 
protein (myomegalin) 1q21.1 0 (0) 4 (25)  
PVT1 
Pvt1 oncogene homolog, MYC 
activator (mouse) 8q24.21 5 (33) 4 (25)  
ABL1 
v-abl Abelson murine leukemia viral 
oncogene homolog 1 9q34.12 0 (0) 4 (25)  
ERG 
v-ets erythroblastosis virus E26 
oncogene homolog (avian) 21q22.2 0 (0) 4 (25)  
FCGR2B Fc fragment of IgG, low affinity IIb, 1q23.3 4 (27) 4 (25)  
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receptor (CD32) 
KDSR 3-ketodihydrosphingosine reductase 18q21.33 2*(13) 4 (25)  
ITK IL2-inducible T-cell kinase 5q33.3 0*(0) 4 (25)  
KIT 
v-kit Hardy-Zuckerman 4 feline 
sarcoma viral oncogene homolog 4q12 1*(7) 4 (25)  
RAB31 
RAB31, member RAS oncogene 
family 18p11.22 2*(13) 4 (25)  
RAB33B 
RAB33B, member RAS oncogene 
family 4q31.1 0*(0) 4 (25)  
RAB39B 
RAB39B, member RAS oncogene 
family Xq28 n/a 4 (25)  
 
* = locus that showed copy number loss in a number of samples.  
n/a = copy number data not applicable on the X chromosome.  
NPC OG = gene previously implicated as an oncogene in NPC. 
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93 (range 40 – 120). To determine whether the overexpression of the potential NPC 
oncogenes could be caused by their copy number status, the copy number data for 
these genes are also displayed. 
 
Several oncogenes in our list (labelled “NPC OG” in the table) have previously been 
determined to be associated with NPC. Among these NCOA3 has been reported to be 
overexpressed in 51% and gained in 7% of NPC tumours (Liu et al., 2008), and our 
data show it to be upregulated in 94% and gained in 7% of NPC. A recent publication 
suggested that NOLC1 had a higher expression level in most NPC cell lines and 
biopsies compared with normal cells, and the activation of this gene is necessary for 
p53-mediated MDM2 expression and is associated with cell proliferation in NPC cells 
(Hwang et al., 2009). This gene showed 75% upregulation in our expression data. 
TP63 is a suppressor of wide type p53 and its expression was found to be elevated in 
primary NPC and immortalised nasopharyngeal epithelial cells at their proliferation 
stages (Crook et al., 2000; Yip & Tsao, 2008). TP63 was observed to be upregulated 
in 50% of our NPC tumours. Other genes including NRAS, PIK3CA and EGFR were 
identified by a genome-wide study of NPC (Hui et al., 2002; Or et al., 2005). They 
are also found to have a copy number gain in several samples and upregulated in most 
of NPC. Recent evidence suggested that polycomb group genes can act as oncogenes. 
BMI1 is one of the polycomb group proteins and has been shown to be overexpressed 
in 38.7% of primary NPC tumours. Furthermore, the oncogenic potential of this gene 
was revealed by its ability to immortalise normal nasopharyngeal epithelial cells, 
induce epithelial-mesenchymal transition (EMT) and enhance the motility and 
invasiveness of human nasopharyngeal epithelial cells (Song et al., 2006; Song et al., 
2009). BMI1 was upregulated in 63% of NPC tumours in our data.  
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In addition to the candidate oncogenes revealed previously, the majority of genes in 
the oncogene list are novel potential NPC oncogenes although their upregulation has 
been reported to be associated with other types of cancer. The IHC staining for 
several genes of interest was performed in the tissuearrays and frozen sections from 
biopsies that have been used for array analysis.  
 
EZH2 along with BMI1 which was introduced above is another member of the 
Polycomb group of genes. Elevated expression of this gene has been reported in 
several cancers including prostate cancer (Varambally et al., 2002; van Leenders et al., 
2007), breast cancer (Kleer et al., 2003) and glioblastoma multiforme (Suva et al., 
2009) based on its ability to modulate transcription of key genes implicated in cell 
cycle control, DNA repair, and cell differentiation and invasiveness (Shi et al., 2007a; 
Cao et al., 2008; Friedman et al., 2009). Our data demonstrated that EZH2 was also 
elevated in NPC tumours. In the expression data, EZH2 transcripts were upregulated 
in 94% (15/16) of NPC tumours. IHC staining of EZH2 in frozen sections from the 
biopsies used for array analysis confirmed increased expression in tumours at the 
protein level. In addition, tissuearray data revealed that EZH2 was overexpressed in 
71% (10/14) of NPC tumours (Figure 3.6 A).    
 
WHSC1 is expressed ubiquitously in early development and consistently appears in 
glioblastoma multiforme tissue but not in normal brain. Its expression increased 
tumour proliferation activity (Li et al., 2008). This indicates that WHSC1 might be a 
putative oncogene as emphasised by recent data showing overexpression in 15 types 
of cancer compared to their normal counterparts (Kassambara et al., 2009). In our  
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Figure 3.6: Expression array intensities and immunohistochemical staining for    
oncogenes.  
  
The left panels show normalised expression array intensities for the 4 normal samples 
(grey) and 15 NPCs plus C666-1 (red). The centre panels show examples of 
immunohistochemical staining of NPC tissue samples. Normal epithelial cells 
(Normal) show weak expression, whilst tumour cells (Tumour) show strong 
expression. The right panels show the immunohistochemical scoring results from the 
tissue arrays (normal, grey: tumour, red). At the RNA and protein levels respectively, 
(A) EZH2 is upregulated in 15/16 (94%) and 10/14 (71%) samples, and positive 
EZH2 staining is predominantly observed in the nucleus; (B) SKIL is upregulated in 
13/16 (81%) and 25/34 (74%) samples, and positive SKIL staining is predominantly 
observed in the cytoplasm and membrane; (C) JAK1 is upregulated in 11/16 (69%) 
and 5/11 (45%) samples, and positive JAK1 staining is predominantly observed in the 
nucleus; (D) WNT5A is upregulated in 8/16 (50%) and 10/23 (43%) samples, and 
positive WNT5A staining is predominantly observed in the cytoplasm. Note that in (A) 
the illustrated immunohistochemical staining was performed on frozen sections of 
samples that were used for array analysis (MHAU, XY23) whilst the IHC scoring data 
were obtained from tissue arrays. 
 
AB
C
D
MHAU XY23
NORMAL TUMOUR
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expression data the WHSC1 transcript was upregulated in 88% (14/16) of tumours. 
IHC data revealed protein overexpression in 61% (11/18) of NPC tumours. Taken 
together, WHSC1 might be an NPC-related oncogene although confirmation and 
understanding of the tumour promoting function of this gene in NPC requires further 
study.  
 
SKIL (SKI-like oncogene) is a member of the SKI family of proto-oncogenes. Human 
SKIL is considered to be expressed at a very low level in normal human tissues, 
whereas elevation of its expression is believed to occur in both development and 
tumourigenesis. In oesophageal carcinoma, SKIL is needed for smad3-protein 
complexes involved in TGF-β signalling, and increased expression of SKIL can block 
TGFβ-induced growth arrest (Edmiston et al., 2005; Pot & Bonni, 2008). Genome-
wide studies in NPC revealed that the gene locus of SKIL was amplified in 33% of 
advanced NPC tumours (Sheu et al., 2009). In addition, increased expression level of 
SKIL has been associated with EBV reactivation in NPC cells (Lee et al., 2008). In 
our SNP array data, 20% of NPC tumours showed copy number gain at the SKIL gene 
locus. Expression data revealed that 81% (13/16) of NPC tumours were upregulated at 
the transcript level. This was confirmed at the protein level by IHC staining where 
73.5% (25/34) of tumours showed overexpression compared with normal controls 
(Figure 3.6 B). 
 
JAK is a small family consisting of at least four different tyrosine kinases (JAK1, 
JAK2, JAK3 and Tyk2) that share significant structural homology with each other. 
They play an essential role in mediating biological responses including control of cell 
differentiation and proliferation by modulating several signalling pathways especially 
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the JAK-STAT pathway. The activity of JAK is generally required for STAT 
activation which has been implicated in the pathogenesis of a number of malignancies 
(Verma et al., 2003; Xiong et al., 2008). This indicates that JAK has potential 
oncogenic functions. Our expression data also support this thesis in NPC as both 
JAK1 and JAK2 are upregulated. JAK2 transcripts were upregulated in 88% (14/16) 
of tumours whereas JAK1 transcription was upregulated in 69% (11/16) of NPCs and 
IHC data revealed that its protein was overexpressed in 45% (5/11) of tumour samples 
(Figure 3.6 C). 
 
WNT5A is a representative ligand of the Wnt gene family whose function is essential 
for activation of the Wnt/β-catenin signalling pathway. Wnt signalling will be 
considered in Chapter 5. Abnormal expression and tumour promotion activity of 
WNT5A has been observed in several tumours including gastric cancer (Saitoh et al., 
2002), breast cancer (Leris et al., 2005) and prostate cancer (Yamamoto et al.). The 
expression data displayed upregulation of WNT5A transcripts in 50% (8/16) of NPC 
tumours and tissue array data revealed its protein was overexpressed in 43.5% (10/23) 
of NPCs (Figure 3.6 D).    
 
3.5.2 Tumour suppressor genes 
 
Aside from activation of tumour promoting genes, the loss of tumour suppressors is 
another important factor contributing to the development of NPC. To identify putative 
tumour suppressor genes, the list of downregulated genes identified by expression 
array analysis was compared with a list of previously identified putative tumour 
suppressor genes compiled by an extensive literature search. This revealed 165 
putative tumour suppressor genes (Table 3.2). Examination of these TSGs in  
Chapter 3                                                                                                                                                   Results                                                                                 
104 
 
Table 3.2: 165 Putative tumour suppressor genes downregulated in at least 25% 
of samples. 
 
Gene 
Symbol Gene Title Location 
Number 
(%) with 
Copy Loss 
Number (%) 
Down 
regulated 
Validated 
Down 
regulated 
ANXA1 annexin A1 9q21.13 5 (33) 16 (100) 
11/14 
(79%) 
BRD7 bromodomain containing 7 16q12.1 9 (60) 16 (100) NPC tsg 
CEACAM1 
carcinoembryonic antigen-related 
cell adhesion molecule 1 (biliary 
glycoprotein) 19q13.2 0 (0) 16 (100)  
CLCA2 
chloride channel, calcium activated, 
family member 2 1p22.3 3* (20) 16 (100)  
CLU clusterin 8p21.1 3*(20) 16 (100) 
13/13 
(100%) 
CSK c-src tyrosine kinase 15q24.1 2 (13) 16 (100)  
DLG1 discs, large homolog 1 (Drosophila) 3q29 0 (0) 16 (100)  
DUOX2 dual oxidase 2 15q21.1 5* (33) 16 (100)  
EHF ets homologous factor 11p13 1* (7) 16 (100)  
EPAS1 endothelial PAS domain protein 1 2p21 0* (0) 16 (100)  
FOXC1 forkhead box C1 6p25.3 3 (20) 16 (100)  
GLTSCR2 
glioma tumor suppressor candidate 
region gene 2 19q13.32 1 (7) 16 (100)  
GPX3 glutathione peroxidase 3 (plasma) 5q33.1 5 (33) 16 (100)  
H19 
H19, imprinted maternally expressed 
untranslated mRNA 11p15.5 † 16 (100) NPC tsg 
JUP junction plakoglobin 17q21.2 1*  (7) 16 (100)  
KLF5 Kruppel-like factor 5 (intestinal) 13q22.1 5* (33) 16 (100)  
KLK11 kallikrein-related peptidase 11 19q13.33 0 (0) 16 (100)  
LCN2 lipocalin 2 (oncogene 24p3) 9q34.11 6 (40) 16 (100) 
18/19 
(95%) 
MSMB microseminoprotein, beta 10q11.23 3 (20) 16 (100)  
MSRA methionine sulfoxide reductase A 8p23.1 1*(7) 16 (100)  
PER2 period homolog 2 (Drosophila) 2q37.3 † 16 (100)  
S100A2 S100 calcium binding protein A2 1q21.3 0*(0) 16 (100)  
SERPINB13 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 13 18q21.33 2*(13) 16 (100)  
SFN stratifin 1p36.11 8 (53) 16 (100) NPC tsg 
SOX7 
SRY (sex determining region Y)-
box 7 8p23.1 1*(7) 16 (100)  
YAP1 Yes-associated protein 1, 65kDa 
11q22.1-
q22.2 6 (40) 16 (100)  
ZNF185 
zinc finger protein 185 (LIM 
domain) Xq28 n/a 16 (100)  
CDHR2 cadherin-related family member 2 5q35.2 6 (40) 16 (100)  
CEBPD 
CCAAT/enhancer binding protein 
(C/EBP), delta 8q11.21 2*(13) 15 (94)  
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GJB2 gap junction protein, beta 2, 26kDa 13q12.11 7 (47) 15 (94)  
GRLF1 
glucocorticoid receptor DNA 
binding factor 1 19q13.32 1 (7) 15 (94)  
IGFBP5 
insulin-like growth factor binding 
protein 5 2q35 0*(0) 15 (94)  
ING2 
inhibitor of growth family, member 
2 4q35.1 5 (33) 15 (94)  
MCC mutated in colorectal cancers 5q22.2 4 (27) 15 (94)  
NDUFA13 
NADH dehydrogenase (ubiquinone) 
1 alpha subcomplex, 13 19p13.11 4 (27) 15 (94)  
PDLIM4 PDZ and LIM domain 4 5q31.1 7 (47) 15 (94)  
PPP1R13B 
protein phosphatase 1, regulatory 
(inhibitor) subunit 13B 14q32.33 10 (67) 15 (94)  
PRDX2 peroxiredoxin 2 19p13.13 0 (0) 15 (94)  
PYCARD PYD and CARD domain containing 16p11.2 3*(20) 15 (94)  
SEMA3F 
sema domain, immunoglobulin 
domain (Ig), short basic domain, 
secreted, (semaphorin) 3F 3p21.31 12 (80) 15 (94)  
TACC2 
transforming, acidic coiled-coil 
containing protein 2 10q26.13 3 (20) 15 (94)  
GSTP1 glutathione S-transferase pi 11q13.2 1 (7) 15 (94) NPC tsg 
DUOX1 dual oxidase 1 15q21.1 5*(33) 15 (94)  
CBFA2T3 
core-binding factor, runt domain, 
alpha subunit 2; translocated to, 3 16q24.3 14 (93) 14 (88)  
HINT1 
histidine triad nucleotide binding 
protein 1 5q31.1 5 (33) 14 (88)  
LIMD1 LIM domains containing 1 3p21.31 12 (80) 14 (88)  
LLGL2 
lethal giant larvae homolog 2 
(Drosophila) 17q25.1 3 (20) 14 (88)  
PDCD4 
programmed cell death 4 (neoplastic 
transformation inhibitor) 10q24 3 (20) 14 (88)  
PTPN6 
protein tyrosine phosphatase, non-
receptor type 6 12p13.31 0*(0) 14 (88)  
RARB retinoic acid receptor, beta 3p24.2 8 (53) 14 (88) NPCtsg 
RPS6KA2 
ribosomal protein S6 kinase, 90kDa, 
polypeptide 2 6q27 4 (27) 14 (88)  
SERPINB2 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 2 18q21.33 1*(7) 14 (88)  
SLC9A3R1 
solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 1 17q25.1 1*(7) 14 (88)  
SMAD3 SMAD family member 3 15q22.33 4 (27) 14 (88)  
SOD2 
superoxide dismutase 2, 
mitochondrial 6q25.3 4*(27) 14 (88)  
CSNK1A1 casein kinase 1, alpha 1 5q33.1 6 (40) 13 (81)  
DUSP6 dual specificity phosphatase 6 12q21.33 0*(0) 13 (81)  
HRASLS HRAS-like suppressor 3q29 0 (0) 13 (81)  
IFI16 
interferon, gamma-inducible protein 
16 1q23.1 0*(0) 13 (81)  
KLF6 Kruppel-like factor 6 10p15.1 2 (13) 13 (81)  
RASSF6 
Ras association (RalGDS/AF-6) 
domain family 6 4q13.3 1*(7) 13 (81)  
SPTBN1 spectrin, beta, non-erythrocytic 1 2p16.2 0*(0) 13 (81)  
TMPRSS6 transmembrane protease, serine 6 22q12.3 0 (0) 13 (81)  
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VTA1 
Vps20-associated 1 homolog (S. 
cerevisiae) 6q24.1 1*(7) 13 (81)  
WASL Wiskott-Aldrich syndrome-like 7q31.32 0*(0) 13 (81)  
ZC3H10 
zinc finger CCCH-type containing 
10 12q13.2 0*(0) 13 (81)  
ADAMTS9 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 9 3p14.1 11 (73) 12 (75) NPC tsg 
CXCL14 chemokine (C-X-C motif) ligand 14 5q31.1 8 (53) 12 (75)  
EXT2 exostoses (multiple) 2 11p11.2 1*(7) 12 (75)  
MFN2 mitofusin 2 1p36.22 7 (47) 12 (75)  
MZF1 myeloid zinc finger 1 19q13.43 † 12 (75)  
NPAS2 neuronal PAS domain protein 2 2q11.2 0*(0) 12 (75)  
MIIP  invasion inhibitory protein 45 1p36.22 7 (47) 12 (75)  
SERPINB5 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 5 18q21.33 2*(13) 12 (75)  
TIMP3 
TIMP metallopeptidase inhibitor 3 
(Sorsby fundus dystrophy, 
pseudoinflammatory) 22q12.3 0*(0) 12 (75)  
TMSB10 thymosin, beta 10 2p11.2 0*(0) 12 (75)  
TNFSF10 
Tumor necrosis factor (ligand) 
superfamily, member 10 3q26.31 0*(0) 12 (75)  
CHFR 
checkpoint with forkhead and ring 
finger domains 12q24.33 † 11 (69) NPC tsg 
DDB2 
damage-specific DNA binding 
protein 2, 48kDa 11p11.2 1*(7) 11 (69)  
ETS2 
v-ets erythroblastosis virus E26 
oncogene homolog 2 (avian) 21q22.2 0 (0) 11 (69)  
FBXO31 F-box protein 31 16q24.2 11 (73) 11 (69)  
HPGD 
hydroxyprostaglandin 
dehydrogenase 15-(NAD) 4q34.1 3 (20) 11 (69)  
KLF4 Kruppel-like factor 4 (gut) 9q31.2 4*(27) 11 (69) 
31/37 
(84%) 
LATS1 
LATS, large tumor suppressor, 
homolog 1 (Drosophila) 6q25.1 2*(13) 11 (69)  
PRDX1 peroxiredoxin 1 1p34.1 1*(7) 11 (69)  
VSNL1 visinin-like 1 2p24.2 0*(0) 11 (69)  
FH fumarate hydratase 1q43 1*(7) 10 (63)  
GAK cyclin G associated kinase 4p16.3 † 10 (63)  
GDI2 GDP dissociation inhibitor 2 10p15.1 2 (13) 10 (63)  
IER3 immediate early response 3 6p21.33 4*(27) 10 (63)  
IGFBP3 
insulin-like growth factor binding 
protein 3 7p13 0*(0) 10 (63)  
SMARCA4 
SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily a, member 4 19p13.2 0 (0) 10 (63)  
THRA 
thyroid hormone receptor, alpha 
(erythroblastic leukemia viral (v-erb-
a) oncogene homolog, avian) 17q21.1 1*(7) 10 (63) NPC tsg 
TLE4 
transducin-like enhancer of split 4 
(E(sp1) homolog, Drosophila) 9q21.31 4 (27) 10 (63)  
TP73 tumor protein p73 1p36.32 11 (73) 10 (63) NPC tsg 
TRIM35 tripartite motif-containing 35 8p21.2 3*(20) 10 (63)  
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TRIM8 tripartite motif-containing 8 10q24.32 3 (20) 10 (63)  
WWOX 
WW domain containing 
oxidoreductase 16q23.1 7 (47) 10 (63)  
BNIP3L 
BCL2/adenovirus E1B 19kDa 
interacting protein 3-like 8p21.2 3*(20) 9 (56)  
CDKN2C 
cyclin-dependent kinase inhibitor 2C 
(p18, inhibits CDK4) 1p33 0*(0) 9 (56)  
CTDSPL 
CTD (carboxy-terminal domain, 
RNA polymerase II, polypeptide A) 
small phosphatase-like 3p22.2 11 (73) 9 (56)  
EGR1 early growth response 1 5q31.2 7 (47) 9 (56)  
HIPK2 
homeodomain interacting protein 
kinase 2 7q34 0*(0) 9 (56)  
NDRG1 N-myc downstream regulated gene 1 8q24.22 0*(0) 9 (56)  
PFDN5 prefoldin subunit 5 12q13.13 0*(0) 9 (56)  
PRR5 proline rich 5 (renal) 22q13.31 8 (53) 9 (56)  
PSEN1 presenilin 1 (Alzheimer disease 3) 14q24.2 9 (60) 9 (56)  
RASEF 
RAS and EF-hand domain 
containing 9q21.32 4 (27) 9 (56)  
REEP5 receptor accessory protein 5 5q22.2 4 (27) 9 (56)  
SAR1A 
SAR1 gene homolog A (S. 
cerevisiae) 10q22.1 3 (20) 9 (56)  
TSC1 tuberous sclerosis 1 9q34.13 6 (40) 9 (56)  
SMARCA2 
SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily a, member 2 9p24.3 6*(40) 9 (56)  
EPB41 
erythrocyte membrane protein band 
4.1 (elliptocytosis 1, RH-linked) 1p35.3 6 (40) 8 (50)  
GPNMB glycoprotein (transmembrane) nmb 7p15.3 0*(0) 8 (50)  
MIA3 
melanoma inhibitory activity family, 
member 3 1q41 0*(0) 8 (50)  
PERP PERP, TP53 apoptosis effector 6q23.3 2*(13) 8 (50)  
RND3 Rho family GTPase 3 2q23.3 0*(0) 8 (50)  
RPS14 ribosomal protein S14 5q33.1 5 (33) 8 (50)  
YWHAE 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
epsilon polypeptide 17p13.3 5 (33) 8 (50)  
BLCAP bladder cancer associated protein 20q11.23 0*(0) 7 (44)  
DNAJA3 
DnaJ (Hsp40) homolog, subfamily 
A, member 3 16p13.3 4*(27) 7 (44)  
EEF1A1 
eukaryotic translation elongation 
factor 1 alpha 1 6q13 2*(13) 7 (44)  
FOXO1 forkhead box O1 13q14.11 8 (53) 7 (44)  
GABARAP 
GABA(A) receptor-associated 
protein 17p13.1 5 (33) 7 (44)  
IGFBP7 
insulin-like growth factor binding 
protein 7 4q12 1*(7) 7 (44)  
PA2G4 proliferation-associated 2G4, 38kDa 12q13.2 0*(0) 7 (44)  
PHLDA1 
pleckstrin homology-like domain, 
family A, member 1 12q21.2 0*(0) 7 (44)  
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SDHB 
succinate dehydrogenase complex, 
subunit B, iron sulfur (Ip) 1p36.13 7(47) 7 (44)  
SH3GLB1 
SH3-domain GRB2-like endophilin 
B1 1p22.3 3*(20) 7 (44)  
TJP2 
tight junction protein 2 (zona 
occludens 2) 9q21.11 4 (27) 7 (44)  
UTRN utrophin 6q24.2 1*(7) 7 (44)  
BCLAF1 
BCL2-associated transcription factor 
1 6q23.3 1*(7) 6 (38)  
CD9 CD9 molecule 12p13.31 0*(0) 6 (38)  
DDX3X 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, X-linked Xp11.4 n/a 6 (38)  
FOXO3 forkhead box O3 6q21 1*(7) 6 (38)  
MSH3 mutS homolog 3 (E. coli) 5q14.1 8 (53) 6 (38) 
15/18 
(83%) 
PEBP1 
phosphatidylethanolamine binding 
protein 1 12q24.23 0*(0) 6 (38)  
CD99 CD99 molecule Xp22.33 n/a 5 (31)  
CREG1 
cellular repressor of E1A-stimulated 
genes 1 1q24.2 1*(7) 5 (31)  
DDIT4 DNA-damage-inducible transcript 4 10q22.1 3 (20) 5 (31)  
HMGB1 high-mobility group box 1 13q12.3 7*(47) 5 (31)  
PHB prohibitin 17q21.33 0*(0) 5 (31)  
TES 
testis derived transcript (3 LIM 
domains) 7q31.2 0*(0) 5 (31)  
TFAP2A 
transcription factor AP-2 alpha 
(activating enhancer binding protein 
2 alpha) 6p24.3 2*(13) 5 (31)  
TLE1 
transducin-like enhancer of split 1 
(E(sp1) homolog, Drosophila) 
9q21.31 - 
q21.32 4 (27) 5 (31)  
CCAR1 
cell division cycle and apoptosis 
regulator 1 10q21.3 3 (20) 5 (31)  
PTEN 
phosphatase and tensin homolog 
(mutated in multiple advanced 
cancers 1) 10q23.31 3 (20) 5 (31) NPCtsg 
TSC22D1 TSC22 domain family, member 1 13q14.11 8 (53) 5 (31)  
BECN1 
beclin 1 (coiled-coil, myosin-like 
BCL2 interacting protein) 17q21.31 1 (7) 5 (31)  
RTN4 reticulon 4 2p16.1 0*(0) 5 (31)  
RASSF5 
Ras association (RalGDS/AF-6) 
domain family 5 1q32.1 0*(0) 5 (31)  
CDH1 
cadherin 1, type 1, E-cadherin 
(epithelial) 16q22.1 9 (60) 4 (25) NPC tsg 
RANBP2 RAN binding protein 2 2q13 0*(0) 4 (25)  
RBMX 
RNA binding motif protein, X-
linked Xq26.3 n/a 4 (25)  
ZFHX3 AT-binding transcription factor 1 16q22.3 9 (60) 4 (25)  
BTG3 BTG family, member 3 21q21.1 0*(0) 4 (25)  
ENO1 enolase 1, (alpha) 1p36.23 12 (80) 4 (25)  
HTATIP2 
HIV-1 Tat interactive protein 2, 
30kDa 11p15.1 1*(7) 4 (25)  
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* = locus that showed copy number gain in a number of samples.  
† = copy number data unreliable due to proximity to chromosomal end.  
n/a = copy number data not applicable on the X chromosome. 
NPCtsg = gene previously implicated as acting as a tsg in NPC.  
STAT1 
signal transducer and activator of 
transcription 1, 91kDa 2q32.2 0*(0) 4 (25)  
IRF3 interferon regulatory factor 3 19q13.33 6 (40) 4 (25)  
LITAF 
lipopolysaccharide-induced TNF 
factor 16p13.13 4* (27) 4 (25)  
TOB1 transducer of ERBB2, 1 17q21.33 0*(0) 4 (25)  
TSG101 tumor susceptibility gene 101 11p15.1 1*(7) 4 (25)  
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individual tumours revealed that the mean number of TSGs downregulated in each 
tumour was 109 (range 90 – 135). 
 
Several previously identified, candidate NPC-related TSGs are found in our list 
including BRD7, H19, SFN, GSTP1, RARB, ADAMTS9, CHFR, THRA, TP73, 
PTEN and CDH1. BRD7 transcripts were downregulated in 100% (16/16) of NPC 
tumours in our expression array. This gene has been reported to be downregulated in 
NPC biopsies and cell lines and its expression could inhibit cell cycle progression and 
induce apoptosis (Zhou et al., 2004; Zhou et al., 2006a; Zhou et al., 2006b). The 
transcripts of both H19 and SFN were also downregulated in 100% (16/16) of NPC 
tumours. SFN is a target of p53 and overexpression of SFN could inhibit cell growth 
and block DNA synthesis (Yang et al., 2006). GSTP1, RARB ADAMTS9, CHFR, 
TP73 and CDH1  have been  identified as tumour suppressor genes in NPC by 
methylation analysis (Kwong et al., 2002; Wong et al., 2003; Lung et al., 2008), and 
the expression data revealed that their transcripts were downregulated in 94% (15/16), 
88% (14/16), 75% (12/16), 69% (11/16), 63% (10/16) and 25% (4/16) of NPC 
tumours compared with normal control cells, respectively.   
 
Most of the candidate genes in our tumour suppressor gene list are relatively new in 
the context of NPC although their tumour suppressor behaviour has been observed in 
other types of cancer. IHC staining confirmed downregulation of the TSGs ANXA1, 
LCN2, KLF4, MSH3 and CLU at the protein level (Figures 3.7, 4.8 and 4.11). 
 
ANXA1, at the top of our TSG list, was downregulated in 100% (16/16) of NPC 
tumours. IHC staining revealed the expression of its protein was reduced in 79%  
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Figure 3.7: Expression array intensities and immunohistochemical staining for 
tumour suppressor genes.  
  
The left panels show normalised expression array intensities for the 4 normal samples 
(grey) and 15 NPCs plus C666-1 (red). The centre panels show examples of 
immunohistochemical staining of NPC tissue samples. Normal epithelial cells 
(Normal) show strong expression, whilst tumour cells (Tumour) show weak 
expression. The right panels show the immunohistochemical scoring results from the 
tissue arrays (normal, grey: tumour, red). At the RNA and protein levels respectively, 
(A) ANXA1 is downregulated in 16/16 (100%) and 11/14 (79%) samples, and 
positive ANXA1 staining is predominantly observed in the membrane; (B) LCN2 is 
downregulated in 16/16 (100%) and 18/19 (95%) samples, and positive LCN2 
staining is predominantly observed in the cytoplasm and membrane; (C) KLF4 is 
downregulated in 11/16 (69%) and 31/37 (84%) samples, and positive KLF4 staining 
is predominantly observed in the nucleus. 
NORMAL                       TUMOUR
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(11/14) of tumours compared with the normal counterparts (Figure 3.7A). Although 
the exact function of ANXA1 remains unknown, it has been suggested to play an 
important role in the regulation of tumour growth, invasiveness and metastasis (Ang 
et al., 2009; Inokuchi et al., 2009; Yi & Schnitzer, 2009). Downregulation of ANXA1 
has been found in a number of cancers and the expression of this gene is associated 
with epithelial differentiation status (Garcia Pedrero et al., 2004; Rodrigo et al., 2005; 
Hummerich et al., 2006; Petrella et al., 2006; Shen et al., 2006; Bose et al., 2009). 
 
In the expression array, LCN2 transcripts also showed 100% (16/16) downregulation 
in NPC tumours, and confirmation by IHC staining which revealed that the expression 
of LCN2 protein was decreased in 95% (18/19) of tumours (Figure 3.7 B). LCN2 is a 
25kDa glycoprotein that was initially purified from neutrophil granules. A variety of 
functions of LCN2 have been reported including in cell proliferation. Two studies 
demonstrated that LCN2 might exert tumour suppressor functions as it suppresses 
tumour invasion and metastasis and induces apoptosis (Tong et al., 2005; Lee et al., 
2006).  
 
KLF4 (formerly GKLF) is a zinc-finger transcription factor expressed in the epithelia 
of the skin, lung, gastrointestinal tract and several other organs (Garrett-Sinha et al., 
1996; Shields et al., 1996). In vitro and in vivo studies suggested that KLF4 plays 
important roles in cell proliferation and/or differentiation (Segre et al., 1999; Katz et 
al., 2002; Chen et al., 2003). Loss of expression of KLF4 has been observed in 
several human tumours, especially in those of the gastrointestinal tract. In addition, 
the tumours with loss of KLF4 expression are associated with a more aggressive 
phenotype (Wong et al., 2005). In our expression data, KLF4 transcripts were 
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downregulated in 69% (11/16) of NPC tumours and protein expression was decreased 
in 84% (31/37) of tumours (Figure 3.7C). This suggests that KLF4 might have tumour 
suppressor functions in NPC. However, functional studies are needed to confirm this 
thesis. 
 
3.5.3 Metastasis promotion genes 
 
Distant metastasis at a very early stage is one of the distinct features of NPC. The 
transition from in situ tumour growth to metastatic disease depends on the ability of 
tumours at the primary site to invade local tissues and to cross tissue barriers. This 
process requires the activation of a number of metastasis promoting genes to exert 
their various functions in cell adhesion, proliferation, migration and so on.  
 
Expression array analysis revealed several differentially regulated genes whose 
upregulation might promote the progression of metastasis (Table 3.3). ASAP1 was 
upregulated in 94% of NPC tumours in the expression array data. Overexpression of 
ASAP1 has also been reported to be associated with invasiveness and metastasis of 
prostate cancer (Lin et al., 2008) and breast cancer (Sabe et al., 2009). TNFRSF11A, 
upregulated in 56% of NPC tumours in our data, has been found to be related to 
lymph node (Heymann et al., 2008) and bone metastasis (Armstrong et al., 2008). 
NUDCD1 and SPP1 were upregulated in 75% and 69% of NPC tumours, respectively, 
and have been observed to be involved in cervical cancer metastatic progression 
(Wang et al., 2008) and advanced NPC tumours (Wong et al., 2005). Downregulation 
of another metastasis-associated molecule, CD44, has been shown to inhibit the 
metastatic potential of an NPC cell line, whereas induction of its expression by LMP1 
was associated with lymphoma dissemination (Shi et al., 2007). In the expression  
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Table 3.3: Upregulated genes involved in promotion of metastasis and resistance 
to anoikis or apoptosis. 
Gene 
Symbol Gene Title Location 
Number 
(%) with 
copy gain 
Number  
       (%) 
upregulated Validation 
Metastasis Promotion     
MALAT1 
metastasis associated lung 
adenocarcinoma transcript 1 (non-
protein coding)  0*(0) 16 (100)  
ASAP1 
ArfGAP with SH3 domain, ankyrin 
repeat and PH domain 1 8q24.21 8 (53) 15 (94)  
NUDCD1 NudC domain containing 1 8q23.1 8 (53) 12 (75)  
TNFRSF10B 
tumor necrosis factor receptor 
superfamily, member 10b 8p21.3 5*(33) 11 (69)  
TGFBI 
transforming growth factor, beta-
induced, 68kDa 
5q31.1 - 
31.2 0*(0) 11 (69)  
SPP1 
secreted phosphoprotein 1 
(osteopontin) 4q22.1 1*(7) 11 (69)  
TNFRSF11A 
tumor necrosis factor receptor 
superfamily, member 11a, NFKB 
activator 18q21.33 2*(13) 9 (56)  
TNFRSF11B 
tumor necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin) 8q24.12 8 (53) 6 (38)  
CD44 
CD44 molecule (Indian blood 
group) 11p13 2*(13) 6 (38) 
NPC-A 
6/12 (50%) 
Anoikis Resistance     
ITGAV integrin, alpha V  2q32.1 1 (7) 16 (100)  
NTRK2 
neurotrophic tyrosine kinase, 
receptor, type 2 9q21.33 0*(0) 15 (94)  
CFLAR 
CASP8 and FADD-like apoptosis 
regulator 2q33.1 1 (7) 14 (88)  
XIAP X-linked inhibitor of apoptosis Xq25 n/a 14 (88)  
CTNNB1 
catenin (cadherin-associated 
protein), beta 1, 88kDa 3p22.1 0*(0) 13 (81) 6/18 (33%) 
PLAU plasminogen activator, urokinase 10q22.2 0*(0) 10 (63)  
ITGB6 integrin, beta 6 2q24.2 1 (7) 10 (63)  
Apoptosis Resistance     
BCL2 B-cell CLL/lymphoma 2 18q21.33 2*(13) 16 (100) NPC-A 
TNFAIP3 
tumor necrosis factor, alpha-
induced protein 3 6q23.3 2*(13) 15 (94) 9/18 (50%) 
BIRC3 baculoviral IAP repeat-containing 3 11q22.2 0*(0) 14 (88) NPC-A 
TNFAIP8 
tumor necrosis factor, alpha-
induced protein 8 5q23.1 0*(0) 13 (81)  
BCL2A1 BCL2-related protein A1 15q25.1 0*(0) 9 (56)  
CLDN1 Claudin 1 3q28 0 (0) 8 (50) NPC-A 
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* = locus that showed copy number loss in a number of samples.  
n/a = copy number data not applicable on the X chromosome.  
NPC-A = NPC-associated.  
Chapter 3                                                                                                                                                   Results                                                                                 
117 
 
array data, the transcript level of this gene was upregulated in 38% (6/16) of NPC and 
IHC staining in the NPC tissue array showed it to be upregulated at the protein level 
in 50% (6/12) of tumours (Figure 3.8A).  
 
3.5.4 Apoptosis associated genes 
 
Aberrant apoptosis, as in all malignancies, is also essential for NPC development. The 
inhibition of apoptosis is critical for the progression of malignant cell proliferation 
and NPC tumour formation. A number of antiapoptotic factors have been identified 
and are listed in Table 3.3. BCL-2, upregulated in 100% of NPC tumours, is an 
oncoprotein whose overexpression interferes with apoptosis (Hockenbery et al., 1990), 
and it has also long been recognised as an oncogene in NPC (Lu et al., 1993). 
TNFAIP3 (A20) was upregulated at the RNA level in 94% (15/16) of samples and 
IHC staining on tissue arrays showed upregulation at the protein level in 50% (9/18) 
of tumours (Figure 3.8 B). It has been suggested that stable expression of TNFAIP3 
could inhibit p53-mediated apoptosis (Fries et al., 1996) and upregulation of 
TNFAIP3 was associated with undifferentiated NPC tumours (Codd et al., 1999). 
Another antiapoptotic gene BIRC3 (also called c-IAP2) which is upregulated in 88% 
of NPC tumours in our array data, has been  recently found to be overexpressed in 
EBV-associated NPC and  play critical roles in the resistance to Toll-like receptor 3-
mediated apoptosis (Friboulet et al., 2008). These apoptosis associated genes were 
also introduced in Section 1.4.3.  
  
3.5.5 Anoikis Resistance genes 
 
Anoikis, a form of apoptosis induced by loss of cell-matrix interactions, has been 
suggested to act as a physiological barrier to metastasis. Resistance to anoikis may  
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Figure 3.8: Expression array intensities and immunohistochemical staining for 
other tumour-associated genes.   
 
The left panels show normalised expression array intensities for the 4 normal samples 
(grey) and 15 NPCs plus C666-1 (red). The centre panels show examples of 
immunohistochemical staining of NPC tissue samples. Normal epithelial cells 
(Normal) show weak expression, whilst tumour cells (Tumour) show strong 
expression. The right panels show the immunohistochemical scoring results from the 
tissue arrays (normal, grey: tumour, red). At the RNA and protein levels respectively, 
(A) the metastasis-related gene CD44 is upregulated in 6/16 (38%) and 6/12 (50%) 
samples; and positive CD44 staining is predominantly observed in the membrane; (B) 
the antiapoptotic gene TNFAIP3 is upregulated in 15/16 (94%) and 9/18 (50%) 
samples; and positive TNFAIP3 staining is predominantly observed in the cytoplasm; 
(C) the anoikis resistance gene CTNNB1 is upregulated in 13/16 (81%) and 6/18 
(33%) samples, and positive CTNNB1 staining is predominantly observed in the 
cytoplasm and membrane. 
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allow survival of cancer cells during systemic circulation, thereby facilitating distant 
metastasis. In the expression array data, several genes involved in anoikis resistance 
were upreguated in many NPC tumours (Table 3.3). These include NTRK2, which 
showed suppression of anoikis and induction of metastasis in human cancers (Douma 
et al., 2004); PLAU, whose upregulation induces the resistance to anoikis in prostate 
cancer cells (Hasanuzzaman et al., 2007); and CTNNB1 that is also a key member of 
the Wnt signalling pathway (Chapter 5), which was found to be up regulated in 81% 
(13/16) of tumours at the RNA level  and 6/18 (33%) samples at the protein level 
(Figure 3.8 C).  
 
The metastasis-related, anti-apoptotic and anoikis-resistance genes are presented in 
Table 3.3, in which genes that have previously been reported as having an NPC 
association are labelled “NPC-A”. 
 
3.6 Discussion       
 
In this study, we performed expression array analysis in 16 NPC tumours and 4 
normal epithelial samples. The RNA samples used in this work were extracted from 
microdissected NPC tumour and normal epithelial cells. This made it possible to 
compare the cellular gene expression level in pure populations of tumour and normal 
cells. 
 
The samples consisted of 4 normal epithelial samples, one cell line C666-1, and 15 
NPC biopsies from high- and intermediate- incidence areas. At a global gene 
expression level a sample correlation analysis was carried out. This clustering analysis 
revealed that there is no geographical difference of gene expression in the samples. 
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Tumour cells and normal controls have their distinct expression features, and more 
importantly, C666-1 was clustered with other tumours and thus appears to be a good 
tumour model for NPC.  
 
To identify differentially regulated genes in NPC tumours, the expression data were 
normalised with RMA and analysed with RP and also analysed using GCOS. The RP 
analysis revealed a large number of differentially expressed genes but had a tendency 
to miss some important genes whose up- or down-regulation occurred in only a small 
proportion of NPC tumours. Regarding the behaviour of specific single genes in 
individual tumours, these genes are probably important in a small fraction of tumours. 
Thus, an analysis which concerned the gene expression levels in individual samples 
was used to determine up- or down-regulated genes. This revealed a number of genes 
that are involved in diverse functions of biological processes including oncogenes, 
tumour suppressor genes, apoptosis/anoikis- suppressing or metastasis-associated 
genes.  
 
Our findings confirmed and also extended previous observations. Some genes 
displayed in the tables have been reported previously, but most of the genes identified 
have not been related to NPC. Although over 160 previously characterised TSGs were 
found to be downregulated in the current sample set, even this number is an 
underestimate. Several well-known candidate NPC TSGs were not defined in our list. 
For instance, TSGs W1F1 (Chan et al., 2007), RASSF1 (Chow et al., 2004), FHIT 
(Ko et al., 2002) and DLC1 (Peng et al., 2006) were expressed at low levels in both 
tumour and normal and called “absent” by the GCOS software. The relative 
expression level can not be compared, thus, these genes were excluded in our TSGs 
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list. Similarly, other NPC-associated TSGs CDKN2A (Baba et al., 2001), ZMYND10 
(Agathanggelou et al., 2003; Liu et al., 2003) and ATM (Bose et al., 2009) were 
called “present” in only 3 of the 4 normal samples, so they also were not included in 
our list. On ther other hand, although some genes were found to be downregulated in 
a large propotion of NPC samples and defined as tumour suppressor genes, they 
appear to have both tumour suppressive and tumour promoting activities. For example, 
LCN2 was downregulated in 100% NPC tumours at the RNA level and 95% tumours 
at the protein level in our data. Nonetheless, it has been suggested to be a tumour 
promoting factor in several cancers (Cui et al., 2008; Moniaux et al., 2008; Yang et 
al., 2009). Our data revealed that KLF4 expression was significantly reduced in NPC 
tumours. However, it also seems to function as a dominant oncogene since it has been 
shown to be overexpressed in human breast tumours and squamous cell carcinomas 
and contributes to oncogenic transformation of cultured cells (Foster et al., 1999; 
Foster et al., 2000; Chen et al., 2008). 
 
It is generally accepted that for the majority of genes, changes at the mRNA level will 
usually result in similar alterations at the protein level. On this basis, we used IHC 
staining to verify the reliability of the array data. The results revealed that the up- or 
down-regulation of the genes of interest in expression array data showed increased or 
reduced protein expression following IHC staining, but the proportion of samples are 
somewhat different (see Table 3.1-3.3). For example, in the expression array data, 
MSH3 was down-regulated in 38% NPC tumours, whilst the IHC data showed it to be 
down-expressed in 83% tumours. This observation that genes were differentially 
regulated in a different proportion of samples at the RNA and protein level could be 
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due to gene post-transcriptional regulation, but most likely, it was caused by the 
different sample sets that were used for expression array and IHC data analysis.     
  
In conclusion, the expression array analyses revealed a large number of putative NPC-
related genes that might play important roles in NPC development and progression. 
IHC staining confirmed the expression array data. To further explore the pathogenesis 
of NPC, functional analyses are needed to understand better the roles of these 
potential tumour-related genes.  
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CHAPTER 4 
 
Cellular genetic alterations of nasopharyngeal carcinoma 
 
4.1 Introduction 
  
NPC is a genetic disease exhibiting a series of abnormalities such as chromosomal 
loss, gain or mutation during the process of carcinogenesis. Such abnormalities have 
been found by a number of previous studies that used karyotyping, FISH, CGH or 
microsatellite analyses. Most notably, consistent genetic changes in NPC include 
frequent deletions on chromosomes 1p, 3p, 9p, 9q, 11q, 13q, 14q and 16q and 
frequent gains on chromosomes 1q, 3q, 8q and 12 (see Section 1.4.1). However, the 
genetic analyses mentioned above have limited resolution and are inadequate in 
defining the fine boundaries of genetic changes and pinpointing tumour-associated 
genes. Some potential tumour-related genes within small regions of genetic 
aberrations might have been overlooked. Therefore, in this study, we took advantage 
of the high-resolution of Affymetrix 500K SNP arrays to profile the genetic changes 
in NPC biopsies and the NPC cell line C666-1. A number of genetic changes in NPC 
tumours were detected by the SNP array analyses. The extensive regions of loss or 
gain that are frequently detected in NPC tumours by SNP array are consistent with 
previous observations. Furthermore, the delineation of small genetic aberrations by 
this high-resolution array allows us to identify some potential tumour-related genes 
involved in the critical regions. Q-PCR analyses were used to validate SNP array-
predicted copy number changes of the genes of interest.  
 
13 NPC tumour samples used for SNP array analysis have also been used for 
expression array analysis (see Table 2.1), which makes it possible to compare gene 
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expression changes with chromosomal abnormalities in the same sample. It has been 
considered that gene copy number loss is often accompanied by downregulation of 
their expression, whereas gene copy number gain is associated with upregulation of 
expression. However, when analysing the relationship between copy number changes 
and gene expression levels, we found that in some instances this might be the case, 
whilst in others, copy number changes do not correlate directly with differential 
expression. None of the previous work performed the gene expression analysis and 
chromosomal genetic studies in the same NPC tumour, thus, our work will provide a 
valuable framework for the discovery of novel NPC-related genes as well as further 
exploration of the mechanism of NPC tumourigenesis. 
 
As was mentioned in Section 1.3.5, SNP arrays can analyse DNA copy number and 
LOH in parallel in the same patient across the whole genome. By combining LOH 
with copy number data, this new technique is also capable of identifying UPD regions 
that are likely to harbour genes important for the carcinogenic process.  
 
Usually, the size of NPC biopsies is quite small and the DNA extracted from 
microdissected tumour cells is insufficient for direct SNP array analysis as well as 
subsequent verification of SNP array data. In order to obtain enough material, a DNA 
amplification step is necessary. The bacteriophage φ29 polymerase-based Genomiphi 
kit has been successfully used for the amplification of small amounts of genomic 
DNA prior to SNP array analysis (Paez et al., 2004; Wong et al., 2004). Typically, the 
yield of amplified DNA is about 3-5 μg from 1 0 ng  of g enomic DNA as starting 
material. To study the fidelity of amplified DNA, a preliminary experiment was 
performed by Dr. John Arrand using the C666-1 cell line as a vehicle. 10ng and 1ng 
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of C666-1 DNA were amplified and analysed on 10K SNP arrays and compared with 
unamplified C666-1 DNA. The data revealed that concordance of SNP calls between 
unamplified DNA and DNA amplified from 10ng was 99.90%, whereas between 
unamplified DNA and DNA amplified from 1ng it was 99.89%. As a further 
confirmation, the LMP1 DNA was isolated by PCR from the 1ng-amplified DNA and 
sequenced by Ms Sim Sihota. The sequence was identical to that obtained from non-
amplified C666-1 DNA. These preliminary data indicate that amplification of 
genomic DNA using the Genomiphi kit can produce a high fidelity, near-complete 
genome representation suitable for high resolution genetic analysis. 
 
4.2 Comparison of unamplified and amplified C666-1 DNA on 500K arrays 
Although genome representation of the amplified DNA on the 10K array is quite 
comprehensive and estimated to be 99.90%, when unamplified and DNA amplified 
were compared on 500K arrays it was found that the copy number profiles of the 
amplified samples were somewhat noisier than those obtained from intact DNA. In 
particular, comparing the copy number data generated from amplified and 
unamplified C666-1 DNA, we found that isolated, small (-200kb) apparent 
amplifications or deletions appeared in amplified DNA that were not present in the 
intact sample (Figure 4.1). For this reason, in all subsequent experiments, isolated, 
apparent copy number changes of 300kb or less were filtered out. In addition, losses 
close to chromosomal termini were often observed. This phenomenon has also been 
noted by others (Pan et al., 2008) to be artefactual and such apparent losses were 
ignored.  
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Figure 4.1: Comparison of unamplified and amplified C666-1 DNA on 500K SNP 
arrays. Unamplified and amplified C666-1 DNA were analysed on 500K SNP arrays. 
The traces show an example of copy number states of unamplified and amplified C666-1 
on chromosome 6. The “2” dashed line is used as a baseline to depict DNA copy number 
2, and the solid vertical line represents the value of smoothed DNA copy number.  It is 
defined as copy number loss if the value of the solid vertical line is below the “2”, and 
gain if above the “2” line. Compared to unamplified C666-1 DNA, the amplified DNA 
shows several additional isolated, small (-200kb) apparent gains or deletions, as well as 
losses close to chromosomal termini. 
 
Amplified C666-1  Chr 6 
C666-1  Chr 6 
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4.3 Characterisation of NPC biopsies and NPC cell line C666-1 
 
14 NPC biopsies (Table 2.1) diagnosed as undifferentiated NPC and one NPC cell 
line, C666-1, were used for SNP array analysis. 9 biopsies were from Cantonese 
patients, 3 were from Maghreb patients, and 2 were Italian. Within the EBV genome, 
the BamHI-W region is a repetitive, highly conserved region. The EBV status in the 
NPC biopsies and the C666-1 cell line was determined by PCR using BamHI-W-
specific primers (Hill et al., 2006). As shown in Figure 4.2, all samples except one 
showed the expected amplified fragment. Considering the near 100% of EBV 
positivity in undifferentiated NPC tumours that was reported previously (Dickens et 
al., 1992; Gulley et al., 1995), sample MMAH was reviewed again by an experienced 
NPC pathologist who confirmed the diagnosis of undifferentiated NPC. 
 
The detection of copy number changes in tumour DNA could be confounded by the 
presence of DNA from surrounding non-neoplastic tissue. Tumour-normal mixing 
experiments to assess the effects of contaminating non-neoplastic cells on genetic 
changes using SNP arrays found the best performance for LOH was achieved with 
90% tumour purity and above, and DNA copy number gains can be detected in 
mixtures containing 60% tumour DNA, whereas copy number losses can be detected 
at more than 90% tumour purity (Lindblad-Toh et al., 2000; Zhao et al., 2004). 
Although the NPC biopsies selected for array analysis showed well-defined islands of 
tumour cells, they still had infiltrating lymphocytes. Therefore, for reliable and best 
results of genetic analysis, laser microdissection and pressure catapulting (LMPC) 
was carried out on NPC biopsies to obtain a pure and homogeneous population of 
tumour cells.  
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Figure 4.2: Determination of the EBV status of NPC samples used for SNP array 
analysis. Genomic DNA was extracted from microdissected NPC tumour cells and 
amplified using a Genomiphi kit. 200 ng of DNA from each sample were used for 
analysis of EBV status by amplifying the BamHI-W-specific region using PCR. 
Products were viewed by agrose gel electrophoresis. All samples except MMAH 
showed the expected 114-base-pair amplified product.   
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4.4 SNP array analysis 
Since matched normal DNA is not always available as a reference, the recent release 
of the initial phase of a haplotype map of the human genome provides an opportunity 
for un-paired analysis of SNP array data, which has been successfully used to detect 
genetic alterations. In our SNP array analysis, the copy number data were obtained by 
unpaired analysis using array data derived from 40 normal individuals (23 Chinese, 
10 Japanese and 7 Utah residents of Central European descent), which were 
downloaded from the HapMap project 
(http://www.hapmap.org/downloads/index.html.en). The Affymetrix GeneChip 
Chromosome Copy Number Tool v4 using the default settings and Genotyping 
Console v2.1 (Affymetrix) with genomic smoothing set to 1Mb estimate the copy 
number of individual SNPs by comparing the signal intensity of each SNP from the 
tumour sample with the mean of the corresponding SNP in the reference set. The SNP 
call rates generated from the analysis reached above 90% in all the samples. To locate 
the genes implicated in the regions of chromosomal aberrations, the physical position 
of corresponding SNPs on the arrays was mapped according to the Human Genome 
(Build 35, hg17).    
 
4.5 Genetic aberrations in NPC tumour cells 
4.5.1 Overall genetic changes of NPC biopsies 
Amplified DNA from 14 NPC biopsies and DNA from the C666-1 cell line were 
analysed on 500K SNP arrays. Extensive regions of chromosomal copy number 
changes and UPD were observed. The overall genetic aberrations are shown in Figure 
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4.3, which displays the frequency and patterns of the genetic aberrations across the 
whole genome in all the samples. The most frequent deletions are observed in 
chromosomes 3p, 5q, 9, 13q, 14q and 16, and frequent gains are observed in 
chromosomes 1q, 3q, 8 and 12. Chromosome 6 exhibits most frequent UPD. The 
minimal overlapping regions of copy number loss or gain in all the 14 biopsies were 
also determined and are summarised in Table 4.1. These results are in broad 
agreement with the data obtained from conventional and array-based CGH analyses in 
a number of previous studies. These have been reviewed and summarised by meta 
analysis (Li et al., 2006) as well as a tree model analysis (Shih-Hsin Wu, 2006). 
 
4.5.2 Genetic changes of the C666-1 cell line 
500K SNP array analysis identified several extensive regions of genetic changes in 
the C666-1 cell line including chromosome losses on 6pter-q14, 11q14-qter and 
18q21-qter, and chromosome gains on 7q, 8pter-p22, 8p12-q12, 14q21-23, and 
16pter-q12. It also additionally identified several smaller regions of copy number 
changes such as small deletions on chromosome 3p, 5q, 6q, 8q, 12p and gains on 
chromosome 14q. The genetic changes in the C666-1 line are shown in Figure 4.4.  
 
In the SNP array analysis, the C666-1 cell line has been used as a vehicle for 
validation of copy number predicted by SNP array data. Regions of chromosome 8 
that showed gain, loss or no change in C666-1 DNA were examined by q-PCR using 
the genes FGF20, NRG1, KIAA1967, CLU and CYP7A1 as markers and confirmed 
the copy number changes predicted by SNP array analysis (Figure 4.5). As CYP7A1 
showed two copies in C666-1 and also in most of the NPC biopsies examined by SNP  
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Figure 4.3: Summary of Gains, Losses and uni-parental disomy (UPD). 
  
An overview of genetic changes of 22 chromosomes in a total of 14 microdissected 
NPC biopsies and cell line C666-1 is presented. “Genetic gains” are shown as blue 
arrows, “losses” as red arrows and “UPD regions” as green bars aligned along each 
chromosome in each sample.   
1               2                3                   4                 5
6                    7                8                      9             10
11                 12                 13                 14            15
16              17             18         19       20 21       22
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Table 4.1: 
 
A. Minimal Regions of “Extensive” Loss in 14 Primary Tumours. 
 
REGION NUMBER % 
1pter - p35.1 6 43 
1p22.1 - p13.3 3 21 
3pter - p12.3 12 86 
4p15.1 - p12 4 29 
4q28.2 - qter 5 36 
5q12.3 - q15 7 50 
6p22.1 - p21.3 3 21 
9pter - p21.2 7 50 
9q12 - q32 4 29 
9q34.11 - qter 8 57 
10q21.1 - qter 3 21 
11q22.3 - q23.3 9 64 
13q 7 50 
13q14.11 - 
11qter 1 7    (57) 
14q 6 43 
14q24.2 - qter 2 14  (57) 
15q14 - q21.1 5 36 
16 5 36 
16q 3 21  (57) 
17p11.2 - pter 7 50 
 
 
B. Minimal Regions of “Extensive” Gain in 14 Primary Tumours. 
 
REGION NUMBER % 
1p33 - p22.3 7 50 
1q32.1 - q41 6 43 
3q11.2 - 
q13.32 8 57 
5p15.1 - p12 5 36 
6q14.1 - 24.3 4 29 
8p12 - q24.3 4 29 
8q23.1 - q24.3 4 29  (58) 
12p13.2 - 
p11.1 7 50 
12q12 - q24.3 4 29 
 
The numbers in parentheses indicate the frequency of chromosomal abnormality 
(including not only the smaller regions but also a larger region containing this smaller 
region). 
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Figure 4.4: Chromosomal copy number analysis of cell line C666-1.  
C666-1 cell DNA was extracted and analysed on 500K SNP arrays. The traces show 
the log2 ratio of the copy number of C666-1 on several chromosomes compared to the 
reference. The “0” dashed line is used as a baseline to depict DNA copy number 2, 
and the solid black line represents the value of smoothed DNA copy number. It is 
defined as copy number loss if the value of the solid black line is below the “0”, and 
defined as gain if above the “0” line. The sizes of the “small” deletions discussed in 
the text are indicated.  
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Figure 4.5: q-PCR validation of gene copy number changes on chromosome 8 in 
C666-1.  
(A) The figure displays the genomic copy number trace of C666-1 on chromosome 8. 
The locations of the genes FGF20, KIAA1967, CLU, NRG1 and CYP7A1 are 
indicated by arrows.  
(B) The copy number analysis software calculated these genomic regions respectively 
as having a copy number of 4, 1, 1, 4 and 2 (purple columns). Genomic q-PCR 
validation of the copy number within these regions gave values of, respectively, 4.8, 
1.2, 1.1, 4.4 and 2.0 (blue columns). 
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FGF20
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FGF20
A
B
138
Chapter 4                 Results 
139 
 
array, this gene was used as a reference gene when determining the copy number of 
other genes of interest by q-PCR analyses. 
 
4.5.3 Small copy number changes    
The 500K SNP array analysis takes advantage of its enhanced resolution and 
delineates more precise physical boundaries of chromosomal breakpoints in NPC. As 
a result, a number of substantially smaller regions of copy number changes have been 
identified. Although both the extensive and smaller chromosomal abnormalities are 
supposed to be critical for NPC pathogenesis, the smaller aberrations allow us more 
easily to pinpoint the genes involved. Especially, those common minimum regions of 
chromosomal loss or gain often contain genes that may play important roles in the 
process of cancer development. By integrating the Human Genome (Build 35, hg17) 
and DNA copy number data obtained from SNP array analyses, the genes encoded in 
the smaller regions of genetic alterations are defined. Some of the genes are well-
known TSGs or oncogenes already identified previously in NPC or other types of 
tumour, whereas others have not been reported before but might be potential NPC-
related genes. On this basis, the minimal segments of genetic copy number changes 
and genes included are summarised in Table 4.2. Here, we will draw attention to these 
small genetic changes. Q-PCR data are used to validate the copy number changes of 
genes located in the corresponding loci. In addition, the copy number data were 
analysed in the context of their expression at the RNA level determined by expression 
array analysis. Some of them were also analysed at the protein level by IHC staining. 
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Table 4.2: Small regions of copy number change and the genes included. 
SMALL LOSSES 
Chromosomal 
Locus 
Physical position Minimum 
Common 
Loss 
Number 
Showing 
Loss 
Genes Within Minimum 
Region Start                 Stop 
3p14.2 59964552 61028019 1.06Mb 12 FHIT 
4q13.1 63804596 66196603 2.40Mb 1 SRD5A2L2, EPHA5 
5q14.1 77358197 80545692 3.19Mb 9 
22 genes including THBS4, 
MSH3, RASGRF2 
5q31.1-31.2 133726836 135799356 2.07Mb 7 
24 genes including PITX1, 
CXCL14, TGFBI 
5q11.2 
 
50425128 
 
54143484 3.72Mb 3 12 genes including ITGA2 
6q23.3 136679431 138220854 1.54Mb 3 
MAP7, MAP3K5, PEX7, 
IL20R1, IFNGR1, OLIG3, 
TNFAIP3 
8p21.3-p12 22533530 27843228 5.31Mb 3 
44 genes including 
TNFRSF10B, CLU 
9p21.3 
 
21717208 
 
22014351 297kb 12 
MTAP, CDKN2A, 
CDKN2B 
9p23-p22.3 
 
13606431 
 
14329236 723kb 7 NFIB 
14q11.2-q12 
 
21631939 
 
23934069 2.30Mb 7 58 genes including TINF2 
1p13.1 – p12 117391884 118686724 1.29Mb 1 
TTF2, TRIM45, VTCN1, 
MAN1A2, FAM46C, 
GDAP2, WDR3, SPAG17 
1q25.3 181280422 183870395 2.59Mb 2 
LAMC2, NMNAT2, SMG7, 
NCF2, RGL1, APOBEC4, 
GLT25D2, 
C1orf19,21,25,26, EDEM3, 
FAM129A, RNF2, 
IVNS1ABP 
8q23.1-q23.3 110401143 113408633 3.01Mb 1 
77 genes  including 
PKHD1L1, EBAG9, 
GOLSYN, KCNV1 
12p13.2-p12.3 11853840 15065706 3.21Mb 1 
35 genes including 
CDKN1B 
SMALL AMPLIFICATION 
8p11.22-11.21 39740721 42425970 2.69Mb 1 
INDOL1, C8orf4, ZMAT4, 
SFRP1, GOLGA7, GINS4, 
AGPAT6, ANK1, MYST3, 
AP3M2, PLAT, IKBKB, 
POLB, DKK4 
SMALL GAINS 
1q41-q42.11 220828751 222157313 1.33Mb 7 
9 genes including AIDA, 
SUSD4 and TP53BP2 
17q11.2 25273428 25728007 455kb 2 
EFCAB5, CCDC55, 
SLC6A4, BLMH, TMIGD1 
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Chromosome 3  
12 out of 15 NPC samples showed extensive loss of chromosome 3p. Three samples 
(MKAV, MMAH and C666-1) did not follow this pattern. Uniquely, C666-1 
displayed only a 1.06Mb homozygous deletion at 3p14.2 and this region appeared to 
be diploid in only three samples (MKAV, MMAH, and 235326) (Figure 4.6 A). A 
well-known TSG, FHIT, is located in this small region. We designed a q-PCR 
primer/probe set specific for the FHIT deleted locus and confirmed the copy number 
predicted by SNP array in 8 samples (Figure 4.6 B). Deletion of 3p14.2 and 
inactivation of FHIT has been frequently observed in NPC tumours (introduced in 
Section 1.4.2.1), whereas our SNP array delineating the finer boundary of deletion at 
this minimal locus further suggests that FHIT is a critical TSG whose aberration 
might contribute to NPC development and progression. However, functional 
investigation of this gene is required for understanding its particular role in 
carcinogenesis. 
 
Chromosome 4 
A 2.4Mb region of loss at 4q13 containing two genes called SRD5A2L2 and EPHA5 
(ephrinA5) was observed in only one sample (XY8) (Figure 4.7). The function of 
SRD5A2L is poorly understood so far, whereas a recent study of ephrinA5 in breast 
cancer reveals that the expression of ephrinA5 was significantly decreased in breast 
cancers compared to their normal control (Fu et al., 2009), indicating its potential 
TSG function. In our expression array data, ephrinA5 was called “absent” by GCOS 
in most of the NPC tumour and normal epithelial samples and therefore changes in 
expression could not be determined.  
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Figure 4.6: Small deletions on chromosome 3p. 
  
 
(A) Extensive deletions were found in most of the NPC biopsies. C666-1 displayed 
only a 1.06Mb deletion at 3p14.2. This is labelled by black lines and arrows. This 
region was diploid in only three samples (MKAV, MMAH, and 235326). The tumour 
suppressor gene FHIT is within this small deletion. 
 
(B) Comparison of DNA copy number in the FHIT gene locus identified by SNP 
array analysis (purple columns) and q-PCR analysis (blue columns) in 9 samples.  
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Figure 4.7: Small deletion on chromosome 4. A 2.40Mb region of loss at 4q13 
containing two genes called SRD5A2L2 and ephrinA5 (EPHA5) was found in one 
sample (XY8). 
 
 XY8   Chr 4                              2.40Mb 
SRD5A2L2, EPHA5 
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Chromosome 5 
C666-1 contained two regions of loss on chromosome 5. The first deletion, a 3.19 Mb 
region at 5q14.1 was also within larger regions of loss in a further 8 samples (173570, 
235326, MMAH, MKEC, XY5, XY8, XY16, XY23) and encodes 22 genes, including 
RASGRF2, MSH3 and THBS4 (Figure 4.8 A), whose reduced expression has been 
associated with tumourigenesis. RASGRF2 was found to be down-expressed in 
human non-small cell lung cancer (Chen et al., 2006), but the precise function of this 
gene remains to be elucidated. MSH3 is a mismatch repair gene, genetic alterations 
such as LOH in cancer have been reported before (Benachenhou et al., 1999), and 
down-regulation of MSH3 was observed in bladder cancer compared to their normal 
counterparts (Kawakami et al., 2004). In the expression array data,  MSH3 was shown 
to be down-regulated at the RNA level in 38% (6/16) tumours of which four are 
haploid samples (C666-1, 173570, XY8, XY23) and two are diploid (68(8) and 
MDIG) (Figure 4.8B, upper, left panel). IHC staining in paired NPC tumour and 
normal epithelial tissue array revealed MSH3 expression was reduced in 83.3% 
(15/18) tumours (Figure 4.8B, upper, right panel). 
 
The second deletion is a region of 2.07Mb, at 5q31.1-31.2, and this region was also 
encompassed by larger deletions in 6 more samples (68(8), 173570, MKEC, MMAH, 
XY8 and XY6). 24 genes including PITX1, CXCL14 and TGFBI are within this 
deletion (Figure 4.8A). PITX1 was recently identified as a tumour suppressor gene, 
inhibition of which induces the RAS pathway and tumourigenicity (Kolfschoten et al., 
2005), whereas expression of PITX1 leads to cell-cycle arrest and apoptosis by 
transcriptional activation of p53 (Liu & Lobie, 2007). Reduced expression of PITX1  
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Figure 4.8: Small deletions at 5q14.1 and 5q31.1-31.2. 
 
 
(A) C666-1 exhibits two small regions of loss on chromosome 5. Deletion 1, located 
at 5q14.1 is labelled between two black arrows and contains the genes RASGRF2, 
MSH3 and THBS4. Deletion 2 is at 5q31.1-31.2 and includes the genes PITX1, 
CXCL14 and TGFBI. 
(B) MSH3 expression was analysed using expression arrays and IHC. The upper left 
panel shows normalised expression array intensities for the 4 normal samples (grey) 
and 15 NPCs plus C666-1 (red), whilst the upper right panel shows the IHC scoring 
results from the tissue arrays (normal, grey: tumour, red). The bottom panels show 
examples of IHC staining in NPC tumour (T) and normal epithelial cells (N). At the 
RNA and protein levels respectively, MSH3 is downregulated in 6/16 (38%) and 
15/18 (83%) samples. Copy number analysis at the MSH3 locus showed four of the 
six downregulated samples (173570, XY8, C666-1 and XY23) to be haploid (red 
arrows), whilst the other two (MDIG and 68(8)) were diploid (green arrows). Three 
more haploid samples (MKEC, XY5 and MMAH) (black arrows) did not appear to be 
downregulated at the RNA level. 
(C) The figure shows normalised expression array intensities for the 4 normal samples 
(grey) and 15 NPCs plus C666-1 (red). At the RNA level, PITX1 is down-regulated in 
all the tumours (left panel), and CXCL14 is down-regulated in 75% (12/16) tumours 
(right panel). 
(D) TGFBI expression was analysed using expression arrays and IHC. At the RNA 
and protein levels respectively, TGFBI is upregulated in 10/16 (63%) and 7/13 (54%) 
samples. Haploid samples are indicated by red arrows. 
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has been observed in oesophageal carcinoma (Lord et al., 2005), gastric cancer (Chen 
et al., 2008), prostate and bladder cancers (Kolfschoten et al., 2005). CXCL14 is a 
chemokine, and loss of CXCL14 expression was found in tongue squamous cell 
carcinoma (Shellenberger et al., 2004). The expression of CXCL14 has been shown to 
suppress tumour growth in oral carcinoma and prostate cancer (Schwarze et al., 2005; 
Ozawa et al., 2006). In the expression data, PITX1 was down-regulated in all the 
tumours (Figure 4.8 C, left panel) and CXCL14 was found to be down-regulated in 
75% (12/16) tumours (Figure 4.8 C, right panel). However, TGFBI, although being 
single copy in a number of samples, was up-regulated in 63% (10/16) tumours (Figure 
4.8 D, upper left panel). IHC staining revealed that the expression of this gene was 
increased in 54% (7/13) tumours at the protein level (Figure 4.8 D, upper right panel). 
TGFBI expression is induced by transforming growth factor-beta and acts to inhibit 
cell adhesion. The expression and function of TGFBI in cancers appears to be context 
dependent. Loss of TGFBI expression has been reported in breast cancer (Calaf et al., 
2008) as well as lung cancer (Zhao et al., 2006), and correlates with tumour formation 
and progression. However, in colon cancer, TGFBI was overexpressed and was 
associated with increased metastatic potential and poor patient prognosis (Ma et al., 
2008). 
 
Another locus, a 3.72 Mb loss at 5q11.2 was observed in MOUZ (Figure 4.9 A), and 
this segment was also included within larger deletions of samples 173570 and MKEC. 
58 genes including ITGA2 are encoded in this region. ITGA2 was down-regulated at 
the RNA level in 81% (13/16) tumours (Figure 4.9 B, upper left panel). This was 
further confirmed by IHC staining as reduced protein expression in 78% (14/18) 
tumours (Figure 4.9 B, upper right panel). ITGA2 belongs to the integrin alpha chain  
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Figure 4.9: Small deletions at 5q11.2. 
 
 
(A) A 3.72 Mb region of loss at 5q11.2 in sample MOUZ is labelled between two 
black arrows. The gene ITGA2 is encoded in this region. 
 
(B) The expression of integrin alpha 2 (ITGA2) was analysed by expression array and 
IHC. The upper left panel shows normalised expression array intensities for the 4 
normal samples (grey) and 15 NPCs plus C666-1 (red), whilst the upper right panel 
shows the IHC scoring results from the tissue arrays (normal, grey: tumour, red). The 
bottom panel shows examples of IHC staining in NPC tumour (T) and normal 
epithelial cells (N). At the RNA and protein levels respectively, ITGA2 is 
downregulated in 13/16 (81%) and 14/18 (78%) samples. Haploid samples are 
indicated by red arrows. 
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family that is involved in cell adhesion and also participates in cell-surface mediated 
signalling. Reduction of ITGA2 expression was previously reported to be related to 
cell immortalisation and malignant progression in oesophageal keratinocytes 
(Sashiyama et al., 2002). 
 
Chromosome 6 
Two samples (C666-1, XY5) showed a 1.54Mb region of loss at 6q23.3, while sample 
MDIG showed a big deletion in 6q including the loss of 6q23.3. 7 genes (MAP7, 
MAP3K5, PEX7, IL20RA, IFNGR1, OLIG3, TNFAIP3) are included in this small 
deletion (Figure 4.10A). q-PCR validations for MAP3K5 and IL20RA confirmed the 
copy number predicted by SNP array (Figure 4.10B). Among the above 7 genes, 
TNFAIP3 is considered to be a potential NPC-associated oncogene (Section 1.4.3). 
Expression data revealed that MAP7 was down-regulated in 94% (15/16) tumours at 
the RNA level (Figure 4.10C). Although the function of MAP7 in cancers is still 
unclear, it is predominantly expressed in cells of epithelial origin and is thought to be 
involved in microtubule dynamics, which is essential for cell polarisation and 
differentiation (Suzuki et al., 2003). 
 
Chromosome 8 
On chromosome 8, both copy number loss and gain have been observed in the C666-1 
cell line. Two regions of loss are included in C666-1 cell line. One is a 3.01 Mb loss 
at 8q23.1 – q23.3 that is described later. Another is a 7.6 Mb region of loss at 8p21.3-
p12 that is partially overlapped by deletions in samples XY5 and MMAH. The 
common region of loss (5.31 Mb) in all three contains 44 genes including the gene 
CLU (clusterin) (Figure 4.11A). Copy number loss of CLU in C666-1 was confirmed  
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Figure 4.10: Deletions on chromosome 6. 
  
 
(A) Samples C666-1, XY5 and MDIG showed a minimal 1.5Mb common region of 
loss at 6q23.3 as the region labelled with black lines and arrows. Genes MAP7, 
MAP3K5, PEX7, IL20RA, IFNGR1, OLIG3 and TNFAIP3 are included in this small 
deletion. 
 
(B) Comparison of DNA copy number in NPC tumours at the MAP3K5 and IL20RA 
loci predicted by SNP array data (purple columns) and q-PCR analysis (blue columns).  
 
(C) Normalised expression array intensities for MAP7 in the 4 normal samples (grey) 
and 15 NPCs plus C666-1 (red) shows MAP7 is down-regulated in 94% (15/16) 
tumours.   
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by qPCR analysis (see Figure 4.5B). Expression array data revealed that CLU was 
down-regulated in all 16 NPCs (Figure 4.11B). In addition, IHC staining in tumour 
and normal samples showed down-expression of clusterin at the protein level in 100% 
(13/13) NPCs (Figure 4.11B). CLU is a multivalent glycoprotein with ubiquitous 
tissue distribution and appears to be involved in several basic biological events 
including cell death, apoptosis, and tumour progression. CLU has been shown to be 
downregulated during prostate cancer onset and progression, and its upregulation 
inhibits DNA synthesis and cell cycle progression of immortalised human prostate 
epithelial cells (Bettuzzi et al., 2002; Caccamo et al., 2003).  
 
A 2.69 Mb minimal overlapping region of gain at 8p11.22 – 11.21 was found in 7 
samples (173570, C666, MKAV, MKEC, MMAH, XY8 and XY16). Sample 173570 
exhibited the minimum region of change (Figure 4.12A). The Affymetrix copy 
number algorithm defines copy number state only up to a maximum of ≥4 and 
therefore q-PCR analysis at the IKBKB locus was used to confirm the copy number 
gain in this sample. This suggested that this region was actually amplified to 8-9 
copies (Figure 4.12B). This is the only example of an amplification (5 or more copies), 
rather than a gain, that is found in the cases under study. In expression array data the 
relative mRNA levels of the genes encoded in this amplified region were visualised 
using dChip software, which revealed that the majority of genes throughout this 
region have a higher expression level in the amplified sample (173570) but were 
relatively unchanged in samples with two or three copies (Figure 4.12C).  
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Figure 4.11: Small deletions at 8p21.3-p12. 
 
(A) C666-1 exhibits two small regions of loss, a 7.6Mb region of loss at 8p21.3-p12 
in which the gene CLU is encoded as labelled between two black arrows, and a 
3.01Mb loss at 8q23.1 – q23.3.  
 
(B) The expression of CLU was analysed with expression array and IHC. The upper 
left panel shows normalised expression array intensities for the 4 normal samples 
(grey) and 15 NPCs plus C666-1 (red), whilst the upper right panel shows the IHC 
scoring results from the tissue arrays (normal, grey: tumour, red). The bottom panel 
shows examples of IHC staining in NPC tumour (T) and normal epithelial cells (N). 
At the RNA and protein levels respectively, CLU expression is downregulated in 
16/16 (100%) and 13/13 (100%) samples. Haploid samples are indicated by red 
arrows. 
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Figure 4.12: Amplification on chromosome 8. 
(A) High-level amplification detected by SNP array at 8p11.22 – 11.21 in sample 
173570. The amplicon size is approximately 2.69 Mb.  
(B) The copy numbers of gene IKBKB calculated by SNP array are 2, 3 and 4 in 
sample XY23, C666-1 cells and 173570, respectively (purple columns),  whereas they 
are 1.7, 3.6 and 8.7 as measured by q-PCR (blue columns).   
(C) Heatmap of the relative expression levels of the genes found within the 8p11.22 – 
11.21 amplified region of tumour 173570. The samples appear in columns with the 4 
normal samples on the left whilst the individual genes within the amplified region 
form the rows. The relative expression level of each gene across all samples is 
indicated by colour with increasing expression being represented by the intensity of 
red and downregulation by the intensity of blue. No change is white. The brackets at 
the bottom indicate tumour samples with genome copy numbers of 2 or 3 throughout 
this region. Almost all genes in tumour 173570 are highly expressed as indicated by 
the intense red colour. 
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Chromosome 9 
Loss of the 9p21.3 region was found in 12/15 (80%) of samples. The deletions in 5 
samples (XY6, XY8, MMAH, 125855, and XY5) were relatively small (Figure 
4.13A). The minimal overlapping region of loss was approximately 300Kb and 
contained the genes MTAP, CDKN2A and CDKN2B. Q-PCR validation was 
performed at the CDKN2A locus on 7 samples and confirmed the array-predicted 
copy number change (Figure 4.13B). Loss of 9p21 has been frequently detected in 
NPC tumours (see Section 1.4.2.1), and the SNP array data mapped the minimum 
deletion to 9p21.3 locus containing only three genes. This further suggests that 
aberrations of the genes involved are critical for NPC carcinogenesis. As described in 
Chapter 1, CDKN2A and CDKN2B are considered to be important NPC-associated 
TSGs and their functions have been extensively investigated. In expression array data, 
although expression in the normal samples was somewhat variable (being called 
“present” in only 3 of the 4), it was expressed at low levels in several tumours, being 
called “absent” in 7/16 (44%). Moreover, a relatively low level of expression was 
observed in the samples showing small deletions (Figure 4.13C). Although the 
function of the co-deleted gene (MTAP) has not been investigated in NPC, it has been 
shown to be downregulated in a number of cancers and contributes to carcinogenesis 
(Christopher et al., 2002; Hustinx et al., 2005; Hellerbrand et al., 2006). 
 
Chromosome 14 
On chromosome 14, a 2.3 Mb deletion at 14q11.2-q12 in MOUZ (Figure 4.14A) was 
also lost in 6 more samples. This segment contains 58 genes of which TINF2, a 
component of the shelterin complex, was downregulated in all samples.  
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Figure 4.13: Deletions on chromosome 9p.
(A) Sample XY6, XY8, MMAH, 125855 and XY5 show a minimal overlapping region of
loss at 9p21.3. The minimum deletion is approximately 300Kb and contains the genes
MTAP, CDKN2A and CDKN2B.
(B) Comparison of DNA copy number at the CDKN2A locus identified by SNP array data
(purple columns) and q-PCR analysis (blue columns) in 7 samples.
(C) CDKN2A expression at the RNA level in the 4 normal samples (grey) and 15 NPCs
plus C666-1 (red) is presented using normalised expression array intensities. Samples
that showed deletion of 9p21.3 are indicated by red arrows.
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Downregulation of TINF2 has been associated with telomere maintenance in gastric 
cancer cells (Yamada et al., 2002), and reorganisation of this gene is associated with 
the control of cell proliferation in mammary epithelial cells (Kaminker et al., 2005). 
In expression array data, TINF2 expression appeared to be downregulated in all the 
NPCs (Figure 4.14B). 
 
Other small regions of copy number change 
In addition to the regions described above, there are some other small regions of copy 
number loss or gain. Although these genetic changes were not detected or significant 
in previous data, our data suggest that they might have been missed by the older 
methodology or important in only a minority of samples. These include a 1.29 Mb 
deletion at 1p13.1 – p12 in MMAH, an overlapping 2.59 Mb loss at 1q25.3 in two 
samples (XY6, MKEC) and four additional small changes in the C666-1 cell line. Of 
the four deletions in the C666-1 cell line, the first, a 1.33 Mb gain at 1q41 – q42.11 
was part of larger gains in 6 more tumours. The second region, a 3.01 Mb single copy 
segment at 8q23.1 – q23.3 was uniquely lost in C666-1 but part of large gains in 
several other samples. The third region, 3.21 Mb at 12p13.2 – p12.3 formed another 
locus that was single copy in C666-1, but which was duplicated in a number of 
tumour samples. The fourth additional small change observed in C666-1 was a 455 kb 
gain at 17q11.2 that was also duplicated in one other tumour. These small genetic 
changes and the genes involved are shown in Table 4.2.        
 
4.5.4 LOH analysis 
9 tumour samples and C666-1 showed extensive regions of homozygosity 
(uniparental disomy, UPD). These were distributed among the majority of  
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Figure 4.14: Deletion at 14q11.2-q12.
(A) Sample MOUZ shows a small region of loss at 14q11.2-q12, which is
approximately 2.30Mb and contains 58 genes including TINF2.
(B) TINF2 expression at the RNA level in the 4 normal samples (grey) and 15 NPCs
plus C666-1 (red) is presented using normalised expression array intensities. It
appears to be downregulated in all the NPCs compared to normal controls.
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chromosomes (chromosomes 1, 2, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18 and 20; 
Figure 4.15). Chromosome 6 was completely homozygous in 3 samples whilst a 
substantial portion of 6q was homozygous in a fourth sample. Chromosome 9 showed 
regions of UPD in four samples. Putative tumour suppressor genes GAS1, SYK, 
GADD45G and DAPK1 are located in the overlapping small region of UPD at 9q21-
22 in three samples.  
 
4.6 Relationship of chromosomal copy number to level of gene expression  
In the above sections, we introduced several potential NPC tumour-associated genes 
that are involved in small regions of loss or gain. Their copy number change was 
analysed in the context of gene expression level. This reveals that in some cases, gene 
up- or down- regulation is associated with regions of gain or loss, but in others, it is 
not the case. For instance, TGFBI is within a deletion at 5q31.1-31.2, but its 
expression was found to be upregulated at both the RNA and protein levels. 
 
In addition, our expression array data identified a number of tumour-related genes 
(Chapter 3). 13 samples from which both copy number and expression data were 
available (cell line C666-1 and 12 biopsies, see Table 2.1) were examined for copy 
number status at the loci of each of the putative tumour-associated genes, and the data 
are summarised in Tables 3.1 – 3.3. This revealed that in the oncogene list some genes 
such as PIK3CA, EGFR and SKIL might be activated by DNA copy number gain in 
NPC since previous studies and our data taken together show that more than 20% of 
NPC tumours are duplicated (Hui et al., 2002; Sheu et al., 2009). However for the 
majority of genes increased transcript levels are not a consequence of DNA copy  
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SYK
GAS1
GADD45G
DAPK1
Figure 4.15: Regions of uniparental disomy. The coloured bars alongside the
ideograms indicate homozygous diploid regions. Different samples are identified by
individual colours. Chromosomes 6 and 9 show most frequent UPD. Genes GAS1,
SYK, GADD45G and DAPK1 are located in the minimal overlapping region of UPD
on chromosome 9q in three samples (as indicated).
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number gain since it is not a frequent event at their respective loci. Conversely, a 
number of upregulated genes showed chromosomal loss. For example, enhanced 
expressions of single-copy oncogenes (e.g. RAF1, RAB5A, THRB, CTNNB1 and 
WNT5A on chromosome 3p) are observed. A similar phenomenon was also observed 
in the TSGs list. Although the down-regulation of some candidate TSGs appeared to 
be associated with copy number loss, e.g. SFN and BRD7 which were both 
downregulated in 100% of tumours and single copy in 60% and 53% of tumours 
respectively, the expression of many candidate TSGs did not correlate with copy 
number loss. Some TSGs, e.g. CEACAM1, DLG1, KLK11, showed downregulation 
in 100% of NPC tumours but no copy number loss, whilst for others e.g. EPAS1, 
S100A2, frequent copy number gains were detected.  
 
To ascertain further whether there was any consistent correlation between up- or 
down-regulation of the genes of interest (genes involved in small regions of loss or 
gain, and families of tumour-related genes) and genomic copy number changes, the 
relationship between expression level and copy number status was further analysed in 
the 13 NPC samples for each gene in these two groups (Table 4.2, and Tables 3.1-3.3). 
This reveals that in the genes involved in small regions of loss or gain, 62.4% of 
instances of copy number loss is associated with gene down-expression, whereas only 
25% of copy number gain correlates with gene up-expression. On the contrary, in 
about 50% of instances of copy number gain, gene down-expression was observed 
(Table 4.3 A). A similar phenomenon is also found in the tumour-related genes (Table 
4.3 B). 
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Table 4.3: The relationship between copy number and expression changes. 
 
A． Genes involved in small regions of loss or gain 
 
 
 
B． Tumour-related genes 
 
 DOWNREGULATED NO CHANGE UPREGULATED 
COPY LOSS 64.1% 21.5% 14.4% 
(535) (343) (115) (77) 
    
COPY NEUTRAL 51.9% 23.9% 24.3% 
(1899) (985)  (453) (461) 
    
COPY GAIN 40.8% 24.8% 34.4% 
(218) (89) (54) (75) 
 
 
The 13 samples from which both copy number and expression data were available 
(cell line C666-1 and 12 biopsies, see Table 1) were examined for copy number status 
at the locus of each gene that is called “present” by GCOS in all four normals in the 
two groups (A: Table 4.2, B: Tables 3.1-3.3). Copy number was scored as “loss” (0 – 
1 copy, top row), “neutral” (2 copies, middle row) or “gain” (>2 copies, bottom row). 
Gene expression was classified as “downregulated” (fold change ≥ -1.5, left column), 
“no change” (fold change -1.4 – 1.4, middle column) or “upregulated” (fold change ≥ 
1.5, right column). The numbers in parentheses indicate the number of instances of 
the given condition whilst the percentage figures represent the proportions of 
downregulated, unchanged or upregulated genes in each of the three copy-number 
classes. 
 
 
 
 DOWNREGULATED NO CHANGE UPREGULATED 
COPY LOSS 62.4% 24.3% 13.4% 
(202) (126) (49) (27) 
    
COPY NEUTRAL 40.6% 29.2% 30.2% 
(281) (114)  (82) (85) 
    
COPY GAIN 50.0% 25.0% 25.0% 
(24) (12) (6) (6) 
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4.7 Discussion 
In the present study, we identified multiple regions of chromosomal loss, gain, and 
LOH using a panel of 14 NPC biopsies and one NPC cell line C666-1. A number of 
potential tumour-associated genes involved in the altered regions were implicated. 
The copy number changes predicted by SNP array were verified using an independent 
method based on q-PCR and reveals that our SNP array analysis is both sensitive and 
specific. 
 
We determined the EBV status of the NPC samples. All samples except MMAH were 
EBV positive. After review of the histological morphology of this sample by an 
experienced NPC pathologist it was confirmed to be undifferentiated NPC. There is 
thought to be near 100% EBV positivity in undifferentiated NPC, but we failed to 
confirm the presence of the virus in tumour MMAH even when using the most 
sensitive way of EBV detection i.e. detecting the amplified BamHI-W region. This 
suggests that this sample might be an example of a relatively rare, EBV negative, 
undifferentiated NPC.     
  
NPC tissues are especially heterogeneous with an extensive lymphocytic infiltrate 
surrounding the tumour cells. Previous studies have shown that the quality of the data 
obtained from SNP arrays is highly dependent on tumour purity. Up to 20% of 
contamination with non-neoplastic cells should be acceptable for the detection of 
genomic abnormalities, whereas more than 30% of contamination will result in a 
significant reduction of the sensitivity of the analysis (Lindblad-Toh et al., 2000; 
Huang et al., 2004; Zhao et al., 2004). Tissue microdissection enables the collection 
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of purified populations of NPC tumour cells. However, a DNA amplification step is 
needed in order to obtain sufficient DNA from microdissected cells. The preliminary 
data from 10K SNP arrays confirmed (at more than 99% concordance) the fidelity of 
amplified DNA by comparison of amplified and unamplified DNA derived from 
C666-1 cells, as well as DNA sequence analysis of the LMP1 region. But in 500K 
SNP arrays, the amplified DNA showed some artefactual genetic changes (e.g. 
isolated, ~200kb regions of genetic copy number loss or gain across the chromosome 
and deletion at the chromosomal termini). Thus, when analysing the SNP array data, 
we filtered out 300kb or less small genetic changes as well as losses close to 
chromosomal termini. 
 
In our SNP array data, the most frequent deletions were observed in chromosomes 3p, 
5q, 9p and q, 13q, 14q, 16p and q. Frequent gains were observed in chromosome 1q, 
3q, 8p and q, 12p and q, which is general agreement with previous studies obtained 
from CGH analysis (Chen et al., 1999; Hui et al., 1999; Fang et al., 2001; Wong et al., 
2003).  
 
However, it is worthy to note that the genetic changes in the C666-1 cell line obtained 
by SNP array analysis are somewhat different from those described previously (see 
Section 3.5.2). This line was originally described in 1999 and chromosomal 
aberrations were examined using conventional CGH where gains of 7q and 8q, and 
losses of 6pter-q12, 11q14-qter, 14q23-qter, 16q and 18q21-qter were found (Cheung 
et al., 1999). Our data additionally identified several smaller regions of copy number 
loss or gain, which might have been missed by the previous studies since they used a 
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detection technique with much lower resolution. Whilst the discrepancy in some 
extensive regions of genetic changes detected by their study and ours might be partly 
due to cell allelic variation as a consequence of long-period passage and different 
condition in culture. In addition, a closer examination of the earlier data revealed hints 
of some of the changes that were observed in our data (e.g. gains of 8pter-p22, 8p12-
q12 and 16pter-q12). Although these were not significant in the earlier work, it could 
suggest that the original population was heterogeneous and that some of the 
previously minor components are now in the majority. 
 
Our methodology had high resolution and additionally identified several novel small 
regions of copy number loss, gain and LOH which might have been overlooked by 
conventional methods. We identified a 2.4 Mb loss at chromosome 4q13 that 
contained two genes, SRD5A2L2 and ephrinA5 (EPHA5). Since this deletion was 
detected in only one sample, it might suggest that this deletion is important in only a 
small proportion of NPC tumours. Deletions on chromosome 5q have not been 
frequently observed in previous studies, whereas we detected 3 small deletions 
including 5q14.1, 5q31.1-31.2 and 5q11.2. Among them, 9/15 (60%) loss of 5q14.1 
and 7/15 (47%) loss of 5q31.1-31.2 was observed in our samples. Several genes 
encoded in these regions (e.g. THBS4, MSH3, RASGRF2 PITX1, CXCL14 and 
TGFBI) are found to have tumour suppressor potential, suggesting that these deletions 
might be critical for carcinogenesis. Further functional investigation of these genes in 
NPC might provide new insight to its pathogenesis. Although another deletion on 
chromosome 5, deletion of 5q31.1-31.2, was observed in only three samples, one of 
the genes encoded in this region was ITGA2, whose reduction was previously 
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reported to be associated with cell immortalisation and malignant progression (see 
Section 4.5.3). 
 
Small gains are not detected as frequently as small deletions in our SNP array data. 
High-copy number at 8p11.22 – 11.21 in one sample was identified by SNP array and 
confirmed by q-PCR as having 8-9 copies. This is the only example of an 
amplification (5 or more copies) observed in our data. 14 genes have been implicated 
in this amplification. This amplified region has been also noted in breast cancer where 
several putative oncogenes were defined and found to be overexpressed including 
genes GOLGA7, MYST3 and AP3M2 that are also implicated in our data (Gelsi-
Boyer et al., 2005). Although their functions in NPC are still unclear, the notable 
amplification may indicate their potential relevance to the oncogenic process.  Recent 
investigations demonstrate that two novel regions of gain at 11q13.1-13.3 and 
12p13.3 have been detected in more than 50% of NPC tumour samples (see Section 
1.4.2.2). However, in our data, gain of 11q13.1-13.3 is rarely observed, whereas gain 
of 12p13.3 is mostly detected within an extensive region of gain on chromosome 12p.        
 
Our study integrated expression data with DNA copy number data in the same NPC 
tumour samples, thus allowing an exploration of the relationship between 
chromosomal copy number and gene expression in the genes that are potentially 
important in tumourigenesis. It is generally considered that gene copy number loss or 
gain is one of the mechanisms resulting in reduced or increased gene expression level. 
In our data, it is probably true in some cases, and a good example was shown in 
chromosome 8p11.22 – 11.21 in which several genes encoded were unambiguously 
upregulated in a single tumour that exhibited amplification. However, some cases do 
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not seem to follow this concept. A number of tumour-associated genes that showed 
down- or up-regulation in NPC tumours did not definitely display copy number loss 
or gain. Conversely, the upregulated genes exhibited chromosome loss and down-
regulated genes showed chromosome gain. For instance, chromosome 3p which has 
been reported to be frequently deleted in NPC tumours (Hui et al., 1999; Chan et al., 
2000; Chien et al., 2001) were single copy in 80% (12/15) of our samples, and a 
number of TSGs are located here. Nevertheless, several putative oncogenes are also 
found in these monosomic regions (e.g. RAF1, RAB5A, THRB, CTNNB1 and 
WNT5A on chromosome 3p), which were found to be up-regulated in over half of 
NPC tumours in expression array data.  
 
When the relationship between expression level and copy number status was 
examined in the 13 NPC samples for each tumour associated gene (Table 4.2, and 
Tables 3.1-3.3), it revealed that although in 60% of instances of copy number loss 
appeared to be associated with gene down-expression. However, in more than 40% of 
instances of copy number gain, gene expression was downregulated (Tables 4.3 A and 
B). Thus, with regard to this analysis, it seems to have a tendency that copy number 
loss correlates with gene down-regulation, whereas copy number gain is not 
associated with gene up-regulation.  However, for the individual genes, the concept 
that gene up- or down-expression is driven by gene copy number gain or loss might 
be overestimated or oversimplified, at least in NPC tumours. The gene expression 
changes in NPC might be caused by more complicated mechanisms such as mutation, 
methylation or regulated by some key factors during the tumour biology process.     
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SNP array data can integrate copy number data with LOH status, so as to identify 
UPD regions (copy neutral LOH). Several UPD regions have been identified in our 
data and are found in a number of chromosomes. The most frequently involved are 
chromosomes 6 and 9. Although in previous studies LOH of chromosome 9p was 
considered to be a frequent event, LOH of 9q has not been mentioned before. 
However, in our data, a small minimal overlapping region of UPD at 9q was observed 
in three samples, indicating that this UPD region may be a non-random event in NPC 
tumours. Putative tumour suppressor genes SYK, GAS1, DAPK1 and GADD45G are 
found to be encoded in this small UPD region. It has been considered that a UPD 
region often harbours genes targeted by somatic mutation. To understand whether 
these genes are mutated in NPC, sequence analysis in these three samples is needed. 
 
In summary, we detected a number of allelic imbalances (including copy number 
changes, LOH and UPD) in NPC tumours by using high density SNP arrays. The 
altered fragments are narrowed in a minimal boundary, which makes it possible to 
identify critical NPC-associated genes and provides more clues for understanding the 
mechanisms of NPC pathogenesis. The integrated analysis of SNP array data and 
expression data suggested that frequently there is no direct or strong correlation 
between gene chromosome abnormalities and expression changes. Other mechanisms 
may be involved such as abnormal signalling pathways that could regulate gene 
expression. 
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CHAPTER 5 
 
Dysregulated signalling pathways  
 
5.1 Introduction  
In common with other tumours, the complex process of NPC tumour formation has 
been distilled to a series of stochastic events that occur gradually in the tumour 
development and progression and are required for tumour cell growth and survival. 
These include the ability to resist growth inhibitory factors, and to facilitate 
proliferation, invasiveness and metastasis. These functions are obtained not only from 
genetic alterations such as activation of oncogenes or inactivation of tumour 
suppressor genes, but also from altered production of, or responsiveness to, the 
components and functional target genes of multiple signal transduction pathways that 
normally control cellular homeostasis. Thus, NPC tumourigenesis can be viewed as a 
disruption of these pathways through genetic, epigenetic or somatic alterations. To 
determine novel hypotheses on the most relevant pathways engaged in the 
pathogenesis of NPC, the differentially expressed genes identified from expression 
array data by RP analysis were examined using the FatiGO program (Al-Shahrour et 
al., 2004) and KEGG database (Kanehisa et al., 2002). This revealed a substantial 
enhancement in the expression of genes involved in several signalling pathways 
including the TGF-β/activin, Wnt/β-catenin and Hedgehog (Hh) pathways that were 
differentially regulated in NPC tumours compared to normal control epithelia.  
 
Expression profiles of NPC in previous studies have discovered dysregulation of the 
TGF-β and Wnt/β-catenin pathways in NPC tumours (Sriuranpong et al., 2004; Shi et 
al., 2006; Zeng et al., 2007). Data presented here confirm and extend these findings. 
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As was mentioned in Section 1.4.4.1, dysregulation of the NF-кB signalling pathway 
is critical for NPC tumourigenesis. In previous studies this pathway has been more 
extensively investigated. Thus, it is not considered here although our data show this 
pathway to be abnormally regulated in our NPC samples. Activation of the Hh 
pathway has been reported in several other types of cancer (Bailey et al., 2009; 
Kasper et al., 2009; Zhao et al., 2009), whereas it has not been investigated thus far in 
NPC. Our findings could provide a new insight to the mechanism of NPC 
development. To validate the accuracy of array predictions, some up- and down-
regulated gene components involved in these signalling pathways were validated 
either at the transcriptional level by PCR and q-RT-PCR or at the protein level by 
IHC staining.  
 
5.2 The TGF-β signalling pathway 
 
The TGF-β superfamily members and TGF-β signal transduction were described in 
detail in Section 1.4.4.2. Like other cell signalling pathways, the activities of the 
TGF-β signalling pathway are closely related to the gene status and expression levels 
of their components. Alterations in the expression of TGF-β family members are 
associated with a number of human malignancies (Diaz-Chavez et al., 2008; Kapral et 
al., 2008; Langenskiold et al., 2008). In NPC tumours, although previous gene 
expression profiling revealed that a small number of genes involved in the TGF-β 
pathway were deregulated (Zeng et al., 2007), the expression patterns of the family 
members in this particular tumour still remain elusive due to the limited studies.  
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5.2.1 Dysregulation of the TGF-β signalling pathway in NPC 
 
The significantly differentially regulated genes identified from expression array data 
by RP analysis were examined for groups of functionally related proteins by the 
FatiGO program (Al-Shahrour et al., 2004) and protein interaction networks of 
signalling pathways using the KEGG database (Kanehisa et al., 2002). Figure 5.1 
generated through this analysis presents a schematic model for the main components 
involved in this pathway. Table 5.1 presents the fold change and statistical 
significance of the individual genes included in the TGF-β pathway as revealed by RP 
analysis. This showed that a number of TGF-β family members including ligands 
(BMP2, INHBA), receptors (TGFBR1, TGFBR2, ACVR1, BMPR1A and BMPR2), 
SMADs (SMAD1, 2, 4, 5 and 7) and a number of target genes (e.g. TGFBI, SKIL) 
were generally upregulated in NPC tumours. Although some genes were not regarded 
as being significantly changed following RP analysis, they are either important 
components in this pathway (e.g. TGFβ1) or found to be upregulated in several NPCs 
when analysed using GCOS and the rules that were employed in the previous chapters 
(e.g. SERPINE1). These are also included in Table 5.1. To validate the reliability of 
the array data, the protein expression of several differentially regulated genes was 
examined by IHC staining in NPC tumour and normal control tissue arrays as well as 
in frozen sections from the same biopsies that had been used for array analysis (see 
below).  
 
5.2.1.1 TGF-β family ligands 
 
Elevated expression of TGF-β family ligands could enhance signal transduction 
through the sustained activation of SMAD signalling. In our expression array data, the 
expression levels of ligands BMP2 and activin A (inhibin-βA homodimers), showed  
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Figure 5.1: A number of genes involved in the TGF-β signalling pathway are 
dysregulated in NPC. The significantly differentially regulated genes identified from 
expression array data by RP analysis were examined using the FatiGO program and 
KEGG database. The figure generated through this analysis represents a schematic 
model of the main components involved in the TGF-β signalling pathway. A number 
of genes involved in this pathway ranging from ligands, receptors, Smads and target 
genes are generally upregulated as shown by the red boxes, whereas ID1 appears to be 
downregulated in NPC tumours (yellow box). The green boxes indicate genes whose 
expression was not significantly changed.   
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Table 5.1: Differentially regulated genes involved in the TGF-β signalling 
pathway.  
 
Gene Symbol Name p value (t) 
FC 
(overall) 
FC 
 (C666-1) 
TGF-β ligands     
TGFB1 transforming growth factor, beta 1   A  
TGFB2 transforming growth factor, beta 2  A  
TGFB3 transforming growth factor, beta 3  A  
INHBA inhibin, beta A 0.0028 2.8 -1.6 
INHBB inhibin, beta B (activin AB beta 
polypeptide) 
 A  
BMP2 bone morphogenetic protein 2 0.0014 2.4 4.6 
TGF-β receptors     
TGFBR1 transforming growth factor, beta 
receptor I (activin A receptor type 
II-like kinase, 53kDa) 
0.0013 3.7 2.9 
TGFBR2 transforming growth factor, beta 
receptor II (70/80kDa) 
0.057 2.1 A 
ACVR1 activin A receptor, type I 0.0000082 5.2 5.9 
ACVR1B activin A receptor, type IB 0.0023 2.9 1.0 
ACVR2B activin A receptor, type IIB NS   
BMPR1A bone morphogenetic protein 
receptor, type IA 
0.0028 4.0 7.3 
BMPR2 bone morphogenetic protein 
receptor, type II (serine/threonine 
kinase) 
0.0000003 5.8 2.7 
TGF-β antagonists     
FST follistatin 0.21 2.0 14.2 
SMAD transducers     
SMAD1 SMAD family member 1 0.00073 5.1 3.5 
SMAD2 SMAD family member 2 0.000057 3.5 5.7 
SMAD3 SMAD family member 3 NS 1.3 -1.2 
SMAD4 SMAD family member 4 0.00016 3.2 2.3 
SMAD5 SMAD family member 5 0.13 2.4 -1.8 
SMAD7 SMAD family member 7 0.0030 4.4 6.1 
Protein Phosphatases     
PPP2R2A protein phosphatase 2 (formerly 
2A), regulatory subunit B, alpha 
isoform 
0.15 2.0 1.0 
PPP2R1B protein phosphatase 2 (formerly 
2A), regulatory subunit A, beta 
isoform 
0.0018 1.9 2.7 
PPP2R3C protein phosphatase 2 (formerly 
2A), regulatory subunit B'', gamma 
0.025 3.5 9.6 
PPP2R5E protein phosphatase 2, regulatory 
subunit B', epsilon isoform 
0.0086 3.5 10.1 
PPP2CB protein phosphatase 2 (formerly 
2A), catalytic subunit, beta isoform 
0.020 2.8 6.2 
PPA1 pyrophosphatase (inorganic) 1 0.0098 2.0 3.7 
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PTPRK protein tyrosine phosphatase, 
receptor type, K 
0.11 4.3 3.9 
Protein kinases     
RPS6KB1 ribosomal protein S6 kinase, 
70kDa, polypeptide 1 
0.012 2.5 5.5 
ROCK1 Rho-associated, coiled-coil 
containing protein kinase 1 
0.0013 2.2 3.2 
MAPK1 mitogen-activated protein kinase 1 0.0045 2.4 2.2 
MAPK6 mitogen-activated protein kinase 6 0.023 2.1 1.9 
MAP3K7 mitogen-activated protein kinase 
kinase kinase 7 
0.000087 4.4 4.3 
Transcription factors     
SMURF2 SMAD specific E3 ubiquitin 
protein ligase 2 
0.17 3.1 5.4 
LTBP1 latent transforming growth factor 
beta binding protein 1 
0.000065 4.7 7.8 
E2F5 E2F transcription factor 5, p130-
binding 
0.00086 2.8 5.7 
SP1 Sp1 transcription factor 0.016 1.9 -1.4 
WWP1 WW domain containing E3 
ubiquitin protein ligase 1 
0.024 3.7 3.4 
ZFYVE16 zinc finger, FYVE domain 
containing 16 
0.0019 3.2 1.4 
TGF-β targets     
TGFBI transforming growth factor, beta-
induced, 68kDa 
0.023 2.0 A 
ITGB6 integrin, beta 6 0.16 2.0 -5.6 
SKIL SKI-like oncogene 0.0000038 5.4 1.8 
SERPINE1 serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator 
inhibitor type 1), member 1 
NS 1.7 -1.2 
NEDD9 neural precursor cell expressed, 
developmentally down-regulated 9 
0.0076 4.6 -2.0 
COL4A1 collagen, type IV, alpha 1 0.0013 10.5 6.8 
NET1 neuroepithelial cell transforming 
gene 1 
0.053 2.4 4.4 
CLDN1 Claudin 1 0.011 2.7 A 
JUN jun oncogene 0.0066 4.9 13.4 
ID2 inhibitor of DNA binding 2, 
dominant negative helix-loop-helix 
protein 
0.21 1.8 8.2 
BTG1 B-cell translocation gene 1, anti-
proliferative 
0.028 14.2 9.3 
SGK1 serum/glucocorticoid regulated 
kinase 1 
0.047 2.0 1.4 
RNF111 ring finger protein 111 0.0027 4.2 9.9 
COPS5 COP9 constitutive 
photomorphogenic homolog 
subunit 5 (Arabidopsis) 
0.14 1.8 3.1 
SOX4 SRY (sex determining region Y)-
box 4 
0.0014 14.3 8.8 
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GATA3 GATA binding protein 3 0.0020 2.7 1.0 
ID1 inhibitor of DNA binding 1, 
dominant negative helix-loop-helix 
protein 
0.020 -3.7 -2.2 
RUNX1 runt-related transcription factor 1 
(acute myeloid leukemia 1; aml1 
oncogene) 
0.0044 -2.5 -3.3 
ELK3 ELK3, ETS-domain protein (SRF 
accessory protein 2) 
0.12 -2.6 1.0 
HES1 hairy and enhancer of split 1, 
(Drosophila) 
0.000028 -5.7 -3.7 
LEFTY2 left-right determination factor 2 NS -1.6 -1.4 
 
“FC” indicates fold change determined by comparing the 4 normal samples with both 
the whole tumour set (overall) and with cell line C666-1 alone (C666-1) 
 
“A” indicates that expression was called “absent” by GCOS. 
 
“NS” indicates not significantly changed 
 
The red boxes indicate genes whose expression change in C666-l is in the opposite 
direction to that in the whole tumour set. The yellow boxes indicate genes whose 
expression level in C666-1 is relatively unchanged. 
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more than 2-fold upregulation in tumour samples compared to normal control 
epithelia. Increased expression of activin A has been observed in lung 
adenocarcinoma tissue where its over-expression was associated with cell 
proliferation (Seder et al., 2009). Conversely, the main member of the canonical TGF-
β pathway ligands, TGF-β1, was called “absent” in both tumour and normal controls 
by GCOS analysis. TGF-β can regulate the growth of cancer cells in an autocrine or 
paracrine fashion. The tumour development and progression are controlled by the 
synergistic interplay of cancer cells and activated stroma. Although the tumour cells 
do not appear to make TGF-β1  themselv es, they could  still resp ond  to TGF-β1 
secreted from the surrounding stromal cells (Yue & Mulder, 2001; Tobin et al., 2002). 
 
5.2.1.2 TGF-β family receptors 
 
TGF-β family receptors couple extracellular ligands to the SMADs and are essential 
for the activation of entire pathways. In the expression array data, several TGF-β 
family receptors (BMPR1A, BMPR2, TGFBR1, TGFBR2, and ACVR1) were found 
to be upregulated in NPC tumours compared to control normal epithelia. TGFBR1 
and TGFBR2 are TGF-β type І and type ІІ receptors, respectively. In the array data, 
TGFBR2 showed 2-fold upregulation in NPC tumours using RP analysis. However, 
when TGFBR2 expression was analysed using the GCOS rules, 6 samples showed 
upregulation compared to controls. IHC staining for this gene product in matched 
NPC and normal nasal epithelial (NP) samples revealed over-expression of TGFBR2 
protein in 65.4% (17/26) of NPC tumours (Figure 5.2 A). Another TGF-β receptor, 
TGFBR1, exhibited 3.7-fold upregulation at the RNA level in RP analysis. GCOS 
analysis revealed that TGFBR1 was upregulated in 75% (12/16) NPCs. IHC staining 
of TGFBR1 was performed in frozen sections from the same sample used for  
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Figure 5.2: Expression array intensities and immunohistochemical staining on 
NPC and nasopharyngeal epithelial (NP) samples reveals differential regulation 
at both the RNA and the protein levels for genes TGFBR2, SMAD7 and 
SERPINE1. 
 
The left panels show normalised expression array intensities for the 4 normal samples 
(grey) and 15 NPCs plus C666-1 (red). The centre panels show examples of 
immunohistochemical staining on NPC and NP tissue samples. The right panels show 
the immunohistochemical scoring results from the tissue arrays (normal, grey: tumour, 
red). At the RNA and protein levels respectively, (A) TGFBR2 is upregulated in 6/16 
(37.5.5%) and in 65.4% (17/26) samples, and positive TGFBR2 staining is 
predominantly observed in the cytoplasm and membrane. (B) SMAD7 is upregulated 
in 69% (11/16) and 60% (21/35) samples, and positive SMAD7 staining is 
predominantly observed in the cytoplasm; (C) SERPINE1 is upregulated in 37.5% 
(6/16, YH7, MKEC, 125855, XY6, 400(3) and XY5) and 53.6% (15/28) samples, and 
positive SERPINE1 staining is predominantly observed in the cytoplasm and 
membrane. 
NORMAL TUMOUR
A
B
C
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Figure 5.3: Expression array intensities and immunohistochemical staining on 
frozen samples reveals differential regulation at both the RNA and protein levels 
of genes involved in the TGF-β signalling pathway.  
IHC staining of genes (TGFBR1, SMAD2, BTG1, ID1 and SP1) was performed on 
the same frozen samples used for array analysis. The left and middle panels show 
examples of immunohistochemical staining in normal and tumour samples, whilst the 
right panels show the normalised expression array signal intensities for the 4 normal 
samples (grey) and 15 NPCs plus C666-1 (brown).  
(A)  At the RNA level, TGFBR1 is upregulated in 75% (12/16) of NPC samples. At 
the protein level, the tumour sample MKEC (high array intensity) shows intense 
cytosolic staining of TGFBR1, whereas in the normal sample MSTA (low array 
intensity) TGFBR1 protein expression is not detectable.    
(B) At the RNA level, SMAD2 is upregulated in 81% (13/16) of NPC tumours. 
Tumour MMAH (high array intensity) shows strong cytosolic expression of SMAD2 
protein whereas normal MHAU (low array intensity) shows very weak expression of 
SMAD2. 
(C) At the RNA level BTG1 is upregulated in 93% (15/16) of NPC tumours. Tumour 
MDIG (high array intensity) shows strong cytosolic expression of BTG1 protein 
whereas normal MHAU (low array intensity) shows weak expression of BTG1. 
(D) At the RNA level ID1 is downregulated in 81% (13/16) of NPC tumours. Tumour 
MMAH (low array intensity) shows weak expression of ID1 protein whereas normal 
MHAU (high array intensity) shows strong cytosolic expression of ID1. 
(E)  At the RNA level SP1 is upregulated in 69% (11/16) of NPC tumours. Tumour 
MMAH (high array intensity) shows strong nuclear expression of SP1 protein 
whereas normal MHAU (low array intensity) shows weak expression of SP1. 
MSTA MKEC 
Normal Tumour
MHAU MMAH 
MHAU MDIG 
MHAU 
MMAH  
MHAU MMAH
A
B
C
D
E
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array analysis, and the results confirmed the array prediction as shown in Figure 5.3A. 
A recent publication indicated that reduced expression of TGFBR1 may contribute to 
decreased risk of developing pancreatic cancer (Adrian et al., 2009), findings which 
support the notion that over-expressed TGFBR1 can act as a tumour promoting factor.  
 
5.2.1.3 TGF-β family SMAD signalling 
 
As mediators of TGF-β signalling, the SMADs play central roles in signal 
transduction and transcriptional regulation of this pathway. The array data revealed 
that expression of most of the SMADs including SMAD1, 2, 4, 5 and 7 was 
upregulated in NPC. SMAD4, as a common-mediator SMAD, is a link between 
receptor SMADs and downstream effectors. Inactivation of SMAD4 has been 
frequently observed in pancreatic and colorectal cancer and is associated with 
malignant progression (Miyaki & Kuroki, 2003; Bardeesy et al., 2006), whereas in a 
subset of advanced pancreatic tumours, intact SMAD4 induces TGF-β-dependent cell 
proliferation (Bardeesy et al., 2006). Activation of SMAD2 is essential for TGF-β and 
activin signal transduction. RP analysis estimated 3.5-fold upregulation of SMAD2 
expression in NPC. With GCOS analysis, it was shown to be upregulated in 81% 
(13/16) NPCs. IHC staining for this gene in frozen sections verified the array 
predictions (Figure 5.3B). SMAD7 is an inhibitory SMAD for TGF-β and activin 
signalling, as it binds to type І receptors and interferes with the phosphorylation of the 
receptor SMADs, SMAD2 and 3. Transcription of inhibitory SMAD7 mRNA is 
induced by TGF-β stimulation and acts as an autoregulatory negative feedback signal 
for TGF-β and activin signal transduction (Nakao et al., 1997). In RP analysis, this 
gene showed 4.4-fold upregulation in NPC, whereas GCOS analysis revealed that it 
was upregulated in 69% (11/16) samples. The protein level of SMAD7 in NPC 
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tumour and normal epithelial tissue was determined by IHC staining, and the results 
showed that 60% (21/35) of NPC tumours displayed increased expression of SMAD7 
compared to normal nasal epithelia (Figure 5.2 B).         
 
5.2.1.4 TGF-β family target genes 
 
TGF-β family members exert a variety of biological effects by modulating the 
transcriptional responses of a number of target genes (Levy & Hill, 2005). TGF-β and 
activin utilise the same set of SMADs (SMAD2, 3 and 4) for signal transduction. 
Comparative expression profiling of cell lines overexpressing constitutively active 
type І TGF-β or activin receptors revealed that they modulate similar transcriptional 
responses (Ryu & Kern, 2003). BMP signalling utilises different pathway-restricted 
SMADs (SMAD1/5/8), and its targets might be somewhat different (Miyazono et al., 
2005). A number of well-known TGF-β family target genes were found to be 
upregulated in our expression array data. These included TGFBI, a TGF-β-responsive 
gene (Thapa et al., 2007), that was described in Chapter 4. This gene was found to be 
located in chromosome 5q31.1-31.2, a small region of loss. Transcripts of TGFBI 
were elevated 2 fold and GCOS analysis and IHC data revealed that its expression 
was increased in 63% (10/16) and 54% (7/13) NPC tumours at the RNA and protein 
level, respectively. SKIL, an oncogene that was introduced in Chapter 3, showed 5.4-
fold upregulation in NPC by RP analysis. Another well-established TGF-β-responsive 
gene (Kortlever et al., 2008), plasminogen activator inhibitor-1 (PAI1), also called 
SERPINE1, although not identified by RP analysis, was found to be absent in 4 
normal controls while present in about 37.5% (6/16) of NPCs. The protein expression 
of SERPINE1 was examined by IHC staining in tissue arrays, where protein 
upregulation was observed in 53.6% (15/28) of NPC tumours (Figure 5.2 C). RP 
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analysis revealed that another TGF-β target gene, BTG1, was upregulated 14.2-fold in 
NPCs. By GCOS analysis it was found to be upregulated in 93% (15/16) NPCs. IHC 
staining of BTG1 in the frozen NPC tumour confirmed its upregulation relative to 
normal control epithelium (Figure 5.3C). Overexpression of BTG1 has been 
demonstrated to promote cell migration and play an important role in angiogenesis 
(Iwai et al., 2004). In addition to the transcriptional upregulation, a small number of 
TGF-β target genes were down-regulated in NPC tumours. ID1, which plays an 
important role in the inhibition of cell differentiation and growth arrest was firstly 
found to be a direct target for BMP signalling (Miyazono & Miyazawa, 2002). 
Although ID1 expression is induced by BMP signalling, it has been reported that the 
level of its expression is suppressed in response to canonical TGF-β signalling in 
epithelial cells (Ling et al., 2002). RP analysis identified a 3.7-fold downregulation of 
ID1 transcripts in NPC tumours. GCOS analysis confirmed downregulation of ID1 in 
81% (13/16) of NPC tumours. IHC staining of frozen sections from the same samples 
used for array analysis further confirmed that ID1 protein was reduced in NPC 
compared to normal epithelia (Figure 5.3D).  
 
5.2.2 Dysregulation of TGF-β signalling in the C666-1 cell line   
 
As mentioned in chapter 3, a sample correlation analysis revealed that the C666-1 cell 
line had an overall expression pattern very similar to that of the majority of NPC 
tumour biopsies. To analyse the similarity in the expression of individual genes in 
C666-1 cells and NPC tumour biopsies further, a comparison of gene expression 
between C666-1 and the 4 normal biopsies was carried out. The array-determined fold 
changes determined by comparing the 4 normal samples with both the whole tumour 
set and with cell line C666-1 alone are shown in Table 5.1. In the majority of cases, 
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accounting for 74% (40/54) of genes, C666-1 follows the overall pattern of up- or 
down-regulation but some genes do not follow the average trend (the fold changes for 
these genes are highlighted in the table). For example activin, TGFBR2 and ITGB6 
are predicted to be down-regulated in C666-1 whereas they were estimated to be 
upregulated in NPCs by RP analysis.  
 
Since the sample correlation analysis also indicates that tonsillar epithelial cells 
appear to be a good model for normal nasopharyngeal epithelial cells, they were used 
as a normal control to examine the reliability of array predictions in C666-1 cells. The 
mRNA derived from C666-1 cells and cultured primary tonsillar epithelial cells were 
used for RT-PCR and qRT-PCR analysis. Downregulation of TGFBR2, TGFBI and 
upregulation of SMAD2 were verified by RT-PCR (Figure 5.4), findings which are 
consistent with previous results that demonstrated the absence of TGFBR2 and 
TGFBI expression in C666-1 (Wood et al., 2007). In addition, qRT-PCR analyses 
confirmed the upregulation of BMP2, MAPK1, and E2F5, and downregulation of 
NEDD9, HES1 and ID1 in C666-1 cells (Figure 5.5). Since GCOS called CLDN1 
expression as “absent” in C666-1 cells, its fold change could not be accurately 
estimated. In agreement with the array data, CLDN1 expression was undetectable in 
the qRT-PCR analysis. 
 
5.3 The Wnt signalling pathway 
5.3.1 The Wnt/β-catenin pathway and cancer 
 
The Wnt signalling pathway and its signal transduction were introduced in detail in 
Section 1.4.4.3. The activation of the Wnt canonical signalling pathway ultimately 
leads to the stabilisation and accumulation of β-catenin in the nucleus of cells.  
TGFBR2
TGFβ1
SMAD2
SMAD3
SERPINE1
TGFBI
GAPDH
386 bp
250 bp
250 bp
301 bp
154 bp
388 bp
440 bp
399 bp
300 bp
ACVR2B 440 bp
INHBB 280 bp
TGFβ2
TGFβ3
Figure 5.4: Expression levels of TGF-β family members in C666-1 cells
determined by RT-PCR. RNA was extracted from C666-1 and cultured primary
tonsillar epithelial cells (PEC). Following cDNA synthesis, the expression of TGF-β
family genes was analysed by RT-PCR. The PCR products were viewed by agarose
gel electrophoresis. RT-PCR for the housekeeping gene GAPDH was utilised as an
internal control to confirm equal RNA input into each PCR reaction. Compared to
control primary tonsillar epithelial cells, the downregulation of TGFBR2, TGFBI, and
upregulation of SMAD2 are observed in C666-1 cells.
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Figure 5.5: Validation of expression array data for C666-1 by qRT-PCR
analyses. Three biological replicates of RNA were extracted from C666-1 and
cultured primary tonsillar epithelial cells (PEC). Following cDNA synthesis, the
expression of TGF-β family genes (E2F5, BMP2, MAPK1, NEDD9, HES1, and ID1)
were analysed by qRT-PCR. Each assay on each sample was performed in triplicate.
The mean fold change of RNA expression in C666-1 cells relative to PEC were
determined by using the housekeeping gene GAPDH as an internal control. The fold
change determined by both array (purple bars) and qRT-PCR (blue bars) are in the
same direction (upregulation of E2F5, BMP2 and MAPK1, downregulation of
NEDD9, HES1, and ID1).
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Nuclear β-catenin plays critical roles in tumourigenesis by enhancing the expression 
of a number of functional genes. The aberrant activation of the Wnt/β-catenin 
pathway has been associated with various human cancers, including colorectal cancer 
(Hadjihannas et al., 2006), prostate cancer (Verras & Sun, 2006), liver cancer (Monga, 
2009), and NPC (Zeng et al., 2007). 
 
A distinct feature of the activated Wnt/β-catenin pathway in cancers is the mutation of 
key signalling components. Any mutational inactivation of pathway negative 
regulators (eg, APC, AXIN and GSK3β) and aberrant activation of positive regulators 
(eg, CTNNB1) through mutation could cause abnormal activation of this pathway. A 
large number of tumour types have been described with mutations in APC or 
CTNNB1 (β-catenin), and occasionally mutations in AXIN or other components have 
also been documented. Colorectal cancer is the most notable tumour with mutations in 
genes included in the Wnt/β-catenin pathway. More than 90% of colorectal cancer 
showed abnormal activating mutations of Wnt/β-catenin signalling, approximately 
80% of them carrying APC mutations and more than 10% containing gain-of-function 
mutations in CTNNB1 (Groden et al., 1991; Miyaki et al., 1999; Schneikert & 
Behrens, 2007). Gastric carcinoma is another common cancer with a high number of 
mutations in APC (76%) (Lee et al., 2002)) and CTNNB1 (26%) (Clements et al., 
2002). Whereas AXIN1 mutation has been observed in hepatocellular carcinoma 
(Satoh et al., 2000) and prostate carcinoma (Yardy et al., 2009).     
 
In addition to the frequent observation of mutations in components of the Wnt/β-
catenin signalling in cancers, the aberrant expression of genes involved in this 
pathway is also a common event. Increasingly altered nuclear accumulation of 
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CTNNB1 has been found to be associated with advanced gastric cancer (Ougolkov et 
al., 2000). Reduced APC protein expression has been detected in primary breast 
cancer (Ho et al., 1999). Increased expression of CTNNB1 and GSK3β and reduced 
APC expression have been observed in ovarian carcinoma compared to normal ovary 
(Rask et al., 2003). Several publications have investigated the relationship of gene 
mutation and aberrant expression in cancers. In some cases, the mutational 
inactivation of AXIN1, APC or activation of CTNNB1 did closely correlate with their 
aberrant expression. For instance, in ovarian carcinoma, all the cases with mutation of 
CTNNB1 showed nuclear CTNNB1 protein expression (Wright et al., 1999). The 
nuclear expression level of CTNNB1 was significantly higher in colorectal tumours 
with APC mutations compared to tumours with wild type APC (Dimberg et al., 2001). 
But in others, it suggests that the mutations and abnormal expression might be 
independent events activating the Wnt/β-catenin signalling pathway and contributing 
to tumourigenesis (Cui et al., 2003; Austinat et al., 2008; Tanahashi et al., 2008).  
  
5.3.2 Dysregulation of the Wnt signalling pathway in NPC 
 
Although the precise function of the Wnt signalling pathway in NPC is not fully 
understood, several lines of evidence indicate that Wnt signalling plays roles in NPC 
development. Gene expression profile revealed dysregulation of a number of 
components involved in Wnt signalling (Shi et al., 2006; Zeng et al., 2007). Wnt 
inhibitory factor1 (WIF1) is frequently silenced, and the finding that ectopic 
expression of WIF1 inhibits tumour cell colony formation underscores a possible role 
for WIF1 silencing in NPC pathogenesis (Lin et al., 2006; Chan et al., 2007). In 
agreement with previous findings, our array data revealed a substantial enhancement 
of several Wnt signalling components in NPC including ligands (WNT5A and 
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WNT10B), receptors (FZDs and LRP), signalling adapters (DVL3), transcription 
factors (CTTNB1, LEF and TCF) and targets (JUN and CCND2), whereas a key 
negative regulator, APC, was significantly down-regulated (Figure 5.6 and Table 5.2). 
 
The upregulation of WNT5A and CTNNB1 was verified at the protein level in tissue 
arrays by IHC staining (Section 3.5.1 and 3.5.5). The IHC data revealed that 43.5% of 
NPC tumours showed upregulation of WNT5A compared to adjacent normal epithelia. 
WNT5A can engage both the canonical (β-catenin, TCF/LEF) and non-canonical Wnt 
signalling pathways (Rac/JAK/NLK). This signalling is context-dependent based on 
the expression of its downstream targets, for example, WNT5A engagement of FZD5 
activates the canonical pathway (Katoh & Katoh, 2007). In the expression array, 
FZD5 expression was upregulated 2.4-fold in NPC, which indicates that activating 
Wnt signalling in NPC might be initiated from the interaction of WNT5A and FZD5. 
Upregulation of WNT5A has been frequently detected in cancers, and its upregulation 
has been suggested to enhance tumour cell migration, proliferation and invasiveness 
(Ripka et al., 2007). CTNNB1 is the key mediator of canonical Wnt signalling. IHC 
data showed CTNNB1 was over-expressed in 33.3% (6/18) of NPC (Section 3.5.5). 
Although CTNNB1 mutation has been frequently observed in gastric and colorectal 
cancer (see above section), mutation of CTNNB1 is rarely observed in NPC tumours 
(Li et al., 2004). Therefore, the increased CTNNB1 expression in NPC might be a 
consequence of Wnt signalling activation or mutational inactivation of other 
components.  
 
Our expression array revealed that down-regulation of Wnt signalling components in 
NPC is not a frequent event. However, the destruction complex component, APC,  
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Figure 5.6: A number of genes involved in Wnt signalling are dysregulated in 
NPC. The significantly differentially regulated genes identified by RP analysis of 
expression array data were examined using the FatiGO program and KEGG database. 
The figure generated through this analysis represents a schematic model of the main 
components involved in the Wnt signalling pathway. A number of genes involved in 
the Wnt signalling pathway ranging from ligands, receptors, transcription factors and 
target genes are generally upregulated as shown by the red boxes, whereas APC 
appears to be downregulated in NPC tumours (yellow box). The green boxes indicate 
genes whose expression was not significantly changed. 
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Table 5.2: Differentially regulated genes involved in the Wnt signalling pathway.  
 
Gene Symbol Name p value (t) 
FC 
(overall) 
FC   
(C666-1) 
Wnt Ligands     
WNT10B wingless-type MMTV integration site 
family, member 10B 
0.0057 2.2 2.2 
WNT5A wingless-type MMTV integration site 
family, member 5A 
0.067 1.8 4.1 
Wnt antagonists     
DKK1 dickkopf homolog 1 (Xenopus laevis) 0.010 2.1 1.3 
SFRP1 secreted frizzled-related protein 1 0.062 2.0 -1.2 
Wnt Receptors     
FZD7 frizzled homolog 7 (Drosophila) 0.000001 27.8 65.4 
FZD6 frizzled homolog 6 (Drosophila) 0.022 4.0 4.8 
FZD1 frizzled homolog 1 (Drosophila) 0.00087 2.5 1.9 
FZD5 frizzled homolog 5 (Drosophila) 0.0018 2.4 2.8 
Signalling adapter     
DVL3 dishevelled, dsh homolog 3 
(Drosophila) 
0.00047 3.1 4.8 
Signal 
transduction     
AKT3 v-akt murine thymoma viral oncogene 
homolog 3 (protein kinase B, gamma) 
0.00037 5.5 19.5 
AKT2 v-akt murine thymoma viral oncogene 
homolog 2 
0.032 2.2 1.5 
APC adenomatous polyposis coli 0.18 -4.0 -3.1 
MAP kinases     
MAP3K7 mitogen-activated protein kinase kinase 
kinase 7 
0.000087 4.4 4.3 
MAPK8 mitogen-activated protein kinase 8 0.00017 2.7 6.4 
MAPK9 mitogen-activated protein kinase 9 0.0065 2.3 9.9 
Protein 
Phosphatases     
PPP2R3C protein phosphatase 2 (formerly 2A), 
regulatory subunit B'', gamma 
0.025 3.5 9.6 
PPP2R5E protein phosphatase 2, regulatory 
subunit B', epsilon isoform 
0.0086 3.5 10.1 
PPP3R1 protein phosphatase 3 (formerly 2B), 
regulatory subunit B, alpha isoform 
0.011 3.1 9.9 
PPP3CB protein phosphatase 3 (formerly 2B), 
catalytic subunit, beta isoform 
0.0016 2.9 4.6 
PPP2CB protein phosphatase 2 (formerly 2A), 
catalytic subunit, beta isoform 
0.020 2.8 6.2 
PPP3CA protein phosphatase 3 (formerly 2B), 
catalytic subunit, alpha isoform 
0.035 2.5 1.9 
PPP2R2A protein phosphatase 2 (formerly 2A), 
regulatory subunit B, alpha isoform 
0.15 2.0 1.0 
PPP2R1B protein phosphatase 2 (formerly 2A), 
regulatory subunit A, beta isoform 
0.0019 1.9 2.7 
Protein kinases     
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PRKAR2B protein kinase, cAMP-dependent, 
regulatory, type II, beta 
0.050 3.4 25.2 
PRKAB2 protein kinase, AMP-activated, beta 2 
non-catalytic subunit 
0.0018 2.2 2.1 
PRKCA protein kinase C, alpha 0.056 2.1 1.0 
PRKCI protein kinase C, iota 0.15 2.0 2.2 
NLK nemo-like kinase 0.10 1.9 1.9 
PRKCZ protein kinase C, zeta 0.017 -2.8 -2.1 
Ubiquination     
SIAH1 Seven in absentia homolog 1 
(Drosophila) 
0.000096 2.3 5.5 
BTRC beta-transducin repeat containing 0.00023 -1.8 -1.9 
Miscellaneous     
CACYBP calcyclin binding protein 0.00011 4.7 5.0 
Rho GTPases     
CDC42EP3 CDC42 effector protein (Rho GTPase 
binding) 3 
0.000033 3.1 6.0 
ROCK2 Rho-associated, coiled-coil containing 
protein kinase 2 
0.020 2.2 4.6 
Transcription 
factors     
LEF1 lymphoid enhancer-binding factor 1 0.00028 4.8 6.2 
TCF3 transcription factor 3 (E2A 
immunoglobulin enhancer binding 
factors E12/E47) 
0.015 3.2 3.5 
CTNNB1 catenin (cadherin-associated protein), 
beta 1, 88kDa 
0.058 2.5 2.4 
NFATC2IP nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 2 
interacting protein 
0.000012 6.1 6.4 
NFAT5 nuclear factor of activated T-cells 5, 
tonicity-responsive 
0.0015 2.2 2.1 
NFATC2 Nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 2 
0.022 1.9 4.2 
Wnt targets     
CCND2 cyclin D2 0.0023 4.8 8.0 
JUN jun oncogene 0.0066 4.9 13.4 
 
 
“FC” indicates fold change determined by comparing the 4 normal samples with both 
the whole tumour set (overall) and with cell line C666-1 alone (C666-1). 
 
The yellow boxes indicate genes whose expression level in C666-1 is relatively 
unchanged. 
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showed an overall 4-fold downregulation by RP analysis and reduced expression in all 
the NPCs by GCOS analysis. IHC staining of our tissue array revealed that 46.2% 
(6/13) of NPCs had reduced APC protein expression (Figure 5.7). Although reduced 
APC expression has been reported in a number of tumour types (Ho et al., 1999; Chen 
et al., 2005; Song & Zhang, 2009), the expression pattern of this gene has not been 
reported in NPC. In theory, inactivation of APC could result in the stabilisation of 
CTNNB1 and contribute to activation of Wnt signalling. 
 
5.3.3 Dysregulation of Wnt signalling in the C666-1 cell line   
 
To analyse further the similarity in the expression of individual Wnt family members 
in C666-1 cells and in the whole tumour set, a comparison of gene expression 
between C666-1 and the 4 normal biopsies was carried out. The array-determined fold 
changes determined by comparing the 4 normal samples with both the whole tumour 
set and with cell line C666-1 alone are shown in Table 5.2. Relative expression levels 
of all genes except DKK1, CLDN1 and SFRP1 in C666-1 showed the same direction 
for their up- or down-regulation as the average level in the whole tumour set. 
 
5.4 The Hedgehog (Hh) signalling pathway 
 
In addition to the dysregulation of TGF-β and Wnt signalling in our NPC tumour 
samples, many components of the Hh signalling pathway were also found to be 
dysregulated. The Hh pathway is essential for mammalian development, with 
components acting as morphogens, growth factors and survival factors (Ingham & 
McMahon, 2001; Goetz et al., 2002). The dysregulation of the Hh pathway has been  
APC
TN
Figure 5.7: APC expression is downregulated in NPC at both the RNA and
protein level. APC expression was analysed with expression array and IHC data.
Panel A shows normalised expression array intensities for the 4 normal samples
(grey) and 15 NPCs plus C666-1 (red), whilst panel B shows the IHC scoring
results from the tissue arrays (normal, grey: tumour, red). Panel C shows
examples of IHC staining in NPC tumour (T) and normal epithelial cells (N). At
the RNA and protein levels respectively, APC is downregulated in 16/16 (100%)
and 46.2% (6/13) samples. Positive APC staining is predominantly observed in
the nucleus. Normal epithelial cells (N) show intense APC protein
expression, whereas tumour cells (T) show weak APC expression.
A B
C
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implicated in several cancers (Kayed et al., 2004; Wang et al., 2006; Lee et al., 2007), 
however its dysregulation has not been reported in NPC.  
 
5.4.1 Hh signal transduction 
 
In mammals, the Hh family members consist of Sonic Hh (SHH), Indian and Desert 
Hh. Hh binding to its receptor Patched 1 (PTCH1) initiates Hh signalling. PTCH1 
functions as a negative regulator in this pathway. In the absence of Hh ligands, 
PTCH1 blocks Smoothened (SMO) activity by preventing its localisation to the cell 
surface. The amount of Hh available to bind PTCH1 is tightly controlled by Hh-
binding proteins (HIP) and Growth arrest-specific gene (GAS1). In addition to being a 
signalling receptor, PTCH1 is also an Hh target and is frequently used as an indicator 
of Hh activation. The upregulation of PTCH1 sequesters hedgehog and suppresses its 
spread. Thus, the activity of Hh signalling is affected by the balance between the 
concentrations of Hh and PTCH1 (Chen & Struhl, 1996). When Hh is present, the 
activity of SMO is derepressed. The activated SMO regulates transcriptional factors, 
GLI family (GLI1, 2 and 3), which are responsible for modulating a number of Hh 
target genes (Jiang & Hui, 2008). GLI1 and 2 are thought to be activators for Hh 
targets whereas GLI3 is considered to act mainly as a repressor (Ruiz i Altaba, 1999). 
Suppressor of fused (SUFU) acts as a key negative regulator in the Hh pathway. 
SUFU binds GLI transcription factors, preventing them from activating Hh target 
genes (Evangelista et al., 2006; Cheng & Yue, 2008). The target genes of Hh 
signalling include PTCH1, the Wnt family and Bone Morphogenic Proteins (BMPs), 
members of the TGF-β superfamily (Cohen, 2003), which have been introduced 
earlier. 
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5.4.2 Dysregulation of Hh signalling components in NPC 
 
The expression array data revealed that a number of genes involved in Hh signalling 
were upregulated in NPC relative to control normal epithelia (Figure 5.8 and Table 
5.3). These included the Hh signalling receptor (PTCH1), pathway inhibitors (GAS1 
and RAB23), several protein kinases, Hh pathway mediators and regulators, 
transcription factor (GLI3) and a number of Hh target genes (i.e., FOXM1, CCND2, 
BMI1 and BCL-2) whose abnormal expression has been associated with cell cycle 
progression, proliferation and apoptosis. Conversely, a few genes were found to be 
down-regulated in NPC. These included the Hh pathway inhibitor (SUFU), and 
transcription factor (GLI2). The array-determined fold changes determined by 
comparing the 4 normal samples with both the whole tumour set and with cell line 
C666-1 alone are also shown in Table 5.3. This reveals that in the majority of cases, 
C666-1 followed the same direction for the up- or down-regulation of genes involved 
in Hh pathway. 
  
SHH is the major ligand of the Hh pathway. Although it was called by GCOS as 
“absent” in both the normal and tumour samples, except for sample XY6 (Figure 5.9 
A, upper panel), in a preliminary IHC staining experiment, it appeared to be 
upregulated in NPC tumour cells compared to tonsil epithelial cells (Figure 5.9 A, 
middle and bottom panel). PTCH1 is a crucial receptor and target of this pathway. It 
was shown to be upregulated in 50% (8/16) NPCs in GCOS analysis (Figure 5.9 B, 
upper panel), and a preliminary IHC staining data for PTCH1 showed that it was 
upregulated in NPC tumour cells (Figure 5.9 B, middle and bottom panels).  
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Figure 5.8: A number of genes involved in Hh signalling are dysregulated in 
NPC. The significantly differentially regulated genes identified by RP analysis of 
expression array data were examined using the FatiGO program and KEGG database. 
The figure generated through this analysis represents a schematic model of the main 
components involved in the Hh signalling pathway. A number of genes involved in 
this signalling pathway ranging from ligands, receptors, transcription factors and 
target genes are generally upregulated as shown by the red boxes. The green boxes 
indicate genes whose expression was not significantly changed.    
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Table 5.3: Differentially regulated genes involved in Hh signalling.  
 
Gene Symbol Name p value (t) FC 
(overall) 
FC   
(C666-1) 
Hh receptor     
PTCH1 patched homolog 1 (Drosophila) 0.013 3.3 6.6 
Hh antagonists     
SUFU suppressor of fused homolog 
(Drosophila) 
NS -1.7 -1.7 
GAS1 growth arrest-specific 1 0.18 1.7 2.3 
RAB23 RAB23, member RAS oncogene 
family 
0.0011 2.3 1.2 
Protein kinases     
CSNK1A1 Casein kinase 1, alpha 1 0.049 2.5 2.8 
PRKACB protein kinase, cAMP-dependent, 
catalytic, beta 
0.0046 2.9 -2.0 
DYRK1A dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 1A 
0.064 2.8 5.3 
Signalling mediator 
and regulator 
 
   
DZIP1 DAZ interacting protein 1 NS 1.7 1.0 
FBXW11 F-box and WD-40 domain protein 11 NS 1.5 1.6 
KIF4A kinesin family member 4A NS 3.3 5.0 
ZIC2 Zic family member 2 (odd-paired 
homolog, Drosophila) 
0.00024 2.9 8.4 
Transcription 
factors 
    
GLI2 GLI-Kruppel family member GLI2 NS -1.4 -1.7 
GLI3 GLI-Kruppel family member GLI3 0.025 2.1 2.3 
Hh targets     
PTCH1 patched homolog 1 (Drosophila) 0.013 3.3 6.6 
BMP2 bone morphogenetic protein 2 0.0014 2.4 4.6 
FOXM1 forkhead box M1 0.099 2.0 2.6 
BMI1 B lymphoma Mo-MLV insertion 
region (mouse) 
0.12 2.1 8.6 
BCL2 B-cell CLL/lymphoma 2 0.0000033 30.4 7.4 
SFRP1 secreted frizzled-related protein 1 0.55 2.0 -1.1 
CCND2 cyclin D2 0.0023 4.8 8.0 
 
“FC” indicates fold change determined by comparing the 4 normal samples with both 
the whole tumour set (overall) and with cell line C666-1 alone (C666-1) 
 
“NS” indicates not significantly changed. 
 
The red boxes indicate genes whose expression change in C666-l is in the opposite 
direction to that in the whole tumour set. The yellow boxes indicate genes whose 
expression level in C666-1 is relatively unchanged. 
PTCH1
N
T
SHH
N
T
A B
Figure 5.9: Expression array intensities and immunohistochemical staining for
genes SHH and PTCH1 on NPC and tonsil epithelial sample. The upper panels show
normalised expression array intensities for the 4 normal samples (grey) and 15 NPCs
plus C666-1 (red). The middle and bottom panels show examples of a preliminary
immunohistochemical staining on tonsil epithelial and NPC tissue. (A) SHH is present
in one NPC tumour (XY6) but absent in other NPCs and normal controls at the RNA
level. At the protein level, SHH shows intense cytoplasmic staining in NPC tumour
cells but is absent in tonsil epithelial cells. (B) PTCH1 is upregulated in 50% (8/16)
NPCs at the RNA level. At the protein level, it shows strong nuclear staining in NPC
tumour cells but is weak in tonsil epithelial cells.
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5.5 Discussion  
 
To identify cell signalling pathways whose activity was dysregulated in NPC, the 
differentially regulated genes identified from expression array data by RP analysis 
were examined in the FatiGO program and KEGG database. This revealed that 
several signalling pathways including TGF-β/activin, Wnt/β-catenin and Hedgehog 
(Hh) signalling pathways were differentially regulated in NPC compared to normal 
nasopharyngeal epithelia. The dysregulation of several gene components involved in 
these pathways predicted by array analysis were validated at the protein or RNA 
levels by IHC staining, RT-PCR and qRT-PCR, respectively.  
 
In the expression array data, a large number of components involved in TGF-β 
signalling were found to be upregulated in NPC including TGF-β family ligands, 
receptors, SMADs and targets, findings which indicate that TGF-β signalling is 
abnormally activated in NPC. We know that activation of the TGF-β family is 
initiated through ligand binding to receptors, however, in the array data the expression 
of canonical TGF-β ligands, TGF-β1 , 2  and  3  was estimated  to be absent in NPC 
tumours. How can the pathway be activated without ligand stimulation? One possible 
mechanism is that the NPC tumour cells do not make TGF-β ligands themselves, but 
respond to TGF-β produced by the surrounding stroma (see Section 5.2.1.1). 
Increased expression of TGF-β in the surrounding stroma of head and neck cancer has 
been reported (Rosenthal et al., 2004). To verify this hypothesis, an expression study 
of TGF-β in NPC and its surrounding stroma is required. Although expression of the 
canonical TGF-β lig and s ap p ears to be ab sent in NPC, exp ression of the TGF-β 
family member, activin, is upregulated in NPC. As both canonical TGFβ and non-
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canonical activin signalling utilise the same SMADs and modulate a similar set of 
target genes (see Section 5.2.1.4), it is possible that the differential transcriptional 
levels of some TGF-β family members were abnormally regulated due to activin 
rather than TGF-β signalling. TGFBR2 has been reported to be mutated and/or 
downregulated in a number of tumours (Munoz et al., 2006; Xu et al., 2007; Biswas 
et al., 2008). Transfection of dominant negative TGFBR2 into mice accelerates 
tumourigenesis and contributes to tumour development (Pu et al., 2009), whereas high 
levels of expression can reportedly enhance TGF-β signal transduction and increase 
the specificity of its biological effect (Rojas et al., 2009). In our expression array data, 
the RP analysis revealed 2.1-fold upregulation of TGFBR2 expression in NPCs, with 
IHC staining confirming upregulation of TGFBR2 at the protein level in NPC 
tumours. This observation supports the notion that chronic activation rather than 
disruption of the TGF-β pathway is a consistent feature in NPC tumours. 
 
The subcellular localisation of SMAD2 to the nucleus is an indication of 
transcriptionally active SMAD2 and is essential for activation of the SMAD-
dependent TGF-β signalling pathway. IHC staining of SMAD2 in frozen NPC shows 
a predominantly cytoplasmic localisation in tumour cells. To examine further an 
active form of SMAD2 in NPC, it would be helpful to use a phosphorylated SMAD2 
antibody for IHC staining.  
 
Our expression array, IHC and q-PCR data revealed that ID1 expression was 
downregulated in both the NPC biopsies and cell line C666-1. It has been suggested 
that ID1 expression is suppressed by TGF-β signalling in some cancers (Ling et al., 
2002; Damdinsuren et al., 2006), findings which are consistent with our result 
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demonstrating activation of TGF-β signalling and downregulation of ID1 expression 
in NPC. However, this result disagrees with previous findings in which ID1 
expression was observed to be upregulated in NPC (Wang et al., 2002). The opposing 
results may be due to different sample sets being used in their study and ours. 
Actually, the sample size used in their study is relatively small (only 5 NPC samples). 
To further confirm the expression status of ID1 in NPC, the sample number needs to 
be increased.   
  
In addition to activation of the TGF-β signalling pathway, the Wnt signalling pathway 
was also found to be aberrantly activated in NPC. Expression array and IHC data 
demonstrated that the putative Wnt target, CTNNB1 was upregulated at both the 
transcriptional and protein level in NPC. In response to Wnt signalling, CTNNB1 
becomes stabilised and enters the nucleus to modulate cellular gene expression. 
Therefore, CTNNB1 nuclear accumulation is usually considered to be an important 
indicator of the activation of canonical Wnt signalling. Although increased nuclear 
expression of CTNNB1 has been frequently found in tumours, our CTNNB1 staining 
in NPC was predominantly observed in the cytoplasm and membrane rather than in 
the nucleus. Actually, there is no consensus on the mechanism by which CTNNB1 
travels between cytoplasm and nucleus. In many cases, the activation of Wnt 
signalling causes an overall rise in CTNNB1 protein without clear nuclear preference. 
This indicates that CTNNB1 nuclear import is independent of nuclear localisation 
(Clevers, 2006). In addition, the increased cytosolic localisation of CTNNB1 has 
previously been noticed in NPC (Zeng et al., 2007).  
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Although a large number of Wnt signalling-related genes were upregulated in NPC, 
the tumour suppressor gene APC was found to be down-regulated. Numerous studies 
attest to the importance of APC silencing in the activation of Wnt signalling responses 
in carcinomas. APC has most frequently been observed in the cytoplasm of cells, 
whereas in our IHC staining, APC was predominantly localised in the cell nucleus of 
normal epithelium. Nuclear APC staining has also been observed previously. In the 
nucleus APC can bind to CTNNB1 and export it to the cytoplasm for degradation 
(Henderson, 2000). The reduced APC level will decrease CTNNB1 degradation, and 
the activated CTNNB1 is essential for activation of Wnt signalling.    
 
The expression array data in the context of signalling pathway analysis also revealed 
dysregulation of the Hh pathway in NPC. Although the majority of components were 
upregulated in NPC, the critical pathway antagonist, SUFU, which suppresses the Hh 
pathway at the transcriptional level by binding to GLI proteins (Cheng & Bishop, 
2002; Di Marcotullio et al., 2004; Barnfield et al., 2005), appeared to be 
downregulated in NPC despite the RP analysis not scoring its expression as 
significantly changed. Another antagonist, GAS1, that was identified as a putative 
TSG in our genetic analysis (Section 4.5.4) and has been demonstrated to inhibit cell 
growth and induce apoptosis (Dominguez-Monzon et al., 2009), was found to be 
upregulated in NPC tumours. GAS1 is probably induced in NPC as part of a negative 
feedback loop to limit SHH signalling and can therefore be used as a readout for Hh 
activation. 
 
A link between 17p deletion and abnormal activation of Hh signalling has been 
suggested in medulloblastoma. This study observed frequent chromosome 17p 
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deletion of a region carrying several genes (KCTD11, TP53, HIC1 and MNT whose 
dysregulation interferes with  the Hh signalling cascades, ranging from GLI1, to target 
genes CCNDs, BCL-2 and Myc (De Smaele et al., 2004; Ferretti et al., 2005). In 
Chapter 4, we introduced the genetic changes of NPC and observed deletions of 
17p11.2 - pter in 50% of NPC, which indicate that the aberrant Hh signalling in NPC 
might be driven by the deletion of chromosome 17p. When the expression level of 
genes involved in the chromosome 17 deletion (KCTD11, TP53, HIC1 and MNT) 
was examined using RP analysis, it estimated them to be not significantly changed. 
With GCOS analysis, only MNT appeared to be downregulated in about 50% of 
NPCs compared to normal controls, the other three (KCTD11, TP53 and HIC1) were 
not. This suggests that activation of the Hh pathway in NPC does not seem to be 
linked to dysregulation of genes involved in deletion of chromosome 17p.  
 
Although considered to be a negative regulator in the Hh signalling pathway, GLI3 
was found to be upregulated in our NPC tumour samples. Unlike GLI1 and 2, which 
function as transcriptional activators, GLI3 appears to function as a transcriptional 
repressor. Although evidence for a GLI3 activator form is weak, some studies have 
suggested this possibility, with GLI3 serving to regulate the expression of GLI1 
through binding to the GLI1 promoter (Dai et al., 1999). As overexpression of GLI3 
has been shown to induce cell migration and angiogenesis (Renault et al., 2009), our 
findings suggest that Hh induction of GLI3 may contribute to disease pathogenesis.   
 
In spite of the observation of the activation of transcriptional factors and target genes 
of the Hh pathway as well as repression of pathway antagonists, the Hh ligands were 
scored as absent in our NPC tumour samples. It has been reported previously that the 
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Hh pathway can be activated in the absence of Hh ligands, with both TGFβ and 
activated Ras mutations simulating GLI expression and activity (Dennler et al., 2007; 
Stecca et al., 2007). This finding suggests a model where Hh ligands or other growth 
factors produced by adjacent stromal tissue act in a paracrine manner to activate the 
Hh signalling pathway (Yauch et al., 2008). 
 
The C666-1 cell line is the only cell line used in our array analysis. This is the only 
EBV-positive NPC cell line available and is therefore considered to be more like an 
NPC tumour than are other NPC lines. To investigate whether C666-1 behaves as a 
real tumour in the transcriptional expression of individual genes, the array-predicted 
fold changes were determined by comparing the 4 normal samples with both the 
whole tumour set and with cell line C666-1 alone. The comparison revealed that 
C666-1 exhibited a similar expression pattern for the majority of signalling pathway-
related genes (see Table 5.1-5.3). This indicates that C666-1 approximates a real 
tumour and can be viewed as a good tumour model. However, a few genes do not 
follow the overall expression trend, for example, activin, TGFBR2, ITGB6, NEDD9 
and CLDN1 are predicted to be downregulated in C666-1 whereas they appear to be 
upregulated in tumour samples. The observation of this phenomenon is not surprising 
considering that each gene has its own particular expression pattern in any one sample, 
whereas RP analysis can only produce a fold change by comparing the whole sample 
set. Actually, when the data were analysed with GCOS, it was shown even in the 
authentic NPC biopsies that individual gene expression could be upregulated in some 
samples but downregulated in others. For example, although RP analysis revealed that 
TGFBR2 expression was upregulated 2.1-fold, with GCOS analysis, it was shown to 
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be upregulated in 6 NPC tumours. Therefore, from this viewpoint, C666-1 is not 
unique and some of the tumour samples also behave in the same way.   
 
Although different cell signalling pathways utilise distinct signal transduction 
pathways and perform different functions in tumourigenesis, emerging data suggest 
that crosstalk among TGF-β, Wnt and Hh signalling pathways cooperate and 
contribute to cancer development and progression. The crosstalk between TGF-β and 
Wnt has been suggested to occur at multiple levels. For example, TGF-β can induce 
CTNNB1 nuclear accumulation in a SMAD7-dependent manner in prostate cancer 
(Edlund et al., 2005). In the nucleus, the SMADs and CTNNB1/LEF synergistically 
regulate a set of shared genes (Labbe et al., 2000). SHH can induce TGF-β ligand 
production and TGFBR1 expression, which is essential for an invasive phenotype of 
gastric cancer cells (Yoo et al., 2008). Wnt signalling can stimulate the expression of 
Hh pathway activator, GLI1, which contributes to the proliferation of colorectal 
cancer cells (Noubissi et al., 2009). NPC pathogenesis is a highly complex process, 
and the disruption of various signalling pathways is most likely involved. Here, we 
have focused on the dysregulation of the TGF-β, Wnt and Hh signalling pathways 
with regard to the substantial enhancement of the components included in these three 
pathways. Our knowledge about the molecular nature of these pathways and their 
interactions is still limited in NPC. Since the expression pattern of C666-1 is very 
similar to NPC biopsies in the context of signalling pathway analysis, it could be used 
as a model to investigate the role of dysregulation of these signalling pathways in 
NPC tumourigenesis.    
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CHAPTER 6 
 
In vitro investigation of signalling pathways in NPC cells 
 
6.1 Introduction   
 
The TGF-β signalling pathway has been widely investigated in cancers. It plays an 
important role in epithelial tumour progression by acting both as a tumour suppressor 
at earlier stages of tumourigenesis and as a tumour promoter at later, more advanced 
stages of tumour progression (Bachman & Park, 2005; Massague, 2008). Activin is a 
member of the TGF-β superfamily. The critical role of the activin signalling pathway 
in cancer has drawn attention only more recently. It has been demonstrated to be 
involved in cell proliferation, differentiation, apoptosis, metabolism, homeostasis, 
immune response and wound repair (Risbridger et al., 2001; Chen et al., 2006). The 
Hh pathway has a typical role in mammalian development and in recent years has 
been found to be abnormally activated in cancers (Berman et al., 2003; Thayer et al., 
2003; Yauch et al., 2008). As was introduced in chapter 5, a number of genes 
implicated in the TGF-β pathway (including the canonical TGF-β and activin 
pathways) and Hh pathway were generally upregulated in NPC tumours compared to 
normal nasopharyngeal epithelia (Tables 5.1 and 5.3), which suggests that these 
pathways might have a tumour promoting effect on the process of carcinogenesis. 
However, their precise function in NPC still remains to be elucidated. The present 
study is a preliminary investigation into the potential role of these signalling pathways 
in NPC carcinogenesis. 
 
To address this question, two cell lines were used: the EBV-positive NPC cell line 
C666-1 and the telomerase immortalised oral keratinocyte cell line OKF6 tert-1. Since 
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investigation of the signalling pathways in vivo revealed that C666-1 exhibited a 
similar gene expression pattern as that of NPC biopsies (see Section 5.2.2), this cell 
line probably harbours the same dysregulated cell signalling pathways common to 
authentic NPC tumours and therefore it was used as a model for NPC tumours. OKF6 
tert-1 has been demonstrated to be responsive to TGFβ1-mediated pathway activation 
(Peng et al., 2006). Thus, this line is considered to be a good control line. The 
preliminary data obtained so far reveal that activin A but not TGF-β1 induces TGF-β 
responsive genes in C666-1 cells, indicating that the activin pathway is intact but that 
the TGF-β pathway is not. Both activin A and TGF-β1 induce cell cycle arrest at 
G2/M phase in the OKF tert-1 cell line but not in the C666-1 line.  In addition, 
investigation of the Hh pathway in C666-1 cells reveals that this pathway is intact and 
seems to be activated.  
 
6.2 TGF-β and activin signalling pathways 
6.2.1  Determination of the integrity of the TGF-β and activin signalling 
pathways in the C666-1 line  
 
To characterise the responsiveness of C666-1 and OKF6 tert-1 cells to TGF-β and 
activin signals, a TGF-β and activin-responsive reporter gene construct, SERPINE1 
luciferase reporter (p3TP-luciferase) was used. C666-1 and OKF6 tert-1 cells were 
transiently transfected with p3TP-luciferase and a plasmid expressing Renilla 
luciferase, as described in section 2.10. After serum starvation for 5 hours to remove 
the presence of any serum-derived cytokines, cells were treated with serial dilutions 
of activin A or TGF-β1 for 16 hours. SERPINE1 promoter activity was examined and 
normalised to Renilla luciferase readings to control for transfection efficiency. A 
Chapter 6                                                                                                              Results 
214 
 
representative set of histograms from three independent experiments are shown in 
Figure 6.1. 
 
Both C666-1 and OKF6 tert-1 cells showed increased luciferase reporter activity in a 
dose dependent manner after treatment with activin A, indicating the presence of an 
intact activin signalling pathway in both types of cells. The OKF6 tert-1 cells 
responded to activin A (50ng/ml) by a 3.4-fold upregulation relative to control (Figure 
6.1 B2), whilst the C666-1 cells showed 11.6-fold upregulation (Figure 6.1A). This 
indicates that C666-1 cells have a stronger response to activin A stimulation than do 
OKF6 tert-1 cells. However C666-1 cells did not respond to TGF-β1 stimulation 
(Figure 6.1A), whereas OKF6 tert-1 cells exhibited a dose-dependent increase, with 
the highest response (9.8-fold) following stimulation with only 0.5ng/ml of TGF-β1 
(Figure 6.1 B1) This indicates that TGF-β signalling is intact in OKF6 tert-1 cells but 
not in C666-1 cells. Previous studies and our work (Section 5.2.2) demonstrated that 
C666-1 cells lack TGFBR2 expression, which most likely explains why the cells are 
unresponsive to TGF-β.  
 
To further confirm the integrity of the signalling pathways, the Smad-binding element 
luciferase reporter (CAGA12-luciferase) was also transfected into C666-1 and OKF6 
tert-1 cells. Similarly, activin A upregulated the CAGA12 reporter in both cell types 
in a dose-dependent manner, with the strongest responses being 33.8-fold 
upregulation in C666-1 (Figure 6.2A) and 11.2-fold upregulation in OKF6 tert-1 cells 
(Figure 6.2 B2) to 50ng/ml of activin A. This provides further evidence in support of 
an intact activin response in C666-1 cells. Again, C666-1 cells did not respond to 
TGF-β1 (Figure 6.2A), whilst OKF6 tert-1 cells exhibited a strong response in a dose- 
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Figure 6.1: Activin A but not TGF-β1 induces the TGF-β-responsive, SERPINE1 
reporter activity in C666-1 cells. 
(A) The columns show the relative activity of SERPINE1 luciferase (p3TP) in C666-1 
without stimulation or after stimulation with a serial dilution of TGF-β1 or activin A. 
No increase in reporter activity is observed after TGF-β1 stimulation, whereas an 
increase in a dose dependent manner is observed after activin A stimulation.    
 
(B) The columns show the relative activity of p3TP in OKF6 tert-1 cells after 
stimulation with a serial dilution of TGF-β1 (B1) or activin A (B2). A dose-dependent 
increase in p3TP activity is observed after stimulation.  
 
Reporter assays were performed in biological and technical triplicate, and error bars 
indicate SD from three replicates of a representative experiment. 
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Figure 6.2: Activin A but not TGF-β1 induces SMAD-responsive reporter 
activity in C666-1 cells. 
(A) The columns show the relative activity of SMAD-responsive, CAGA12 luciferase 
in C666-1 cells without stimulation or after stimulation with a serial dilution of TGF-
β1 or activin A. No increase in reporter activity is observed after TGF-β1 stimulation, 
whereas an increase in a dose dependent manner is observed after activin A 
stimulation.   
  
(B) The columns show the relative CAGA12 luciferase activity in OKF6 tert-1 cells 
after stimulation with a serial dilution of TGF-β1 (B1) or activin A (B2). A dose-
dependent increase in CAGA12 luciferase activity is observed after stimulation.  
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dependent manner (Figure 6.2 B1). This result once more suggests that the TGF-β 
pathway is not intact in C666-1 cells. 
 
6.2.2 Analysis of gene expression levels impacted by TGF-β and activin 
signalling 
 
To determine whether downstream targets of TGF-β and activin signalling were 
activated or altered by TGF-β and activin A stimulation, C666-1 and control cells 
were treated with TGF-β1 (10ng/ml) or activin A (100ng/ml) and harvested at varying 
time points. The total cell lysates were analysed for the expression level of known 
TGF-β−responsive genes using immunoblotting. 
 
As was described in Section 1.4.4.2, both the activation of TGF-β and activin 
signalling can induce phosphorylation of SMAD2 and SMAD3. Immunoblotting 
using an antibody against the phosphorylated form of SMAD2 (p-SMAD2) revealed 
the presence of p-SMAD2 in C666-1 cells after activin A stimulation. The highest 
level of p-SMAD2 was observed after 1-hour and appeared to be slightly attenuated 
after that. However p-SMAD2 protein was not detected in C666-1 cells following 
treatment with TGF-β1 (Figure 6.3A). Control cells showed a basal p-SMAD2 level 
and also an increased expression after treatment with both TGF-β1 and activin A 
(Figure 6.3B).  
 
SERPINE1 (PAI-1) has been identified to be a target of both TGF-β1 and activin 
signalling (Ryu & Kern, 2003). Immunoblotting for this protein revealed the presence 
of SERPINE1 expression in C666-1 after 4-hours of treatment with activin A and the 
strongest expression was found after 6 hours (Figure 6.3A).  TGF-β1 did not induce  
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Figure 6.3: Activin A but not TGF-β1 induces phosphorylation of SMAD2 and 
upregulation of SERPINE1 and p21 in C666-1. 
In response to stimulation with TGF-β1（10ng/ml）or activin A (100ng/ml), the 
expression levels for p-SMAD2, SERPINE1 and p21 protein in C666-1 cells (A) and 
OKF6 tert-1 cells (B) are displayed. β-actin is used as a loading control. 
Phosphorylation of SMAD2 and upregulation of SERPINE1 and p21 expression are 
observed in C666-1 cells after activin A stimulation, whereas no response is observed 
after TGF-β1 stimulation (A).   
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SERPINE1 expression. OKF6 tert-1 cells showed basal expression of SERPINE1, 
whereas the strongest accumulation was observed after 2 hours of TGF-β1 or activin 
A stimulation (Figure 6.3B).  
 
P21 is the product of the CDKN1A gene. It is a cyclin kinase inhibitor that is also 
responsive to TGF-β1 and activin signalling (Ryu & Kern, 2003) and has been 
demonstrated to play an important role in TGF-β-induced growth inhibition (Yoo et 
al., 1999; Bachman et al., 2004; Nakamura et al., 2009). In response to activin A 
stimulation, p21 expression was induced in C666-1 cells 6-hours after treatment, but 
induction of p21 was not observed after treatment with TGF-β1 (Figure 6.3A).  The 
strongest induction of p21 was detected in OKF6 tert-1 cells after 2-hours of 
treatment with TGF-β1 or activin A (Figure 6.3B). 
 
6.2.3 Analysis of cell cycle progression impacted by activin A or TGF-β1  
The activin and TGF-β signalling pathways have been shown to disturb cell cycle 
progression and inhibit tumour growth in several types of cells (Iavarone & Massague, 
1997; Yamato et al., 1997; Yoo et al., 1999; Burdette et al., 2005). To investigate the 
effect of these pathways on cell cycle progression of C666-1 cells, the OKF tert-1 and 
C666-1 cells were treated with or without activin A (100ng/ml) or TGF-β1 (10ng/ml) 
for 5 days, stained with propidium iodide and analysed by flow cytometry (see 
Section 2.11). Compared to untreated cells (control), the OKF6 tert-1 cells treated 
with either activin A or TGF-β1 showed an increased cell population in G2/M phase 
(4.4% vs. 10.0% and 12.2%, respectively). However, no difference of cell-cycle 
distribution was observed in activin A or TGF-β1 treated C666-1 cells compared to 
Chapter 6                                                                                                              Results 
223 
 
the control (Figure 6.4). This reveals that whilst both activin A and TGF-β1 induce 
cell cycle arrest at G2/M phase in the OKF tert-1 cell line neither influence cell cycle 
progression in the C666-1 line. These data suggest that whilst C666-1 cells are 
capable of responding to activin, they are refractory to activin-mediated growth 
inhibition.   
  
6.3 Hh signalling pathway 
6.3.1 Determination of the integrity of the Hh signalling pathway in C666-1 
cells 
 
To determine the integrity of the Hh pathway in C666-1 cells, C666-1 and OKF6 tert1 
cells were transfected with an Hh responsive reporter (8xGLI1 luciferase), or pGL2 
basic reporter as a control, and a Renilla plasmid. 24 hours after transfection, cells 
were treated with or without a SHH ligand (2µg/ml) for 16 hours. GLI1 reporter 
activity was measured and normalised to Renilla luciferase readings. Compared to 
OKF6 tert-1 cells, GLI1 reporter was significantly higher in C666-1 cells. 
Furthermore, whilst reporter activity could be stimulated in OKF6 tert-1 cells in 
response to SHH treatment (Figure 6.5), SHH treatment had only marginal affects on 
GLI reporter activity in C666-1 cells (Figure 6.5). This indicates that the Hh pathway 
is constitutively active in C666-1 cells. 
 
6.3.2 Examination of the expression of Hh pathway components at the protein 
level 
 
To examine the expression level of components involved in the Hh pathway, C666-1 
and OKF tert-1 cells were grown in situ for 24 hours, and then examined for SMO, 
PTCH1 and GLI1 expression using a two-step immunofluorescence (IF) staining  
C666-1
Control
10ng/ml TGF-β
G1   = 72.1%
S    = 16.0%
G2/M = 10.2%
G1   = 70.5%
S    = 16.8%
G2/M = 11.8%
G1   = 68.4%
S    = 16.8%
G2/M = 11.9%
100ng/ml Activin A
G1   = 88%
S    = 7.6%
G2/M = 4.4%
G1   = 83.6%
S    = 6.4%
G2/M = 10.0%
G1   = 81.8%
S    = 6.0%
G2/M = 12.2%
OKF6 tert-1
Figure 6.4: Both activin A and TGF-β1 induce cell cycle arrest at G2/M phase in OKF6
tert-1 cell line but not in C666-1 line. Cell-cycle distributions of C666-1 and OKF6 tert-1
in three phases are represented by the figures and percentages. Compared to untreated cells
(control), C666-1 cells treated with either activin A or TGF-β1 shows no difference in cell-
cycle distribution (left panels), whereas compare to the control, both activin A and TGF-β1
treated OKF6 tert-1 cells show an increased cell population at G2/M phase (right panels).
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Figure 6.5: SHH induces the activity of the Hh responsive reporter,
GLI1 luciferase in C666-1 cells. The columns show the relative activity of
Hh-responsive, GLI1 luciferase in C666-1 cells without stimulation or after
stimulation with SHH (2µg/ml). Compared to the basal level (open
columns), an increase in reporter activity is observed in cells transfected
with GLI1 reporter, and the responses are slightly elevated after treatment
with SHH (black columns).
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Figure 6.6: Immunofluorescence staining reveals higher protein
levels of Hh pathway components SMO, PTCH1 and GLI1 in
C666-1. The expression of SMO, PTCH1 and GLI1 in C666-1 (upper
panels) and OKF6 tert-1 cells (bottom panels) are shown. C666-1
cells show higher levels of SMO (cytoplasm), PTCH1 (cytoplasm)
and GLI1 (nucleus) expression.
C666-1
OKF6 tert1
SMO PTCH1 GLI1
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technique as described in section 2.7. Compared to OKF6 tert-1 cells, C666-1 cells 
showed significantly higher expression levels of SMO, PTCH1 and GLI1 (Figure 6.6). 
Localisation of SMO to the cell surface is essential for initiation of Hh pathway 
signalling. GLI1 is an activator for modulating Hh target genes, for example, PTCH1 
(Jiang & Hui, 2008). Therefore, higher expression of these proteins indicates 
activation of the Hh pathway in C666-1 cells.  
 
6.4 Discussion  
 
The present work forms the beginning of a study into the functions of the canonical 
TGF-β, activin and Hh pathways in NPC pathogenesis. To address this question, the 
integrity of the pathways was first investigated by using TGF-β responsive genes and 
suggested that in the C666-1 line the activin signalling pathway is intact but the TGF-
β pathway is not. This was confirmed by immunoblotting which showed that activin 
A but not TGF-β1 could induce SMAD2 phosphorylation and upregulate the 
expression of the TGF-β responsive genes, SERPINE1 and p21 in C666-1 cells. The 
defects of the TGF-β pathway in C666-1 are most likely caused by loss of TGFBR2, 
which when bound to TGF-β ligands is important for pathway activation (see Section 
1.4.4.2). In addition, C666-1 cells transiently transfected with a TGFBR2 expression 
plasmid have been shown to become responsive to TGF-β signalling (unpublished 
work in our group, Date et al). Previous studies demonstrated that loss of functional 
TGFBR2 in cancers results in insensitivity to TGF-β-mediated cell growth inhibition 
or apoptosis (Fukuda et al., 2006; Pu et al., 2009), which contributes to malignant 
transformation at an early step of tumourigenesis and that it can occur through 
mutation or transcriptional repression of the TGFBR2 gene (Park et al., 1994; Hahm, 
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1999). A recent study reveals that induction of p21 expression is associated with a 
high level of TGFBR2 expression (Rojas et al., 2009).  
 
Although the canonical TGF-β pathway has been widely studied in cancers, the 
function of the activin pathway in cancers is relatively poorly understood despite its 
roles in proliferation, apoptosis and carcinogenesis having been reported (Chen et al., 
2006). Activin and TGF-β share the same receptor binding properties and their 
receptors phosphorylate and activate the same SMADs (SMAD2 and SMAD3). 
Therefore, it is possible that they may have some common biological functions in 
carcinogenesis. Although this concept still remains to be elucidated, it has been shown 
that activin and TGF-β induce a similar set of gene responses that have been 
implicated in the control of cell growth and tumourigenesis (Schnepp & Hua, 2003; 
Deacu et al., 2004). These responsive genes include SERPINE1 and p21 that were 
shown to be upregulated in C666-1 after treatment with activin A (Figure 6.3).  
 
P21 is a well-established cyclin-dependent kinase inhibitor that mediates cell cycle 
arrest at G1 phase resulting in cell growth inhibition. An investigation in a model of 
breast cancer reveals that activin A upregulated the expression of cyclin kinase 
inhibitors, p21 and p27, and mediated growth inhibition and cell cycle arrest (Burdette 
et al., 2005). However, a recent publication reported that activin A was overexpressed 
in lung cancer and that this was associated with cell proliferation and poor survival 
(Seder et al., 2009). These observations indicate that the activin pathway may have 
complicated functions in cancers and, like TGF-β, can function as either a tumour 
promoter or a tumour suppressor.  
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To investigate the function of the TGF-β and activin pathways in C666-1 cells, cell 
cycle analysis of activin A and TGF-β1 treated cells was performed. The preliminary 
data reveal that although OKF6 tert-1 cells were arrested at G2/M phase after 
treatment with either activin A or TGF-β1, the C666-1 cells were not. It has been 
demonstrated that the TGF-β signalling pathway is not intact in the C666-1 cell line. 
Thus, it is not surprising that this cell line does not respond to TGF-β1-induced cell 
cycle arrest. However, although the activin signalling pathway is intact, the C666-1 
line also appears to resist activin A-induced cell cycle arrest. Although activin 
signalling mediates cell cycle progression mainly through activation of the SMAD-
dependent pathway, the SMAD-independent pathways such as p38 MAPK also 
appear critical (Cocolakis et al., 2001; Chen et al., 2006). For example, activation of 
p38 MAPK has been shown to be required for activin A-induced cell cycle arrest in 
breast cancer cell lines. The finding that P38 MAPK activity appears to be suppressed 
in EBV infected cells including C666-1 (Lo et al., 2006) suggests that engagement of 
SMAD-independent signalling pathways are defective in this cell line..  
 
In the expression array data (Table 5.1), activin A was found to be upregulated in 
NPC biopsies, whereas it was absent in C666-1 cells. This raises some interesting 
questions. For example, how do C666-1 cells exhibit similar expression patterns of 
TGF-β responsive genes as authentic NPC tumours in the absence of TGFBR2 and 
activin A expression? Do other pathways crosstalk with these two pathways in C666-
1 cells? What precise functions do the TGF-β and activin pathways exert in NPC 
cancer cells? Do they have similar effects in C666-1? If the defects of the TGF-β 
pathway in C666-1 are repaired, do the TGF-β and activin pathways synergistically 
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act as tumour promoters or suppressors in cells? To answer these questions, further 
functional investigations in C666-1 cells are required. 
 
Using the Hh responsive reporter, GLI1 luciferase, the preliminary data reveal that the 
Hh pathway is intact in C666-1. Moreover, the expression of the Hh pathway 
components SMO, PTCH1 and GLI1 was shown to be at a higher level in C666-1 
cells compared to the non-malignant OKF6 tert-1 cells, indicating chronic activation 
of the Hh pathway in C666-1 cells. However, expression array data showed that the 
SHH transcript was called by GCOS as “absent” in C666-1 cells (Section 5.4.2), in 
this context, how is the Hh pathway activated in this line? Studies show that TGF-β 
and Ras can stimulate GLI activity in epithelial cells in a Hh-independent manner 
resulting in activation of its downstream targets (Dennler et al., 2007). A recent study 
has also revealed that Wnt signalling can stimulate expression of the Hh pathway 
activator, GLI1, in colorectal cancer (Noubissi et al., 2009). This might also apply to 
NPC cells since both the TGF-β and Wnt signalling pathways are generally activated 
in C666-1 cells (Table 5.2). However it is also possible that other pathways or viral 
components are involved in regulation of this pathway.  
      
The preliminary data obtained so far from the pathways analysis provide a basis for 
further study. Since the integrity of the activin, TGF-β and Hh signalling pathways 
have been determined in C666-1, this line can be used as an in vitro model for further 
functional investigation of these signalling pathways.  
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CHAPTER 7 
 
General discussion and future work 
 
NPC is a highly malignant tumour arising from the epithelial lining of the 
nasopharynx. Although the molecular basis of NPC pathogenesis is still unclear, it has 
been suggested that it is a multistep process. EBV infection, environmental and 
inherited components are considered to be three major factors for carcinogenesis (Tao 
& Chan, 2007). During the development and progression of this disease, multiple 
somatic genetic aberrations are accumulated, along with the effects of environmental 
factors and EBV infection, synergistically acting together and disrupting normal 
cellular functions and multiple signalling pathways (Lo & Huang, 2002). The aim of 
this thesis was to identify and correlate chromosomal copy number changes with 
abnormal cellular gene expression, and to examine dysregulation of signalling 
pathways in NPC in an attempt to understand the molecular basis of this disease.  
 
The examination of cellular gene expression in NPC tumours and normal 
nasopharyngeal epithelial cells revealed perturbations in a large number of genes that 
are implicated in the process of tumourigenesis. These genes have been found to be 
included in a variety of functional groups (Chapter 3) and signalling pathways 
(Chapter 5) that have been frequently associated with tumourigenesis.  
 
As was introduced in Chapter 1, previous genetic and expression analysis 
characterised a number of NPC-associated oncogenes and TSGs. When these genes 
were examined in our tumour-related gene lists (Tables 3.1-3.3), we found that some 
of them are included but some are not. For example, several putative oncogenes 
Chapter 7                                                                 General discussion and future work 
 232 
identified by previous studies (e.g. MYCL1, PIK3CA, SKIL, TP63, BCL2, EGFR, 
TNFAIP3, BIRC3, MET, and BMI1) were also found to be upregulated in our NPC 
sample set, but a few previously characterised oncogenes e.g. CCND1, LTβR, 
GPR160, EVI1, were not. In addition some, e.g. FGF3, were called by GCOS as 
absent in both tumours and normals so that their expression level could not be 
compared (Tables 3.1 and 3.3). Similarly, several well- established TSGs, e.g. RARB, 
GSTP1, CDH1, BRD7 and PTEN, were found to be downregulated in our samples. 
However, others e.g. ZYMND10, MLH1, RBL2, THY1 and ATM were not included 
because their expression was called by GCOS as absent in both tumours and normals 
or present in less than 4 normals. The discrepancy between our data and previous 
publications might be caused by the different sample sets used in the respective 
studies. Although a number of oncogenes and tumour suppressor genes appear to be 
universally differentially expressed, the majority seem to be important in only a 
fraction of cases. Therefore, different studies that use different sample sets may reveal 
incompletely congruent data. This is also true when we analyse gene expression in the 
context of signalling pathways. The majority of genes’ up- or down- expression is 
consistent with previous data (e.g. upregulation of WNT5A, FZD7, and CTNNB1). 
However, there are a few exceptions e.g. WIF-1 that has been shown to be 
downregulated in NPC cell lines (Lin et al., 2006) but was called by GCOS as absent 
in both tumours and normals and ID1 that has been previously reported to be 
upregulated but was downregulated in our samples (Tables 5.1 and 5.2).      
 
Although our expression array analysis identified such a big list of up- or down- 
regulated genes, it is not clear how many - or how few - are required for 
tumourigenesis. A further examination of the expression of these genes in each 
tumour revealed that the mean number of oncogenes upregulated in each cancer was 
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93 (range 40 – 120), whilst the mean number of TSGs downregulated in each tumour 
was 109 (range 90 – 135). It is clear that each tumour is an individual, possessing its 
own set of up- or down-regulated tumour-associated genes, drawn in various 
combinations from an extensive list. Functional characterisation of putative tumour 
suppressor genes using cell lines or animal models reveals dramatic effects on tumour 
cell growth in response to the perturbation of expression of just a single TSG (Wang 
et al., 1999; Chow et al., 2004; Cheung et al., 2008). On the other hand, functional 
silencing the expression of a single oncogene reveals significant induction of 
apoptosis or inhibition of proliferation in tumour cells (Friboulet et al., 2008; Qin et 
al., 2008; Or et al., 2010). Considering these data alongside the current observations 
that reveal downregulation of over 100 TSGs and upregulation of over 90 oncogenes 
per tumour emphasises the magnitude of the loss of proliferative control in NPC. The 
identification of them paves the way for a number of further investigations. For 
example, the individual oncogenes and TSGs might have their particular function in 
carcinogenesis, therefore, knockdown, overexpression or methylation analysis of 
individual up- or down-regulated genes in NPC cells would be helpful to find some 
critical genes and understand their particular roles.  
 
Meanwhile, the SNP array data identified a number of chromosomal abnormalities in 
NPCs. The extensive regions of loss or gain found in our analysis are consistent with 
previous findings (Table 4.1). One study with conventional CGH and aCGH analysis 
suggests that Mediterranean NPCs have higher frequencies of gains at 1q and losses at 
13q (Rodriguez et al., 2005). Considering the samples used in our SNP array analysis 
are derived from both Mediterranean areas (5 NPCs) and Southern China (9 NPCs), 
chromosomal changes at 1q and 13q were closely examined between both sample sets. 
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It reveals a higher 13q loss in Mediterranean NPCs than in Chinese NPCs (80% (4/5) 
vs. 33.3% (3/9)). However, no significant difference in 1q gain was observed (40% 
(2/5) vs. 44.4% (4/9)). This discrepancy is not surprising considering that the sample 
size performed in this comparison is relatively small, whereas Rodriguez et al drew 
their conclusion by comparing 6 independent studies.  
 
In addition to some extensive regions of chromosomal aberrations, compared to 
previous findings the present work observed several discrete, minimal regions of 
chromosomal changes by taking advantage of the high-resolution of these arrays (see 
Section 4.5.3). The genes involved in the critical regions of genetic changes have also 
been recognised. For example, genes PITX1, CXCL14, TGFBI CLU, TINF2, ITGA2 
and MSH3 were observed within the small deletions, and genes GAS1, SYK, DAPK1 
and GADD45G were found to be located in the minimal region of UPD at 9q21.32 – 
q22.2. The majority of these have been shown to be involved in the process of 
tumourigenesis (see Section 4.5.4). To investigate their importance in carcinogenesis, 
mutational or methylation analysis of some genes in NPC biopsies might provide an 
important clue.  
 
The relationship between cellular gene expression and DNA copy number in NPC 
tumours was analysed in the genes involved in small regions of loss or gain and the 
lists of tumour-related genes. This revealed that the direct copy number/expression 
link applies in about 60% of the instances of copy number loss/down-expression and 
less than 35% of instances of copy number gain/up-expression that were examined 
(Table 4.3). This result indicates that the up- or down- regulation of gene expression 
in NPC might not be a direct consequence of DNA copy number gain or loss. NPC 
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tumour cells seem to upregulate or downregulate the expression of many such genes 
irrespective of the underlying gene copy number. Especially, copy number gain, up to 
about 4 copies, is not generally associated with upregulation of expression but 
amplification appears to be (e.g. amplification at 8p11.22 – 11.21). Actually, more 
complicated mechanisms might be involved in the process of regulation in gene 
expression. For example, the expression of some genes might be tightly controlled by 
cellular regulators of particular signalling pathways.  
 
It is worthy to note that our copy number data were generated by comparing amplified 
DNA with unamplified reference DNA, which could introduce potential confounding 
artefactual copy number variants that are caused by the DNA amplification procedure. 
Since these artefacts have been shown to be relatively small and isolated or that they 
comprise losses close to chromosome termini, such changes were filtered out (Section 
4.2). In addition, whether large or small, the regions of chromosomal abnormalities 
described in our SNP array data are more than 1MB, which are not likely to be 
amplification artefacts. Moreover, Q-PCR data for several genes encoded in the loci 
of loss or gain verified the fidelity of our copy number data. However, when the copy 
number data are analysed in relation to the tumour-related gene lists, it is possibly 
problematic since the regions that the majority of genes are involved are small. One 
study (Pugh et al., 2008) compared copy number data of amplified and unamplified 
DNA in 500K SNP arrays and suggested that many amplification artefacts are 
reproducible and that up to around 700 artefacts were generated, a number that is 
consistent with our estimates when comparing amplified and unamplified C666-1 
DNA. The total size of the amplification artefacts was 21.97Mb or about 0.7% of the 
total genome. Therefore we suggest that these artefacts would make only a small 
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difference to the outcome of our analysis since, in the highly unlikely event that every 
one of the 700 artefacts was in a mRNA-encoding region, this would affect only about 
0.7% of the transcripts that are assayed on the U133Plus2 array, assuming equal 
distribution. Nevertheless we are currently processing a number of amplified, normal 
DNA samples on 500K arrays in order to generate a bioinformatic correction factor 
that will enable a more robust analysis to be performed. 
           
When the expression array data were analysed for signalling pathways, a number of 
pathways were found to be dysregulated. Especially, the expression of numerous 
components involved in the TGF-β, Wnt and Hedgehog signalling pathways were 
differentially regulated. This suggests that the disruptions of these pathways are 
critical for NPC pathogenesis. Nonetheless, their precise functions remain to be 
elucidated.  
 
It has been suggested that EBV latent genes can modulate cellular gene expression in 
NPC tumours (Raab-Traub, 2002). For example, EBNA1 has been shown to repress 
the TGF-β1-induced target gene transcription in tumour cells of nasopharyngeal 
origin (Wood et al., 2007), whereas LMP1 expression upregulates downstream targets 
of the TGF-β signalling pathway in MDCK cells (unpublished work, Laverick et al). 
This reveals that individual viral genes have different or even opposing effects on the 
TGF-β signalling  pathway, which might raise the question as to what and  how does 
coexpression of the EBV latent genes impact on the expression and function of this 
signalling pathway in authentic NPC tumours since both EBNA1 and LMP1 are 
expressed in NPCs? Our pathway analysis showed that the TGF-β signalling pathway 
was universally activated in NPCs (Table 5.1). The authentic NPC tumour exhibits 
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much more complicated cellular and viral components. Therefore, competition for the 
viral genes interaction between cellular coactivators and corepressors may be more 
complicated in determining the outcome of the TGF-β signalling pathway, and the 
balance may shift depending on the relative levels of these viral proteins and on 
signalling inputs that affect their activities. Moreover, the activity of other pathways 
or other factors may also involve and influence the outcome of the TGF-β response. 
This applies not only to the TGF-β signalling pathway but has also been observed in 
other pathways, for example, the NF-ĸB signalling pathway. NF-ĸB was shown to be 
inhibited by EBNA1 in NPC cells (Valentine et al., 2010), whilst it was activated by 
LMP1 (Liu et al., 2009). Although not discussed, our data showed that several 
components of this pathway were upregulated and confirmed that it was activated in 
NPC.  
 
In the context of the interaction between expression of viral and cellular genes, 
determining the EBV gene expression pattern in microdissected samples will enable 
us to monitor the pattern of EBV gene expression alongside any cellular gene changes 
we observe. In addition, the present work mainly focused on analysis of NPC tumour 
cells. However a common feature in NPC is the existence of an extensive lymphoid 
infiltrate surrounding the tumour cells. The interaction between tumour cells and their 
microenvironment is critical to the initiation, progression and maintenance of cancer 
(Gourzones et al., 2009). Therefore, a global analysis of cellular gene expression to 
include this reactive component could identify novel receptor-ligand pairs, including 
chemokines and their receptors that mediate the interaction between reactive cells and 
tumour cells. This would allow us to have a more global view on the mechanisms of 
NPC development and progression.  
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The C666-1 cell line was the only cell line used in the present study. Sample 
correlation analysis as well as pathway studies revealed that the gene expression 
pattern of the C666-1 cell line approximates to that of authentic NPC biopsies. Thus, 
it is considered to be a good tumour model. In vitro investigation of the pathways in 
C666-1 cells may provide a better understanding of cellular mechanisms of NPC 
tumourigenesis. The preliminary data from pathway analyses suggest that the activin 
and hedgehog pathways are intact in C666-1 cells while the canonical TGF-β pathway 
is not. Cell cycle analysis reveals that both activin A and TGF-β1 induce cell cycle 
arrest at G2/M phase in OKF tert-1 cells but not in C666-1 cells. The data obtained so 
far provide a basis for further investigation. Since loss of TGFBR2 expression in 
C666-1 was observed (See section 5.2.2), restoration of TGFBR2 expression in C666-
1 by constructing a C666-1 derivative cell line that stably expresses TGFBR2 would 
be essential for functional investigation of the TGF-β pathway in this line. Since it 
appears that the C666-1 cell line is resistant to both activin A and TGF-β1 induced 
cell cycle arrest, do the activin or TGF-β signalling pathways have any effect on the 
tumour growth or proliferation of this NPC line? What precise functions and by what 
mechanism do these pathways exert in C666-1? To answer this questions, C666-1 
cells with or without TGFBR2 expression can be analysed further for cell cycle, 
proliferation, cell motility and invasiveness, after treatment with TGF-β1 or activin A, 
or they can be analysed for other signalling pathways (e.g. Hedgehog, and Wnt 
pathways) that might be involved in crosstalking with the TGF-β pathway. In addition, 
since the Wnt pathway was generally activated in NPCs, the functional investigation 
in C666-1 cells in vitro might be also important for understanding of NPC 
pathogenesis. This is an ongoing study in our group.  
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